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CHAPTER 1
General introduction and outline of the thesis
The general introduction is based on:
Willem J. Lammers, Kris V. Kowdley, and Henk R. van Buuren. Predicting outcome in primary biliary 
cirrhosis. Annals of hepatology 2014; 13(4): 316-26.
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1
Primary biliary cirrhosis (PBC) is an usually slowly progressive autoimmune liver disease 
characterized by a chronic non-suppurative destructive cholangitis.1 Ultimately the disease 
may lead to severe bile duct loss (ductopenia) accompanied by increasing fibrosis, finally 
resulting in cirrhosis, liver failure and premature death. Liver transplantation has a significant 
beneficial effect on outcome in patients who progress to end-stage disease, however this 
ultimate therapeutic option is only available for a selected group of patients. Ursodeoxycholic 
acid (UDCA) is the only established medical treatment over the past 25 years. It is generally 
accepted that UDCA improves prognosis in the majority of cases. However, the response 
to treatment is insufficient in a subset of patients who still have an unmet medical need 
for effective additional therapy. Timely and reliable assessment of the response to therapy 
and prediction of outcome is of key importance in clinical management and an essential 
requirement for patients counselling and timing of diagnostic and therapeutic interventions. 
WHAT’S IN A NAME?
The name primary biliary cirrhosis was first mentioned in 1950,2 although earlier reports 
described syndromes similar to PBC.3 Contrary to the name, generally considered a classical 
misnomer,1 cirrhosis is only manifest in the late stages of the disease. While the disease 
was often diagnosed in a late, cirrhotic stage in the past, the majority of patients are 
nowadays diagnosed with earlier stage disease and a substantial number will likely not 
develop cirrhosis. Currently there is strong support among patient support groups and the 
professional hepatology community alike for the initiative,  to change the name. In particular, 
to keep the acronym PBC, the new name “primary biliary cholangitis” has been proposed.4  
EPIDEMIOLOGY
PBC is a relatively rare liver disease typically affecting middle-aged females, with a male-
female ratio of 1:9.5 Reported incidence rates are varying from 0.33 to 5.8 per 100,000 
persons/year and prevalence rates from 1.91 to 40.2 per 100,000 persons.6 The incidence 
in the Netherlands is relatively low with a rate of 1.1 per 100.000 persons/year, however 
increasing incidence and prevalence rates have been observed.7 The differences in reported 
prevalence rates are partly explained by differences in the way cases were selected and in 
awareness of the disease among countries. On the other hand, genetic differences between 
populations, as well as differences in environmental circumstances might explain differences 
in prevalence. 
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PATHOGENESIS
PBC is considered to be an autoimmune liver disease. The female predominance and 
the frequently coexistence of other autoimmune conditions, such as Sjögren syndrome, 
thyreoiditis, Raynaud’s syndrome, coeliac disease, sclerodermia/CREST syndrome and 
rheumatoid arthritis, and last but not least the presence of autoantibodies are strong 
indicators of an autoimmune origin.8, 9 
The pathogenesis of PBC is still unresolved, but there is strong evidence that PBC 
is an condition that develops from a complex interaction of genetic predisposition and 
environmental triggers,10-12 leading to immunoregulatory changes and finally resulting in 
destruction of intrahepatic bile ducts and progressive fibrosis.13 
The impact of genetics on the development of PBC has been suggested by numerous 
studies. A remarkable study in sixteen monozygote twins, thus genetically identical persons, 
showed that in 5 of 8 monozygotic twin sets both individuals had PBC while among the 
dizygotic twins no concordance for PBC was found.14 It has also been shown that first-degree 
family members of PBC patients, in particular female relatives, have a higher risk of getting 
PBC.9, 15, 16 Further evidence has been provided by genome-wide-association studies (GWAS) 
that elucidated genetic risk loci for PBC.17, 18 
Environmental risk factors for PBC development have been described by well-defined 
observational studies, such as a positive family history, recurrent urinary tract infections, 
(past) cigarette smoking, use of reproductive hormone replacement, and frequent use of 
nail polish or hair dye.9, 15, 19, 20 
How the exposure to environmental factors in a genetically susceptible individual may 
trigger the loss of tolerance against autoantigens is still incompletely understood. Most 
autoantibodies found in PBC are reacting against antigens on the inner cell membrane of 
mitochondria that contain lipoic acid (antimitochondrial autoantibodies, AMA),21 especially 
to the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). Some studies suggest 
that external factors (e.g. bacteria) have epitopes comparable to PDC-E2 and subsequently 
can trigger a cross-reaction of the immune system (molecular mimicry hypothesis).22, 23 
Others suggest that xenobiotics alter host antigens or form complexes leading to loss of 
tolerance of the immune system.24 
Interestingly, the autoimmune reaction is specifically directed against the mitochondria 
of intrahepatic cholangiocytes, despite the presence of mitochondrial antigens in all 
nucleated body cells. Recent findings suggest an unique immunobiology of cholangiocytes; 
after apoptosis of cholangiocytes PDC-E2 stays intact and immunologically active in contrast 
to PDC-E2 in other cell types.25, 26 Subsequently, a specific auto immune response is triggered, 
that may play a role in the destructive autoimmune process.21, 27 Clearly further research is 
needed to unravel the mysterious pathophysiology of PBC and hopefully this will provide 
clues how to prevent the disease and to treat it effectively in an early stage.
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1
CLINICAL PRESENTATION
Nowadays, about 60% of patients do not have any symptoms at time of diagnosis, although 
most asymptomatic patients will develop symptoms over time.28 The number of asymptomatic 
patients has been increasing over the past decades.29 Fatigue and pruritus are the most 
prevalent symptoms in PBC and can have a major negative effect on perceived quality of 
life.30 Fatigue has the highest impact, especially in patients with a poor social network.31 
Unfortunately, limited progress has been made in unravelling the etiopathogenesis of this 
symptom and no effective treatment is available. Pruritus is another common symptom 
with a potential major effect on mood and well-being. The severity of pruritus may vary 
periodically and is unrelated with disease stage and severity. Pruritus is usually most severe 
during the evening and night. Several therapeutic options are available but the results are 
frequently unsatisfactory.32 
Other less frequent symptoms are sicca syndrome, occasional pain in the right upper 
abdominal quadrant, musculoskeletal pain, arthralgia and xanthomas. A minority of patients 
present initially with signs of decompensated liver disease, such as jaundice, ascites, 
bleeding from oesophageal varices or hepatic encephalopathy.  
DIAGNOSIS 
The diagnosis of PBC is usually straightforward and is based on biochemical, serological and/
or histological features. In patients with or without symptoms with otherwise unexplained 
elevated alkaline phosphatase levels, for at least six months in the presence of AMA or 
AMA type M2 antibodies, PBC can be diagnosed with confidence.32, 33 Liver biopsy is no 
longer considered essential for diagnosis but can be helpful to assess the stage and activity 
of the disease. Liver biopsy can also be indicated when the diagnosis is considered in the 
absence of  specific antibodies  and in case of suspected PBC-autoimmune hepatitis overlap 
syndrome.32 
Up to 95% of PBC patients have AMA autoantibodies against PDC-E2 antibodies detectable 
in serum.34 Additionally, about half of PBC patients have antinuclear autoantibodies (ANA). 
Most specific for PBC are ANA reacting against the nuclear envelop, such as gp210 and 
antigens that are recognized as multiple nuclear dots with immunofluorescence microscopy, 
such as sp100. Interestingly, up to 85% of AMA-negative patients are ANA-positive.21 
Therefore these antibodies may be useful to establish the diagnosis PBC in AMA-negative 
patients.35 
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TREATMENT
Treatment options in PBC are limited. Liver transplantation is an important treatment 
modality with excellent results,36 but is an option only for patients with end-stage liver 
disease. In addition, PBC can recur in the transplanted liver although the course of recurrent 
PBC is usually mild. Currently, UDCA is the only approved medical treatment and advised 
in doses of 13-15mg/kg/day  as first-line treatment in PBC.32, 33 UDCA is a hydrophilic bile 
acid that can protect hepatocytes and cholangiocytes from the toxic effects of hydrophobic 
bile acids. An important proposed mode of action is that UDCA stimulates hepatocellular 
secretion of hydrophobic bile acids and other potential hepatoxins.37 
UDCA has been shown to improve liver biochemistry, liver histology and transplant-
free survival of PBC patients. A beneficial effect on symptoms has not been documented. 
Unfortunately, about 40% of patients have an insufficient response to UDCA and these 
patients should be considered for additional, second-line therapies.38-42 
Considering the presumed autoimmune etiology of PBC, the efficacy of a large number of 
immunosuppressive and immunomodulating agents, such as prednisone, D-penicillamine, 
azathioprine, methotrexate, chorambucil, malotilate and rituximab, has been evaluated 
during the last decades. These studies were largely negative or showed important adverse 
treatment effects.32, 33 More promising results have been reported with budesonide, a 
glucocorticoid with an extensive first-pass metabolism in the liver. The potential adverse 
effect profile of budesonide may be superior to that of prednisone and this drug may be an 
option in non-cirrhotic PBC.43-45 The potential long-term adverse effects of corticosteroids 
remain of concern, such as the negative effect on bone mass.46, 47 The results of a recent 
controlled trial are awaited with much interest.
A potential viral etiology of PBC has been presumed48 and antiviral therapies have been 
assessed,49, 50 though further research is required.    
Currently, a number of new agents are under evaluation that act as agonists of 
nuclear receptors, such as fibrates and obeticholic acid (OCA, INT-747). The evidence of 
beneficial effects of fibrates in addition to UDCA is emerging,51-56 although further evidence 
from phase 3 randomized placebo-controlled trials is awaited. Fibrates are acting on 
peroxisome proliferator-activated receptors (PPAR), which are important in lipid and energy 
homeostasis.57 It is suggested that activation of PPAR can down regulate bile acid uptake 
and synthesis in hepatocytes,54 however the mechanisms leading to anticholestatic effects 
of fibrates are not completely understood. Recently promising results have been obtained 
with OCA, a derivative of the bile acid chenodeoxycholic acid (CDCA).58, 59 In contrast to 
UDCA, OCA specifically acts on the farnesoid X receptor (FXR), which plays an important role 
in bile acid synthesis, transport and metabolism. It seems realistic that within a few years 
evidence-based second-line treatment for PBC will be a reality. The selection of optimal 
candidate patients for these new therapies is a major challenge.     
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1
PROGNOSIS
The natural course of PBC is slowly progressive spanning 10-40 years. The life expectancy of 
affected patients is worse compared with the general population, but on an individual basis 
the course of the disease and the prognosis vary greatly. Currently, patients are more likely 
to be asymptomatic and diagnosed at earlier stages of the disease.28, 29, 60 Table 1 summarizes 
studies published in the last fifteen years reporting 5- and 10- year liver transplant-free 
survival rates based on Kaplan Meier estimates. The reported differences in outcome are 
probably attributable to differences in study populations and variability with respect to 
duration and dose of treatment with UDCA. 
Impact of UDCA treatment on the natural course of PBC
With the introduction of UDCA the prognosis of PBC has markedly improved. Besides an 
improvement of biochemistry several studies with extended follow-up data of earlier 
published randomized, placebo-controlled UDCA trials showed that UDCA can delay 
histological progression after several years, but does not regress fibrosis.61-63 
Its efficacy in terms of survival benefit has been subject of debate over the past decades. 
Several meta-analyses have failed to show a beneficial effect of UDCA in PBC.64-66 However, 
only a few of the included studies in these meta-analyses lasted longer than 24 months, 
a very short period to demonstrate effects on transplant-free survival, and most studies 
were clearly underpowered. In contrast, a pooled analysis of individual patient data from 
the 3 largest placebo-controlled double-blind trials with extended follow-up data from one 
center, showed an improvement in survival with UDCA after four years of treatment.67 One 
meta-analysis showed that the use of UDCA in studies that incorporated placebo control, 
long-term follow-up (more than 2 years) or larger numbers of patients (more than 100 
patients) were associated with both improved serum liver biochemical tests and reduced 
incidence of liver transplantation or death.68 Some other studies have shown that UDCA-
treated patients with early stage disease have survival rates comparable with an age- and 
sex-matched controlled population in contrast to UDCA-treated patients with advanced 
disease.69, 70 In summary, there is strong evidence to support the use of UDCA to delay the 
progression of PBC and currently it remains the only licensed medical therapy.
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1
Prognostic factors
Histological stage
Severity of disease in PBC is based on the Scheuer14 and Ludwig1 histologic scoring systems, 
both recognizing 4 stages. Early histological stages are associated with favourable prognosis. 
The last phase, or cirrhotic phase, is irreversible and classically only this stage is associated 
with an increased risk of liver decompensation and development of hepatocellular carcinoma 
(HCC).33, 79 Thus, liver histology is a strong prognostic factor.  
A particular variant form of PBC, the premature ductopenic variant, is characterized by 
rapid, excessive bile duct loss in relation to the amount of fibrosis. In individuals with this 
subtype, severe cholestasis with progressive jaundice and marked hypercholesterolemia 
may require liver transplantation well before the development of cirrhosis.80
The histological progression of PBC was assessed in patients originally included in a 
clinical trial of D-penicillamine.81 Since this agent does not delay histological progression,82 
this study is considered as representative of histological progression in treatment-naïve PBC 
patients. Approximately 80% of patients had histological progression of at least one stage 
during a median follow-up of 3 years, and 31% with stage I disease progressed to cirrhosis 
within 4 years. Another study followed-up 183 patients treated with UDCA and reported a 
4% incidence of cirrhosis at 5 years in patients with stage I disease,83 suggesting that UDCA 
delays histological progression.  
Several other histologic features have been described as important prognostic parameters 
of worse outcome in PBC, such as central and periportal cholestasis,79, 84 periportal cell 
necrosis and piecemeal necrosis,83, 84 interface hepatitis,83 and ductopenia.62 Many of these 
histological features are not systematically included in the Ludwig and Scheuer histological 
scoring systems; in fact, an expert panel on PBC, working under the auspices of the American 
Association for the Study of Liver Disease (AASLD), agreed that histology should neither be 
included in prognostic scoring models nor used as a primary endpoint in clinical trials.85 A 
recently proposed histologic scoring system taking into account several of the histological 
features discussed awaits further validation.86 
Serological factors
AMA are highly specific for PBC and a cornerstone for establishment of the diagnosis. 
Patients having positive AMA in combination with normal serum liver biochemical tests and 
without symptoms are likely to develop PBC over time.87 However, neither AMA status nor 
AMA titer has been shown to be correlated with prognosis.88, 89 AMA subtypes were found 
to be associated with a progressive course in some studies,90 but this was not confirmed by 
others.91, 92
It has been suggested that patients with ANA of the anti-gp210 subtype have more 
active disease and are more likely to develop liver failure.93-95
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Biochemical prognostic factors
From a diagnostic point of view increased serum alkaline phosphatase with or without 
increased gamma-glutamyl transpeptidase (γ-GT) are of key importance, and both are 
considered as early markers of cholestasis in contrast to elevated serum total bilirubin 
values, which are clearly suggestive of more advanced disease.96 
It has been known for several decades that serum bilirubin is one of the most powerful 
predictors of prognosis in PBC and this variable has been incorporated in most scoring and 
prediction models. A classical study demonstrated a two-phase pattern of bilirubin during the 
course of the disease;97 a first phase in which serum bilirubin remains stable for many years 
and a second phase of rapidly increasing values, the so called ‘acceleration phase’. Repeated 
measurements of serum bilirubin >2.0mg/dl was a sign of late stage disease and preceded 
death within a few years.97 A French study showed that persistent abnormal bilirubin levels 
were predictive for extensive fibrosis, with a positive predictive value of 90%.83 In patients 
in whom serum bilirubin normalizes upon treatment with UDCA, transplant-free survival 
was found to be comparable with that in placebo-treated patients with initial normal serum 
bilirubin levels.98 The same applied to survival of patients without normalization of bilirubin 
and placebo-using patients with abnormal bilirubin values at baseline. In other words, 
serum bilirubin values retain prognostic utility irrespective of treatment, underlining the 
utility of serum bilirubin as a useful surrogate endpoint of outcome. 
Albumin is regarded as another important and powerful biochemical predictor of liver 
decompensation. Both, low serum albumin and high bilirubin values were shown to be 
independent predictors of the development of cirrhosis83 and mortality.70 
Angulo and colleagues were the first to report on the prognostic impact of changes in 
alkaline phosphatase values upon treatment with UDCA, showing that alkaline phosphatase 
values ≥2-fold the upper limit of normal (ULN) after 6 months of treatment predicted future 
treatment failure.99 Several recent studies have also clearly demonstrated that quantitative 
decreases in bilirubin, albumin, alkaline phosphatase, aspartate aminotransferase (AST) and/
or γ-GT levels after 6 months, 1 year or 2 years UDCA treatment, are predictive for improved 
transplant-free survival (Table 2). Responders according to these criteria were likely to have 
survival rates comparable with a general population. These biochemical response criteria 
are useful and now generally accepted tools for stratification purposes and for identifying 
patients in need of additional treatment.
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Table 2. Biochemical response criteria for risk stratification in UDCA-treated primary biliary cirrhosis 
patients
Criteriaref Definition of biochemical response Evaluation
time point
N
Mayo, 199999 ALP <2.0xULN 6 months 180
Barcelona, 200638 >40% decrease of ALP or normalization 1 year 192
Paris-1, 200839 ALP <3.0xULN, AST <2.0xULN and bilirubin ≤1mg/dL 1 year 292
Rotterdam, 200940 Normalization of abnormal bilirubin and/or albumin 1 year 375
Toronto, 201041, 100 ALP ≤1.67xULN 2 years 69
Paris-2#, 201142 ALP ≤1.5xULN, AST ≤1.5xULN and bilirubin ≤1mg/dL 1 year 165
Ehim^, 2011101, 102 ≥70% decrease of γ-GT 6 months 138
Momah/Lindor, 2011103 ALP ≤1.67xULN and bilirubin ≤1mg/dL 1 year 73
Trivedi, 2014104 Paris-I, Paris-II, Barcelona or Toronto criteria and APRI ≤0.54 1 year 386
Abbreviations: ALP, alkaline phosphatase; AST, aspartate transaminase; APRI, AST to platelet ratio 
index
#only early PBC patients, ^Japanese population 
Presence of symptoms at time of diagnosis 
Risk stratification according to the presence of symptoms at time of diagnosis has been 
the subject of many studies over the past decades.84, 105-110 Of note, most studies did not 
use validated symptom assessment measures, which is essential for assessing the impact 
of subjective parameters, such as fatigue or pruritus. Therefore interpretation of such 
studies may be difficult. Most studies have reported that asymptomatic patients have 
earlier histologic stage of disease compared with symptomatic patients, in addition to 
more favourable liver enzyme profiles and lower bilirubin and higher albumin levels.111 
Several studies showed that a substantial proportion of asymptomatic patients will develop 
symptoms over time.87, 106, 109, 111, 112 The vast majority (95%) of asymptomatic patients followed 
for up to 20 years will become symptomatic.28 Once symptoms appear, survival of initially 
asymptomatic patients is comparable with survival of patients who initially presented with 
symptoms.108, 111 Therefore asymptomatic PBC patients rather appear to represent an earlier 
stage of the disease than a separate clinical entity.  
Gender and age at time of diagnosis
Data on the prognostic significance of factors such as gender or age are scare. The low 
prevalence of male or young patients with PBC (e.g. <35 years) has limited the possibility 
of studying these factors. In a large population-based study from Canada a higher risk 
of worse outcome was reported for males with PBC compared with females.75 However, 
importantly is has been observed by several studies that male patients appear to present 
in a later stage of disease and this might be an important prognostic confounder explaining 
differences in prognosis between males and females. A recent landmark study from the UK 
PBC consortium clearly showed the impact of important disease subgroups in a study cohort 
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including 2353 PBC patients.113 Importantly, male patients were less likely to respond to 
UDCA treatment and were at higher risk of worse outcome. Another important finding was 
an inverse relationship between age and likelihood to respond to UDCA. Thus, gender and 
age appear to be important in predicting prognosis in PBC. 
PREDICTION OF OUTCOMES
Liver transplant-free survival
The ability to reliably predict outcome in patients with PBC is critically important in clinical 
management and an essential requirement for patient counselling and timing of diagnostic 
procedures and therapeutic interventions. Mathematical prediction models, either time-
fixed or time-dependent, have been developed to predict the probability of survival using 
biochemical, clinical and/or histological features. Serum bilirubin and age are the main 
components of almost all proposed models.79, 84, 114-117  
In the early eighties Roll et al. showed that age at time of diagnosis, presence of 
hepatomegaly and increased serum bilirubin were all independently associated with 
survival.84 Notably, portal fibrosis was an independent predictor of prolonged survival in this 
study. Other studies identified (log)bilirubin,107, 117, 118 variceal bleeding107 albumin, age and 
ascites118 as independent predictors of outcome. In a later study Bonsel et al. constructed 
a prognostic model incorporating nine variables: log(bilirubin), age, albumin, HBsAg, 
neurological complications, varices, ascites, clinical icterus and Quick-time prolongation.115  
Two well defined and cross-validated models are the European Model and the Mayo risk 
score. The European model was published in 1985 by Christensen et al. based on data from 
248 patients, originally included in an azathioprine placebo-controlled trial.79 This time-fixed 
model included age at time of diagnosis, bilirubin, albumin, cirrhosis, central cholestasis 
and usage of azathioprine at baseline. In 1993 this group published two time-dependent 
models; one included only clinical and biochemical variables (bilirubin, ascites, albumin, age 
and gastrointestinal bleeding) and one extended version included additionally IgM and two 
histological variables (central cholestasis and cirrhosis). On the other hand, the Mayo risk 
score is the most frequently used model in PBC to predict short-term survival probability. 
This model was published in 1989 and cross-validated in independent cohorts.114, 119 The 
following clinical and biochemical variables were included:  age, serum bilirubin, serum 
albumin, prothrombin time (PT) and severity of edema. A great advantage of this model was 
that liver histology was not required to calculate the risk score. The original model was based 
on baseline characteristics and less useful to predict survival over time. An adapted Mayo 
model was proposed in 1994 using the same variables (INR instead of PT) to predict short-
term (<2 years) survival or time to transplantation at any time point during follow-up.120 
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Data on the predictive value of the Mayo score after the introduction of UDCA treatment 
is conflicting. Kilmurry et al. showed that in a group of 222 patients originally included 
in an UDCA trial, the Mayo model remained a useful tool for prediction of survival when 
calculations are repeated after 6 months treatment.121  Later studies suggested that the 
Mayo score overestimated the risk of death when applied before the start of treatment.70, 
72, 122 In a general sense the Mayo Risk Score is a useful tool to stratify patients for survival 
and possibly for clinical trials. A simplified model of the Mayo model was proposed by Kim 
et al.,123 and web based applications are available for the Mayo model, which facilitate its 
usage in clinical practice. 
In addition, more general prediction liver scores are used in PBC, such as the Model of 
End-Stage Liver Disease (MELD) score and the Child-Turcotte-Pugh-score.124, 125 The MELD 
score is based on  serum bilirubin, serum creatinine and INR. This score was originally 
proposed as a prognostic marker for the outcome after placement of a transjugular 
intrahepatic portosystemic shunt (TIPSS),126 and currently used for liver organ allocation. 
We believe that the MELD score does not perform well in PBC and may result in excessive 
waiting time. 
Portal hypertension and esophageal varices
Esophageal varices may develop in the cirrhotic and pre-cirrhotic stages of PBC.68, 69 
Survival of PBC patients who develop esophageal varices has been reported to be poor.127, 
128 Patanwala et al. reported a 5-year survival rate of 63% and 91% for patients with and 
without esophageal varices, respectively. The poor prognosis associated with esophageal 
varices may partly reflect the advanced stage of the disease in the majority of cases who 
develop varices, but may also be related to mortality associated with variceal bleeding. 
Therefore tools for timely diagnosis of varices and institution of prophylactic treatment are 
of obvious clinical importance. 
A Mayo risk score ≥4.0 was seen in 93% of patients who developed esophageal varices,99 
while another study identified a Mayo risk score ≥4.5 together with a platelet count of 
<140.000/mm as independent risk factors for development of esophageal varices.129 The 
current AASLD guideline on PBC recommends surveillance for esophageal varices of patients 
with a platelet count of <140.000/mm3 or Mayo risk score >4.1.33 
Recently the Newcastle Varices in PBC Score was proposed to predict esophageal 
varices,128 based on a retrospective study including 330 PBC patients. This score was 
validated externally in two independent cohorts. Low albumin, low platelet count, abnormal 
alkaline phosphatase values and splenomegaly were independent predictors of varices 
development. An adapted score was proposed excluding splenomegaly to improve the 
usability in clinical practice and an online calculator is available (http://www.uk-pbc.com/
resources/uk-pbc-varice-prediction-tool.html).  
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Prediction of hepatocellular carcinoma (HCC)
Primary liver cancer is a top five cause of cancer in men versus seventh in women and one 
of the most common causes of cancer death worldwide. HCC is most common form of liver 
cancer. HCC usually arises in patients with underlying chronic liver diseases, such as viral 
infections with chronic hepatitis B and C and alcohol hepatitis.130 A recent systematic review 
and meta-analysis demonstrated a pooled relative risk of the development of HCC of 18.80 
(95% CI, 10-81-26.79) for PBC patients compared with a general population, making HCC the 
most prevalent cancer in PBC.131 The outcome of patients with HCC is poor. 
HCC is less frequently seen in patients who initially present with early stage disease.132, 
133 Jones et al. followed-up 667 patients with early (stage I or II) and late (stage III or IV) 
stage disease, and both groups over the same period of time. All 16 HCC cases in this study 
were found in patients with advanced disease (stage III or IV) and not in patients with early 
disease (stage I or II).134 A similar finding was reported by Floreani et al.135 Additional Greek 
and Dutch studies clearly showed that despite the differences in disease stages at baseline, 
all HCC cases had advanced disease at time of HCC diagnosis.40, 136 However, a study from 
Japan of 178 HCC cases, described HCC cases among all four histological stages,137 especially 
in males. Histological stage at time of PBC diagnosis was independently associated with 
development of HCC for females, but not for males. These findings suggest that once 
cirrhosis occurs, risk of HCC development increases for females, but males may be at risk 
at any histological stage of disease. The Japanese study also showed a 10-year incidence of 
HCC for males versus females of 6.5% versus 2.0% (P < 0.0001). Several other studies also 
have demonstrated that in general males are more likely to develop HCC than females.132-134 
Estrogens are considered as having possibly protective effect on HCC development.   
Male gender and advanced disease are the most frequently reported risk factors for HCC 
in PBC (Table 3). Suzuki et al. proposed a highly accurate prediction model (area under the 
curve of 0.95) to predict development of HCC. Patients with older age, male sex, history 
of blood transfusion and any signs of portal hypertension or cirrhosis were more likely 
to develop HCC.133 These intriguing results await confirmation by other studies. Recently, 
absence of biochemical response in UDCA-treated PBC patients was proposed as another 
important risk factor for HCC. 138 
Surveillance strategies resulting in early diagnosis of HCC may improve outcome. Clearly, 
routine screening of all PBC patients on a regular basis is not practical. The current AASLD PBC 
guideline suggests that surveillance of HCC in PBC should be performed in cirrhotic patients 
and older men.33 Possibly, the recently reported overwhelming prognostic importance of 
biochemical response to UDCA may prompt future modifications of present guidelines.
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OUTLINE OF THE THESIS
This thesis focuses on risk stratification in PBC. Studies included in this thesis address 
surrogate endpoints, biochemical response to UDCA treatment, and risk factors for mortality 
and liver cancer.
Chapter 1 provides an introduction to the epidemiology, pathogenesis, clinical presentation, 
diagnosis, treatment, prognosis and the prediction of outcomes in PBC.  
Chapters 2.1 and 2.2 focus on surrogate endpoints in PBC. PBC is a rare and chronic liver 
disease, that slowly progresses to cirrhosis if untreated. UDCA, the only available medical 
treatment for PBC, has markedly improved the expected transplant-free survival probability, 
however, a substantial number of patients have an insufficient response to UDCA and these 
patients have an unmet medical need for new therapies. Presently, new therapies are under 
evaluation, however, it is debated what study endpoints should be used. Early clinical trials 
of UDCA evaluated clinical endpoints such as liver transplantation and death, but most 
cases of PBC are now diagnosed at an earlier stage of disease and UDCA therapy is initiated 
shortly after diagnosis, further affecting the ability to assess the clinical benefit of new 
therapies in a timely and realistic manner. Thus, surrogate endpoints of clinical outcomes 
are urgently needed to evaluate treatments effects. In chapter 2.1 and 2.2 we assess the 
utility of the non-invasive biochemical variables serum alkaline phosphatase and bilirubin as 
robust surrogate endpoints of liver transplant-free survival. Their association, alone and in 
combination, with liver transplant-free survival is tested in different settings. 
Chapters 3 and 4 deal with the significance of therapeutic response to UDCA and methods 
to quantify this response. Reliable identification of patients with an inadequate response to 
UDCA is of obvious key importance in clinical management, in particular for selecting those 
individuals who could benefit from additional, second-line medical therapies, but equally 
of those in whom UDCA mono-therapy can safely be continued. Over the past years several 
stratification tools using biochemical variables have been identified to identify high- and 
low-risk patients early in the treatment course. However, it is unclear how this concept of 
biochemical response to UDCA is used to guide further decision-making. Chapter 3 contains 
a Dutch nationwide study exploring the impact of the concept of biochemical treatment 
response to UDCA in daily practice. Current biochemical response criteria have limitations 
to accurately identify PBC patients with an insufficient response to UDCA. In chapter 4 a new 
stratification tool is presented based on non-invasive biochemical and clinical variables for 
early identification of patients with an insufficient treatment response to UDCA.
HCC is an infrequent, but critical event in PBC. Given its relative rarity, robust risk 
assessment has remained a challenge and current guidelines are mainly based on relatively 
small, single-centre studies. Chapter 5 shows the results of a multicentre international 
cohort study assessing incidence and risk factors for HCC in PBC.
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1
PBC predominantly affects middle-aged females. Considering its low prevalence, limited 
data is available on specific subgroups, such as male patients and young patients. Therefore, 
the aim of chapter 6 is to identify sex and age differences in biochemical response and 
transplant-free survival among PBC patients. 
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ABSTRACT
Background & Aims: Non-invasive surrogate endpoints of long-term outcomes of patients 
with primary biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate 
potential treatments. We performed a meta-analysis of individual patient data from cohort 
studies to evaluate whether patients’ levels of alkaline phosphatase and bilirubin correlate 
with their outcomes and can be used as surrogate endpoints.
Methods: We performed a meta-analysis of data from 4845 patients included in 15 North 
American and European long-term follow-up cohort studies. Levels of alkaline phosphatase 
and bilirubin were analyzed in different settings and subpopulations at different time points 
relative to the clinical endpoint (liver transplantation or death).
Results: Of the 4845 patients, 1118 reached a clinical endpoint. The median follow-up 
period was 7.3 years; 77% survived for 10 years after study enrollment. Levels of alkaline 
phosphatase and bilirubin measured at study enrollment (baseline) and each year for 5 years 
were strongly associated with clinical outcomes (lower levels were associated with longer 
transplant-free survival). At 1 year after study enrollment, levels of alkaline phosphatase 
that were 2.0 times the upper limit of normal (ULN) best predicted patient outcome (C 
statistic, 0.71) but not significantly better than other thresholds. Of patients with alkaline 
phosphatase levels ≤2.0 times the ULN, 84% survived for 10 years compared with 62% of 
those with levels >2.0 times the ULN (p<.0001). Absolute levels of alkaline phosphatase 1 
year after study enrollment predicted patient outcomes better than percentage change in 
level. One year after study enrollment, a bilirubin level 1.0 times the ULN best predicted 
patient transplant-free survival (C statistic, 0.79). Of patients with bilirubin levels ≤1.0 times 
the ULN, 86% survived for 10 years after study enrollment compared with 41% of those with 
levels >1.0 times the ULN (p<.0001). Combining levels of alkaline phosphatase and bilirubin 
increased the ability to predict patient survival times. We confirmed the predictive value of 
alkaline phosphatase and bilirubin levels in multiple subgroups, such as patients who had 
not received treatment with ursodeoxycholic acid, and at different time points after study 
enrollment.
Conclusions: Levels of alkaline phosphatase and bilirubin can predict outcomes (liver 
transplantation or death) of patients with PBC and might be used as surrogate endpoints 
in therapy trials.
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INTRODUCTION
Primary biliary cirrhosis (PBC) is a rare, chronic, and slowly progressive autoimmune 
hepatobiliary disease. PBC typically progresses to cirrhosis, which may lead to complications 
from liver failure and premature death.1 Presently, most patients with PBC are treated with 
ursodeoxycholic acid (UDCA), the only approved therapy for PBC, which is in keeping with 
treatment guidelines.2, 3 Although UDCA therapy has a marked impact on clinical outcomes 
in patients with PBC, up to 40% of patients have an insufficient response to this treatment 
and accordingly have a significantly increased risk of developing an adverse outcome, such 
as liver transplantation or death.4-8 Therefore, there is a pressing unmet medical need for 
better therapies for this serious disease. 
A major challenge for patients, health care providers, and drug developers is the slowly 
progressive nature of PBC, which effectively precludes the evaluation of classic clinical 
outcomes such as transplant-free survival. The low prevalence of PBC also represents a 
significant barrier to conducting large controlled clinical outcome trials in patients with this 
disease. Clinical endpoints such as liver transplantation and death were evaluated in an 
early primary interventional trial of UDCA in patients with PBC,9 but most cases of PBC are 
now diagnosed at an earlier stage of disease and UDCA therapy is initiated shortly after 
diagnosis, further affecting the ability to assess the clinical benefit of new PBC therapies in a 
timely and realistic manner. Thus, the evaluation of scientifically valid surrogate parameters 
for clinical outcomes is inevitable at least at some stage in the development pathway. 
Further evaluation of possible surrogates for clinical benefit are needed, particularly with 
a focus on using large data sets that are representative of the spectrum of disease globally 
and sufficiently powered through size, duration of follow-up, and numbers of clinical events 
to refine the scientific validity of specific biochemical surrogates. 
Serum bilirubin is well established as an independent predictor of prognosis in PBC, 
regardless of treatment.10-12 In addition, bilirubin has previously been shown to be predictive 
of clinical outcomes across other liver diseases and is incorporated in several commonly 
used prognostic scoring models, such as the Child–Turcotte–Pugh score,13, 14 the Model of 
End-Stage Liver Disease (MELD),15 and, specifically in PBC, the Mayo PBC score.16 However, 
despite the proven prognostic value of bilirubin, only patients with relatively advanced 
disease are likely to show meaningful changes in bilirubin levels that are stratifying. A 
biochemical variable and potentially more broadly applicable surrogate endpoint is alkaline 
phosphatase, an isoenzyme involved in dephosphorylation.17 An elevated level of alkaline 
phosphatase, a marker of cholestasis, is typically seen across the spectrum of PBC disease 
severity and is a key component of the diagnosis of PBC in both the American and European 
guidelines.2, 3 The relationship between alkaline phosphatase levels and the risk of adverse 
outcomes in PBC has been extensively documented in several relatively small studies,4, 5, 
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7, 8, 18, 19 but no systematic effort has been reported to date using a pooled meta-analysis 
approach to validate a biochemical surrogate for use in clinical studies of PBC. 
We sought to investigate how serum alkaline phosphatase and bilirubin levels 
individually and in combination, correlate with transplant-free survival to determine the 
prognostic significance of these biochemical variables and hence their utility as robust 
surrogate endpoints for therapeutic PBC trials. To do so, we assembled a large, international, 
observational PBC database, allowing for a robust individual patient–level meta-analysis, to 
ensure both a rigorous statistical assessment and widespread applicability.
METHODS
Study design and study population
This study was a meta-analysis performed by the Global PBC Study Group, an international 
and multicenter collaboration between 15 liver centers in 8 North American and European 
countries, which combined individual patient data from major long-term follow-up cohorts. 
Most individual databases contained prospectively collected follow-up data on patients 
starting UDCA therapy. 
This study was conducted in accordance with the protocol and the principles of the 
Declaration of Helsinki. The protocol was reviewed and approved by the institutional 
research board of the corresponding center and at each participating center in accordance 
with local regulations. 
Both UDCA-treated and non-treated patients with an established diagnosis of PBC in 
accordance with European and American guidelines were eligible for inclusion in this study.2, 
3 Patients were excluded from analysis if follow-up data were insufficient or unavailable, the 
start date of treatment or the exact date of major clinical events was unknown, or they had 
concomitant liver disease.
Data collection and quality assessment
Collected clinical and laboratory data included sex, age, diagnosis of PBC, liver histology, 
treatment (type of medication, dosage, and duration), duration and last date of follow-
up, baseline antimitochondrial antibody status, baseline and yearly laboratory levels 
(serum alkaline phosphatase, total bilirubin, albumin, aspartate aminotransferase, alanine 
aminotransferase, γ-glutamyl transpeptidase, and platelets), and outcomes (death and cause 
of death, liver transplantation, hepatocellular carcinoma, ascites, and variceal bleeding). 
Liver histology performed within 1 year of study entry or documented cirrhosis 
before study entry was classified as a baseline biopsy. Histological data was assessed for 
severity according to Ludwig20 and Scheuer’s21 classification. Disease stage was classified 
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histologically as early (stage I and II) or late (stage III or IV) and biochemically using serum 
albumin and bilirubin levels. According to this biochemical classification, early stage was 
defined by normal bilirubin and albumin levels, moderately advanced disease was defined 
by an abnormal bilirubin or albumin level, and advanced disease was defined by abnormal 
bilirubin and albumin levels.22 
Completeness, plausibility, and validity of the data were carefully verified. Extensive 
efforts, including site visits with review of medical charts, were undertaken to retrieve 
missing data. Data of the original cohorts were collected through the end of December 
2012.
Statistical analysis
Study entry was defined as the start date of UDCA therapy or the date of the first center visit 
for patients not treated with UDCA. The primary endpoint was defined as a composite of 
either liver transplantation or death. Patients without documented events during follow-up 
were censored at their last follow-up visit.
To study the association between the absolute alkaline phosphatase and bilirubin levels, 
the hazard ratios (HRs) of liver transplantation or death were estimated by applying a cubic 
spline function of alkaline phosphatase and bilirubin at baseline and yearly up to 5 years of 
follow-up.
To find an optimal threshold for each variable, alkaline phosphatase and bilirubin levels 
at 1 year of follow-up were categorized according to multiple thresholds ranging from 1.0 to 
3.0 times the upper limit of normal (ULN) in steps of 0.1 (including 1.67 times the ULN7 for 
alkaline phosphatase levels).
The C statistic was calculated for each of these thresholds to evaluate their ability to 
predict liver transplant-free survival. Accompanying HRs were calculated for each threshold 
by using the Cox proportional hazard regression model. The log-likelihood test was used to 
assess significance. Transplant-free survival was assessed for the peak thresholds of alkaline 
phosphatase and bilirubin levels and for a combination of both by Kaplan–Meier estimates. 
Log-rank test was used for comparisons between groups.
In addition to the predictive ability of absolute levels of alkaline phosphatase, the 
percentage change in alkaline phosphatase levels4 from baseline to 1-year follow-up was 
evaluated using the same approach. 
All analyses were stratified by center to account for possible heterogeneity across center 
populations. The effects of alkaline phosphatase and bilirubin were adjusted for year of 
diagnosis, age at study entry, UDCA therapy, and sex. 
To investigate if alkaline phosphatase and bilirubin levels are meaningful surrogate 
endpoints, the association with the clinical endpoint must hold true independent of time 
and specific patient subgroups. Therefore, the survival analyses were repeated at different 
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time points and for multiple subgroups of patients. The time points analyzed were baseline 
and yearly up to 5 years of follow-up. Given the nature of this study, alkaline phosphatase or 
bilirubin levels were not always available for every patient at these time points. Accordingly, 
we aimed for the optimal use of the available data by assessing the association with hard 
clinical endpoints at baseline and several intervals thereafter up to 5 years. Subgroups 
were defined by treatment (UDCA-treated and non-treated patients), baseline alkaline 
phosphatase levels (>2.0 times the ULN and >4.0 times the ULN), baseline bilirubin levels 
(>1 times the ULN and >3 times the ULN), PBC disease state based on both histology and 
biochemistry, age at time of diagnosis (younger than 45 years and 45 years or older),23 sex, 
and date of diagnosis (before 1990, 1990–1999, and 2000–2009). 
Normally distributed data are presented as mean ± standard deviation (SD) and skewed 
distributed data as median and interquartile range. All analyses were 2 sided. p<.05 was 
considered statistically significant. Statistical analyses were performed with IBM SPSS 
Statistics 22.0 (SPSS Inc, Chicago, IL) and SAS 9.3 (SAS institute, Cary, NC).
RESULTS
Baseline data
Data were obtained from 6191 patients with PBC, of whom 4845 met the inclusion criteria 
(Figure 1). A total of 65,642 patient visits and a mean of 11 visits per patient were reported 
across the entire cohort, with a median of 132 elapsing days between visits. Cohort 
characteristics per center are summarized in Table 1. The year in which PBC was diagnosed 
ranged from 1959 to 2012. The diagnosis was established after 1990 for 79% of patients, 
and the median year of diagnosis was 1998 (interquartile range, 1991–2004). The median 
follow-up period was 7.3 years (interquartile range, 3.6–11.5 years) for the cohort, ranging 
from 6 months to 34 years. 
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Figure 1. Flow chart
Flow diagram of patients included in this study. 
Clinical and biochemical patient characteristics are shown in Table 2. Overall, the 
demographics were consistent with previous reports of PBC disease epidemiology. Most 
patients (4119 [85%]) were treated with UDCA at a median dosage of 12.3 mg*kg-1*day-1 
(interquartile range 9.4–14.6 mg*kg-1*day-1). Histological stage of disease was available for 
76% of patients who had undergone a liver biopsy; most had a diagnosis of early disease 
(stage I or II). 
During follow-up, 1118 patients reached a clinical endpoint; 389 underwent liver 
transplantation and 729 died; 358 (49%) died of liver-related causes, 245 patients (34%) 
died of other causes, and the cause of death was unknown for 126 patients (17%). In the 
total cohort, 5-year transplant-free survival was 88%, 10-year survival was 77%, and 15-
year survival was 63%; in UDCA-treated patients, these findings were 90%, 78%, and 66%, 
respectively, and in non-treated patients 79%, 59%, and 32%, respectively, (treated vs non-
treated, p<.0001). 
The effects of factors adjusted for in further analyses are shown in Table 3.
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Table 2. Baseline patient characteristics
Total cohort
(n = 4845)
Age at entry (years)a 54.5 (12.0)
Female, n (%) 4348 (90%)
AMA+, n (%) 4280 (88%)
Year of diagnosisb 1998 (1991-2004)
Year of diagnosis, time frame 1959-2012
Histological disease stage, n (%)c
Stage I 1017 (27%)
Stage II 862 (23%)
Stage III 483 (13%)
Stage IV 454 (12%)
Not available 953 (25%)
Biochemical disease stage, n (%)d
Early 2040 (42%)
Moderately advanced 730 (15%)
Advanced 259 (5%)
Not available 1816 (38%)
Baseline alkaline phosphatase levels, n (%)
>2.0xULN 1931 (52%)
>4.0xULN 816 (22%)
Not available 1140 (24%)
UDCA treated patients, n (%)e 4119 (85%)
Laboratory data at entryb
Serum bilirubin (xULN) 0.67 (0.45-1.06)
Not available 1118 (23%)
Serum alkaline phosphatase (xULN) 2.10 (1.31-3.72)
Not available 1140 (24%)
Abbreviations: AMA, antimitochondrial antibody; UDCA, ursodeoxycholic acid; ULN, upper limit of 
normal.
aData is expressed as mean and standard deviation 
bData is expressed as median and interquartile range
cHistological disease stage according to Ludwig and Scheuer’s classification
dBiochemical disease stage according to Rotterdam criteria (using albumin and bilirubin)22
e640 subjects were non-treated and 86 subjects were without definitive information on UDCA use 
Table 3. Univariable and multivariable analysis showing the effects of variables at baseline predictive 
for liver transplantation and death 
Univariable analysis Multivariable analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Year of diagnosis (year) 0.95 (0.94-0.95) <0.001 0.95 (0.94-0.96) <0.001
Age at study entry (year) 1.04 (1.03-1.04) <0.001 1.03 (1.03-1.04) <0.001
UDCA treatment 0.59 (0.50-0.71) <0.001 0.61 (0.51-0.74) <0.001
Male gender 1.52 (1.28-1.80) <0.001 1.46 (1.22-1.75) <0.001
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The association between alkaline phosphatase and bilirubin levels and the risk of liver 
transplantation or death
A log-linear association was observed between alkaline phosphatase levels and the risk of 
liver transplantation and death after 1 year and up to 5 years of follow-up, whereby higher 
alkaline phosphatase levels were associated with reduced transplant-free survival. This 
association was also found for baseline alkaline phosphatase levels, thus irrespective of 
subsequent UDCA therapy (Figure 2A and Figure 3A). Abnormal bilirubin levels were even 
more strongly associated with poor clinical outcome at baseline and up to 5 years of follow-
up (Figure 2B and Figure 3B).
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Figure 2. Hazard of liver transplantation or death for alkaline phosphatase and bilirubin levels 
The hazard of liver transplantation or death for (A) alkaline phosphatase levels and (B) bilirubin levels 
at different time points estimated with cubic spline function.
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Figure 3. Hazard of liver transplantation or death for alkaline phosphatase and bilirubin levels 
The hazard of liver transplantation or death for (A) alkaline phosphatase levels and (B) bilirubin levels 
at different time points estimated with cubic spline function.
Optimal threshold for alkaline phosphatase and bilirubin levels and the risk of liver 
transplantation and death
The study population was analyzed according to a multitude of thresholds for alkaline 
phosphatase levels at 1 year of follow-up. This analysis consistently showed that patients 
with alkaline phosphatase levels below any of these thresholds had significantly improved 
transplant-free survival compared with patients with alkaline phosphatase levels above the 
thresholds (Table 4). 
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2.1
After 1 year of follow-up, while all thresholds were predictive of outcomes, a threshold 
of 2.0 times the ULN for alkaline phosphatase levels was found to have the highest predictive 
ability (C statistic, 0.71; 95% confidence interval [CI], 0.69–0.73). Notably, this threshold was 
not a significantly better predictor than the other thresholds, such as 1.5 times the ULN,8 
1.67 times the ULN,7, 19 or 3.0 times the ULN5 (Table 4 and Figure 4). Similarly, all assessed 
bilirubin thresholds were predictive of outcomes. For bilirubin, a threshold of 1.0 times the 
ULN had the highest predictive ability (C statistic, 0.79; 95% CI, 0.77–0.80) (Table 4). 
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Figure 4. Performance of alkaline phosphatase thresholds 
C statistic was performed for different thresholds for alkaline phosphatase levels at one year follow-
up. The C statistic reflects the predictive accuracy of alkaline phosphatase thresholds to distinguish 
patients with a high risk of liver transplantation or death from patients with a low risk. 
The 5-, 10-, and 15-year transplant-free survival rates for patients with alkaline 
phosphatase levels ≤2.0 times the ULN were 94%, 84%, and 73%, respectively; for patients 
with alkaline phosphatase levels >2.0 times the ULN, these rates were 81%, 62%, and 50%, 
respectively (p<.0001), as shown in Figure 5A. The accompanying 5-, 10-, and 15-year 
transplant-free survival rates for patients with normal bilirubin levels after 1 year of follow-
up were 95%, 86%, and 74%, respectively; for patients with abnormal bilirubin levels these 
rates were 65%, 41%, and 30%, respectively (p<.0001) (Figure 5B).
The prognostic information provided by alkaline phosphatase levels remained important 
in addition to bilirubin levels; the risk of liver transplantation or death of patients with alkaline 
phosphatase levels >2.0 times the ULN was significantly higher in both those patients with 
normal (≤1 times the ULN) and abnormal bilirubin (>1 times the ULN) levels. The 5-, 10-, and 
15-year transplant-free survival rates in the normal bilirubin group for patients with alkaline 
phosphatase levels ≤2.0 times the ULN were 97%, 89%, and 79%, respectively; for patients 
with alkaline phosphatase levels >2.0 times the ULN, these rates were 95%, 82%, and 68%, 
respectively (p<.0001). In the abnormal bilirubin group, these rates were 74%, 51%, and 
39%, respectively, for patients with alkaline phosphatase levels ≤2.0 times the ULN and 63%, 
34%, and 24%, respectively, for patients with alkaline phosphatase levels >2.0 times the ULN 
(p<.0001) (Figure 5C). 
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Figure 5. Liver transplantation-free survival
(A) Transplant-free survival of patients with alkaline phosphatase levels ≤2.0xULN versus >2.0xULN 
at one year follow-up. (B) Transplant-free survival of patients with bilirubin levels ≤1.0xULN versus 
>1.0xULN at one year follow-up. (C) Transplant-free survival of patients with alkaline phosphatase 
levels ≤2.0xULN versus >2.0xULN at one year follow-up within both, patients with bilirubin levels 
≤1xULN and >1xULN. 
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2.1
An alkaline phosphatase threshold of 2.0 times the ULN was also predictive in addition 
to other bilirubin thresholds between 1.0 times and 3.0 times the ULN, but was not 
predictive in addition to bilirubin levels >3 times the ULN (HR, 0.71; 95% CI, 0.39–1.32; 
p=.29). Comparable results were found for other alkaline phosphatase thresholds (eg, 1.5 
times the ULN and 1.67 times the ULN in combination with normal or abnormal bilirubin 
levels) (data not shown).
The predictive value of percentage changes in alkaline phosphatase levels at 1-year follow-
up 
A prior study showed that patients who achieved a normal alkaline phosphatase level or had 
a >40% decrease in alkaline phosphatase levels after UDCA therapy had a normal prognosis.4 
In line with this study, the percentage change in alkaline phosphatase levels from baseline to 
1-year follow-up was predictive of outcome; the greater the percentage decrease in alkaline 
phosphatase levels, the better the transplant-free survival (HR per 10% change in alkaline 
phosphatase levels 0.98; 95% CI, 0.96–0.99; p<.01). 
A >40% decrease in alkaline phosphatase levels was found to be significant in predicting 
outcome (Table 5). The predictive value of percentage decrease of alkaline phosphatase 
levels with UDCA therapy was independent of the baseline alkaline phosphatase levels in 
patients with a decrease between 0–40% and >40% compared with patients without any 
decrease (Figure 6). 
However, the percentage decrease in alkaline phosphatase levels did not add prognostic 
information to absolute alkaline phosphatase levels after 1 year of follow-up (HR per 10% 
change in alkaline phosphatase levels 1.00; 95% CI, 0.99–1.02; p=.72), apart from very high 
alkaline phosphatase levels (>5.0 times the ULN) (HR per 10% change in alkaline phosphatase 
level, 0.86; 95% CI, 0.76–0.96; p<.005).
Table 5. Hazard ratio for predicting liver transplantation or death for percentage change of alkaline 
phosphatase levels from baseline to one year follow-up 
Percentage reduction of alkaline 
phosphatase
Hazard Ratio
(95% CI)
P-value
No reduction 1
0-10% 0.88 (0.63-1.23) .45
10-20% 0.85 (0.60-1.20) .36
20-30% 0.67 (0.48-0.95) .03
30-40% 0.84 (0.61-1.15) .23
40-50% 0.70 (0.51-0.96) .03
50-60% 0.59 (0.42-0.83) .003
>60% 0.62 (0.44-0.86) .005
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Figure 6. Liver transplant-free survival for percent decrease of alkaline phosphatase levels 
Transplant-free survival for percent decrease of alkaline phosphatase levels at one year follow-up. (A) 
Transplant-free survival of patients with >40% decrease of alkaline phosphatase levels, (B) Transplant-
free survival of patients with 0-40% decrease of alkaline phosphatase levels and (C) Transplant-free 
survival for patients with no decrease of alkaline phosphatase levels. 
Predictive ability of alkaline phosphatase and bilirubin levels across subgroups
To assess if alkaline phosphatase can be used as a predictor independent of patient 
characteristics, the previously described analyses were repeated for a range of subgroups 
(Figure 7A). Of note, using an alkaline phosphatase threshold of 2.0 times the ULN after 
1 year of follow-up was not only predictive for UDCA-treated patients but also for non-
treated patients. Similar results were seen in patients with baseline alkaline phosphatase 
levels >2.0 times the ULN and >4.0 times the ULN, patients with histologically early and 
late disease, patients with biochemically early and moderately advanced disease, patients 
45 years of age or younger at diagnosis and older than 45 years of age at diagnosis, male 
and female patients, and regardless of the year of diagnosis. Alkaline phosphatase levels 
were not predictive for patients with advanced biochemical disease (ie, patients with both 
abnormal bilirubin and albumin levels). A bilirubin threshold of 1.0 times the ULN after 1 
year of follow-up was also predictive in several subsets of patients (Figure 7B). 
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      
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Figure 7. Subgroup analyses of alkaline phosphatase and bilirubin levels
Hazard ratio of liver transplantation or death for (A) alkaline phosphatase levels >2.0xULN versus 
≤2.0xULN and (B) bilirubin levels >1.0xULN versus ≤1.0xULN at one year follow-up for different 
subgroups.
Comparable results were found for alkaline phosphatase and bilirubin at other time 
points among almost all subgroups (Table 6).
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Translation into clinical practice
For illustrative purposes, the preceding findings were translated into a practical example 
(Figure 8) to show the association of a composite surrogate endpoint (bilirubin level <1 
time the ULN and alkaline phosphatase level less than the threshold) on 5-year transplant-
free survival in different settings. Three groups of high-risk patients with PBC diagnosed 
after 1990 and treated with UDCA were defined at 2 different time points: baseline (upper 
panels) and after 1 year of UDCA therapy (lower panels). The subgroups were defined as 
follows: (1) all patients with PBC, (2) patients meeting the inclusion criteria of a recent 
clinical trial: bilirubin levels <2 times the ULN and either alkaline phosphatase levels >1.67 
times the ULN or bilirubin levels >1 time the ULN,24 and (3) patients with a bilirubin levels <3 
times the ULN and either alkaline phosphatase levels >2 times the ULN or bilirubin levels >1 
time the ULN. The surrogate endpoint was determined 1 year after inclusion. Figure 8 shows 
the proportion of patients reaching the surrogate endpoint (left panels) and accompanying 
transplant-free survival (right panels). 
If a bilirubin level <1 times the ULN and alkaline phosphatase level <2 times the ULN is 
used as a surrogate endpoint in high-risk PBC population 3 (light gray) and if patients are 
already treated with UDCA for 1 year (lower panels), the proportion of patients reaching the 
surrogate endpoint after an additional year of UDCA therapy is 18% (lower left panel), with 
an accompanying 5-year transplantation-free survival rate of 92% (lower right panel). The 
5-year transplantation-free survival rate for patients not reaching the surrogate endpoint 
was 75%. 
In summary, using higher alkaline phosphatase thresholds resulted in a lower proportion 
of patients not reaching the surrogate endpoint, with a poorer corresponding 5-year 
transplant-free survival. The 5-year transplant-free survival after continued UDCA therapy is 
irrespective of the chosen alkaline phosphatase threshold and risk population. 
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Figure 8. Translation into clinical practice 
The association of a surrogate endpoint, defined as alkaline phosphatase <threshold and bilirubin 
<1xULN, on the 5-year liver transplantation-free survival in different settings. Inclusion (diagnosed 
>1990 and initiated on UDCA) was made at baseline (upper panels) and after one year on UDCA 
treatment (lower panels). Three high risk groups were defined as follows: 1) all patients (black lines), 
2) bilirubin <2xULN and (alkaline phosphatase >1.67xULN or bilirubin >1xULN)35 (dark grey lines), and 
3) bilirubin <3xULN and (alkaline phosphatase >2xULN or bilirubin >1xULN) (light grey lines). The full 
lines represent the patients who reached the surrogate endpoint and the dotted lines those who did 
not. The left panels show the proportion of patients reaching the surrogate endpoint 1 year after 
inclusion and the right panels the corresponding 5-year transplant-free survival. 
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DISCUSSION
This study reports a robust and uniquely powered, independent evaluation of the largest 
meta-analysis of individual data on PBC to date. We unequivocally show that both increased 
serum alkaline phosphatase and bilirubin levels are strongly associated with reduced 
transplant-free survival in patients with PBC and that a combination of both variables 
improves prognostic prediction for patients. These associations are independent of use of 
UDCA and follow-up time and held for multiple subgroups. These data support that both 
alkaline phosphatase and bilirubin provide meaningful surrogate endpoints in PBC that can 
reasonably be used in clinical trials. 
Prior studies have shown an association between normalization, percentage decreases 
or absolute decreases of alkaline phosphatase levels and improved prognosis with UDCA 
therapy.4, 5, 7, 8, 18, 19 The present study reports for the first time a near log-linear association 
between alkaline phosphatase levels and transplant-free survival and clearly shows that 
the lower the alkaline phosphatase levels, the greater the transplant-free survival time. 
This applied not only to alkaline phosphatase levels during follow-up but also to baseline 
levels irrespective of subsequent UDCA therapy. The suitability of alkaline phosphatase as a 
surrogate endpoint for clinical benefit is further supported by the finding that the prognostic 
information provided by alkaline phosphatase levels was confirmed across a wide range 
of subgroups such as non-treated patients, relatively young patients, and patients with 
histologically early and late disease. This finding is of considerable clinical significance 
because alkaline phosphatase constitutes one of the 3 potential diagnostic criteria and is 
used routinely to assess disease activity. 
Our study additionally confirms that as baseline bilirubin levels or bilirubin levels increase 
over time, the likelihood of survival correspondingly decreases.10 The predictive ability of 
alkaline phosphatase levels was shown in addition to bilirubin to discriminate high-risk and 
low-risk patients. This is an important observation because bilirubin on its own is unsuitable 
as a surrogate endpoint in clinical trials because it is typically elevated only when the disease 
has progressed to the stage at which liver function becomes impaired. Most patients likely 
to be included in such studies will have normal levels precluding the possibility of observing 
potential beneficial treatment effects based on bilirubin alone. 
It has been suggested that the best way to evaluate the utility of a biomarker as a good 
surrogate endpoint may be a meta-analysis of clinical trials of one or more interventions.25 
A 4-level hierarchy of evidence to consider the validation of surrogate endpoints has been 
proposed: Level 1: a true clinical-efficacy measure; Level 2: a validated surrogate endpoint 
(for a specific disease setting and class of interventions); Level 3: a non-validated surrogate 
endpoint, yet one established to be “reasonably likely to predict clinical benefit” (for a 
specific disease setting and class of interventions); Level 4: a correlate that is a measure 
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of biological activity but that has not been established to be a higher level.26 The particular 
challenge of confirming biomarkers as surrogate endpoints in PBC is that there is only one 
approved treatment, and previous meta-analyses of published clinical trials that have been 
conducted in PBC have been interpreted in conflicting ways.27-29 Interpretation of the data is 
compromised due to design issues, such as a lack of consistent long-term follow-up.29, 30 Our 
approach was therefore to conduct a more rigorous patient level meta-analysis of existing 
cohorts of patients at centers across North America and Europe with long-term follow-up 
data of large numbers of patients with PBC. This design has sufficient power to intensively 
study alkaline phosphatase and bilirubin as potential surrogate endpoints in different 
settings, subpopulations, and time points. Based on these current results, we postulate that 
alkaline phosphatase and bilirubin levels are “reasonably likely to predict clinical benefit” in 
PBC.26 This is of relevance to future trial design for new therapeutic agents. 
Alternative surrogates have been suggested, such as liver histology,31 which may 
provide key information on treatment effects in PBC. However, liver biopsy is not routinely 
conducted in patients with PBC. Given its invasive nature and small but well-recognized 
risks,32 liver histology, with its added inherent sampling variability, is not an ideal surrogate 
for widespread use in patients with PBC. Non-invasive elastography-based assessment of 
liver fibrosis may potentially be used as a reliable alternative in the prediction of fibrosis33; 
however, further long-term evaluation is required in PBC. Similarly other biochemical 
surrogates have been suggested5, 6, 34 but as of yet are not widely studied. We focused on 
the routine biochemical measurements that have been used for many years in both the 
diagnosis and management of patients with PBC, because this approach is likely to be the 
most easily applied in practice. 
There are some limitations to our study. The availability of some clinical data (such 
as ascites, edema, pruritus, fatigue, or use of diuretics) and laboratory data (including 
prothrombin time, immunoglobulin M, and immunoglobulin G levels) in the individual 
databases varied considerably. In many cases, in particular when databases contained data 
of patients entered more than 10 to 20 years ago, it was not possible to collect these data 
consistently in a reliable way. Further, no uniform or generally accepted or validated methods 
had been used in the contributing centers to quantify subjective signs and symptoms. As a 
consequence, within the context of this study, we were unfortunately unable to include 
this type of information in our analyses and, in particular, were not able to calculate the 
Mayo risk score16 and to compare the prognostic information provided by this established 
prediction tool with that provided by alkaline phosphatase and bilirubin. 
Due to the nature of our study, biochemical data were not always available at the fixed 
time points during follow-up. This was mainly encountered when the original data had 
been collected more than 20 years ago. Data on dose changes or interruption of UDCA 
therapy was also not uniformly available. However, we believe that these limitations had no 
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major impact on the reliability of the results, considering the unique large size of the study 
population, the prospective nature of most of the data, the inclusion of both UDCA-treated 
and non-treated patients, the substantial incidence of clinical endpoints, and the duration 
of follow-up. Additionally, adjusting for missing data by multiple imputations of the data, the 
results did not change (Table 7). 
Table 7. Multivariate analysis of treated and non-treated patients following multiple imputation to 
correct for missing data values
Alkaline phosphatase >2.0xULN Bilirubin >1.0xULN
Cohorts Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Entire cohort 2.46 2.16-2.80 <.0001 4.80 4.13-5.57 <.0001
UDCA treated patients 2.49 2.15-2.88 <.0001 4.95 4.21-5.83 <.0001
UDCA non-treated patients 2.07 1.45-2.95 <.0001 3.79 2.58-5.59 <.0001
Based on our present results, any decrease in alkaline phosphatase or bilirubin levels 
translates into improved prognosis; lower levels are clearly associated with better transplant-
free survival. In our population, the most discriminative alkaline phosphatase threshold 
after 1 year of follow-up was 2.0 times the ULN, which is an earlier proposed threshold,18 
although an alkaline phosphatase threshold of 1.5 times the ULN,8 1.67 times the ULN,7, 19 
or 3.0 times ULN would all work well as a surrogate endpoint in a clinical trial setting. For 
bilirubin, the choice of threshold is even clearer; the spline plots (Figure 2) suggest that a 
choice of bilirubin <1.0 times the ULN is reasonable. However, designing clinical trials implies 
the a priori requirement to estimate the quantitative effect of an experimental intervention 
on a given endpoint. Based on the current study, we are not able to translate these data into 
a specific threshold for a clinical trial in general. 
In conclusion, our study shows that alkaline phosphatase and bilirubin levels strongly 
correlate with the ultimate outcomes of death and liver transplantation in patients with 
PBC; the lower the alkaline phosphatase and bilirubin levels the better the transplant-
free survival times. This robust analysis suggests that these variables can reasonably be 
regarded as useful surrogate endpoints in clinical trials. There is a high unmet medical 
need for new therapies for this rare autoimmune liver disease, and this study provides an 
important impetus for the selection of appropriate endpoints and to facilitate the conduct 
of meaningful therapeutic intervention trials in the absence of long-term outcome studies.
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Reply: Are levels of alkaline phosphatase and bilirubin 
surrogate markers of outcomes of patients with primary 
biliary cirrhosis?
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Dear Editor,
The comments of Giljaca, Stimac, and Gluud regarding our study are very much appreciated 
and timely. Patients with primary biliary cirrhosis (PBC) presently have only 1 therapy, 
ursodeoxycholic acid (UDCA), that is recommended universally for use globally; however, it 
fails to benefit all patients equally.
We agree that bilirubin and alkaline phosphatase have not been validated fully as true 
surrogate endpoints. In bringing together the Global PBC Study Group and publishing 
what we believe to be the largest individual patient data analysis to date in PBC, we 
comprehensively discussed the 4-level hierarchy of evidence for the validity of surrogate 
endpoints proposed by Fleming et al1 as they relate to our findings. This hierarchy is highly 
comparable with the three-level approach of Bucher et al.2 We acknowledge that, based 
on our data, bilirubin and alkaline phosphatase cannot be regarded as surrogate endpoints 
with the highest levels of evidence (level 1, true clinical- efficacy measure; level 2, validated 
surrogate endpoint). However, we clearly showed that the strong association between 
increased serum alkaline phosphatase and bilirubin levels and reduced transplant-free 
survival were independent of UDCA treatment and follow-up time and remained present 
for a range of subgroups. Given the comments raised, we have sought additional supportive 
data by analyzing alkaline phosphatase and bilirubin as time-dependent variables. UDCA-
treated patients who continued to have alkaline phosphatase levels <2-fold the upper 
limit of normal (ULN) and bilirubin levels <1-fold the ULN throughout total follow-up had 
excellent 3-, 5- and 10-year survival rates (97%, 95%, and 91% respectively), compared with 
those whose liver biochemistry did not stay normal throughout follow-up (83%, 78%, and 
62%, respectively, from onset of abnormal liver values) (Figure 1A). The same observation 
applies importantly for non-treated PBC patients. Those with alkaline phosphatase levels 
<2-fold the ULN and bilirubin levels <1-fold the ULN throughout follow-up had better 3-, 5-, 
and 10-year survival rates (92%, 89%, and 84%, respectively), than those without (74%, 61%, 
and 43%, respectively) (Figure 1B). Therefore, we continue to believe that our data robustly 
support the conclusion that both variables meet the criteria for level 3 evidence: variables 
“reasonably likely to predict clinical benefit.” 
Giljaca et al will agree that studies seeking to evaluate classic clinical outcomes, such as 
transplant-free survival, are unlikely to ever be feasible in PBC, and that there is a pressing 
need for alternative outcome measures. Additional validation studies of bilirubin and 
alkaline phosphatase as valid surrogates of outcome are necessary, as well as studies of 
other potential surrogate endpoints. 
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Figure 1. Liver transplant-free survival of primary biliary cirrhosis patients with and without alkaline 
phosphatase levels ≤2.0xULN and bilirubin levels ≤1.0xULN during follow-up
The survival curves were plotted using a clock-reset approach; patients who developed alkaline 
phosphatase levels >2.0xULN and/or bilirubin levels >1.0xULN during follow-up were censored in the 
group with alkaline phosphatase levels ≤2.0xULN and bilirubin levels ≤1.0xULN, and switched to the 
group with alkaline phosphatase levels >2.0xULN and/or bilirubin levels >1.0xULN. This analysis was 
performed in A) UDCA-treated and B) non-treated PBC patients. 
Such studies as presented by the Global PBC Study Group are thus of critical importance 
for our ability to evaluate the efficacy of promising new therapies in PBC3 as well as 
managing individual patient risk across the course of their disease.4 Future approaches and 
efforts, however, need to be realistic and deliverable, so that timely progress can be made 
to address an overt and pressing unmet patient need for new treatments in PBC. 
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CHAPTER 3
How the concept of biochemical response influenced the 
management of primary biliary cirrhosis in 831 patients 
over three decades
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ABSTRACT
Background & Aims: Criteria assessing biochemical response to ursodeoxycholic acid 
(UDCA) are established risk stratification tools in primary biliary cirrhosis (PBC). We aimed 
to evaluate to what extent biochemical response influenced patient management during a 
three decade period, and whether this changed over time.
Methods: 851 Dutch PBC patients diagnosed between 1988 and 2012 were reviewed to 
retrospectively assess patient management in relation to biochemical liver tests after one 
year UDCA treatment. Biochemical response was defined by the Paris-1 criteria. 
Results: Response was assessable for 687/851 (81%) patients; 157/687 non-responders. 
During a follow-up of 8.8 years (IQR, 4.8-13.9) 141 died and 30 underwent liver 
transplantation. Transplant-free survival of non-responders (60%) was significantly worse 
compared with responders (87%) (p<.0001).
Management was modified in 46/157 (29%) non-responders. The most frequent change 
observed, noted in 26/46 patients, was an UDCA dosage increase. Subsequently, 9/26 (35%) 
non-responders became responder within the next 2 years. Steroid treatment was started 
in 1 patient; 19 patients were referred to a tertiary center. No trend towards more frequent 
management change over time was observed (p=0.10). 
Conclusions: Changes in medical management occurred in a minority of non-responders. This 
can largely be explained by the lack of accepted response criteria and of established second-
line treatments for PBC. Nevertheless, the observation that response guided management 
did not increase over time suggests that awareness of the concept of biochemical response 
requires further attention, particularly since new treatment options in PBC will becoming 
available soon. 
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INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of autoimmune origin 
that mainly affects middle aged women.1 To date, ursodeoxycholic acid (UDCA) at a 
recommended dosage of 13-15 mg/kg/day is the only approved therapy.2, 3 
An association between biochemical variables and outcome during treatment with 
UDCA was first reported in 1999.4 Angulo and colleagues showed that patients with serum 
alkaline phosphatase levels <2 times the upper limit of normal (ULN) following 6 months of 
UDCA treatment were less likely to have treatment failure. Subsequent studies found that 
not only levels of alkaline phosphatase,5, 6 but also other biochemical variables including 
aspartate transaminase (AST), bilirubin and albumin values following one or two years of 
UDCA treatment were predictive of liver transplant-free survival.7-10 Generally, patients 
fulfilling criteria for biochemical response were shown to have a normal life expectancy, 
comparable with a matched general population, while non-responders remained at risk for 
requiring liver transplantation or premature death.5 
Despite the clear relevance of biochemical response to UDCA it has not been established 
whether biochemical response is considered an important objective in clinical practice and 
is used to guide further decision-making, in particular on possible additional second-line 
treatment. Therefore we aimed to assess the impact of biochemical response to UDCA on 
management decisions in a large and nationwide cohort of PBC patients.
PATIENTS AND METHODS
Patient population
Patients were derived from a Dutch multicenter study11 and a large epidemiological study 
regarding primary sclerosing cholangitis and primary biliary cirrhosis in the Netherlands.12 
The protocol for this project was approved by the central Committee for Research Ethics 
in Utrecht and the local ethics committees of participating hospitals (trialregister.nl no.: 
NTR2813).
Patients were diagnosed according to established criteria,2, 3 and included between 
November 1988 and December 2011 across 43 university and general hospitals. Patients 
with concomitant liver disorders, such as viral, alcoholic, and autoimmune hepatitis were 
excluded. 
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Endpoints
For current study, entry (baseline) was defined as start date of UDCA therapy. Biochemical 
response to UDCA treatment was retrospectively assessed according to Paris-1 criteria,7 
generally accepted as the criteria with best performance in predicting outcome.13, 14 Paris-1 
was defined as alkaline phosphatase <3 times the ULN, AST <2 times the ULN and bilirubin 
≤1 mg/dl after one year of UDCA treatment, and Paris-2 criteria,9 defined as alkaline 
phosphatase ≤1.5 times the ULN, AST ≤1.5 times the ULN and bilirubin ≤1 mg/dl after one 
year of UDCA treatment. A composite of liver transplantation and death was used as clinical 
endpoint. Patients who did not reach a clinical endpoint were censored at their last follow-
up visit. 
Data collection
The original database comprised clinical and laboratory data at baseline and during follow-
up. Clinical data included gender, age, details about the diagnosis of PBC, antimitochondrial 
antibody (AMA) status, liver histology obtained within one year of study entry, UDCA 
treatment (start date and dosage), and outcome (liver transplantation and death). 
Laboratory data (alkaline phosphatase, AST, alanine aminotransferase (ALT), gamma-
glutamyl transpeptidase (γ-GT), bilirubin, albumin and platelets) were yearly collected.
During site visits additional follow-up information was gathered from medical charts for 
UDCA non-responders within the next two years following the (retrospective) assessment 
of biochemical response (Figure 1). Data collected included changes in UDCA dosage, 
prescription of additional medication, and referral to tertiary centers.
Baseline
Initiation of UDCA therapy
Year 1
Evaluation of response
Year 3 Follow-up (years)Year 2
Evaluation of changes in treatment managment
Figure 1. Study timeline 
The study started at initiation of ursodeoxycholic acid (UDCA). Biochemical response to UDCA was 
retrospectively calculated after one year therapy using Paris-1 criteria.7 Subsequently, modifications in 
treatment management were evaluated in the following two years.  
Statistical analyses 
Normally distributed data was expressed as mean ± standard deviation and skewed data 
was expressed as median and interquartile range (IQR). Differences between responders 
and non-responders were assessed by using the independent t-test and non-parametric 
Mann-Whitney U test, respectively. To assess differences between responders and non-
responders concerning categorical variables the Pearson’s chi-squared test was used. Kaplan-
Meier method was applied for time-to-event analysis and survival difference was tested 
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with log-rank test. Logistic regression modelling was performed to assess the association 
between baseline factors and UDCA response after one year of follow-up in univariate and 
multivariable approaches. 
A p<.05 was considered statistically significant. Analyses were performed using statistical 
package of IBM SPSS Statistics 21.0 (SPSS Inc., Chicago IL, USA). 
RESULTS
Study cohort
The study cohort comprised 851 UDCA-treated PBC patients. The Paris-1 criteria could be 
assessed in 687 (81%) patients; 77% of patients were classified as responder and 23% as non-
responder (Figure 2). Non-responders were generally younger, at a more advanced disease 
stage, diagnosed in an earlier era and had higher serum bilirubin, alkaline phosphatase, AST 
and ALT values and lower albumin at baseline (Table 1). 
Entire cohort
n=851
Included patients
n=687
Response criteria not assessable 
n=164
Non-responders
157 (23%)
Responders
530 (77%)
Figure 2. Flowchart 
Flow diagram of patients included in this study.
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Table 1. Clinical and biochemical characteristics at baseline of responders and non-responders 
according to Paris-1 criteria
Responders
N=530
Non-responders
N=157
P-value
Mean age at study entry, y 57.1±11.6 53.7±12.9 .002
Female, n (%) 461 (87%) 136 (87%) .91
AMA+, n (%)a 501 (95%) 143 (91%) .22
Biochemical disease stage,b n (%) <.0001
Early 306 (58%) 42 (27%)
Moderately advanced 63 (12%) 54 (34%)
Advanced 5 (1%) 29 (19%)
Not available 156 (29%) 32 (20%)
Median year of diagnosis (IQR) 2000 (1993-2005) 1995 (1988-2002) <.0001
Year of diagnosis, time frame 1973-2011 1961-2011
Median UDCA dosage/kgc
Year of diagnosis <2000 9.84 (9.04-11.36) 9.49 (8.70-10.38) .056
Year of diagnosis ≥2000 13.38 (11.25-15.00) 13.43 (10.81-16.19) .46
Laboratory data at entry
Bilirubin (xULN) 0.57 (0.42-0.76) 1.17 (0.67-2.03) <.0001
Not available 42 (8%) 12 (8%)
Alkaline phosphatase (xULN) 1.95 (1.32-3.05) 4.15 (2.56-6.19) <.0001
Not available 25 (5%) 5 (3%)
Aspartate transaminase (xULN) 1.33 (0.95-2.00) 2.20 (1.53-3.10) <.0001
Not available 23 (4%) 7 (4%)
Alanine aminotransferase (xULN) 1.52 (1.02-2.50) 2.49 (1.54-3.65) .0053
Not available 20 (4%) 5 (3%)
Albumin (xLLN) 1.14 (1.06-1.22) 1.08 (0.94-1.20) <.0001
Not available 148 (28%) 31 (20%)
aAMA status was not available for 1 patient (responder)
bDisease severity was classified according to bilirubin and albumin levels. Early disease, normal albumin 
and bilirubin; moderately advanced disease, abnormal albumin or bilirubin; advanced disease, both 
albumin and bilirubin abnormal.11 
cdosage/kg was not calculable for 90/687 (13%) patients: 71/530 (13%) responders and 19/157 (12%) 
non-responders.
The median follow-up period of the entire cohort was 8.8 years (IQR, 4.8-13.9) and 
follow-up for responders was significantly longer than for non-responders (9.2 versus 7.8 
years respectively, p=.047). During follow-up 141 patients died and 30 underwent a liver 
transplantation (47 and 24 non-responders, respectively). Ten-year transplant-free survival 
for non-responders was significantly lower than for responders (60% versus 87%, p<.0001) 
(Figure 3). 
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Figure 3. Liver transplant-free survival rates according to biochemical response (Paris-1 criteria)
Liver transplant-free survival estimated with Kaplan Meier. The 10-year transplant-free survival of non-
responders was significantly lower than of responders (60% versus 87%, P <.0001).
Modification in management
Management was modified in 46/157 (29%) non-responders. The most frequently applied 
change was an increase of the UDCA dosage (26/46, 57%). Steroid therapy was started in 
only one non-responder. No other drugs as second-line therapy were prescribed. Nineteen 
patients were referred for second opinion to a tertiary center. For 6/157 (4%) non-responders 
management changes were not extractable from medical charts.
The relation between publications on biochemical response and changes in patient 
management 
In 1999 a first study was published addressing the significance of biochemical response.4 In 
our cohort the therapeutic approach was modified in 33/104 (32%) of the non-responders 
before 1999 as compared with 13/53 (25%) after that year (p=.10). The key paper of Pares 
et al. on biochemical response was published in 2006.5 When comparing the proportion of 
management changes in non-responders before and after 2006, again no clear difference 
was found (p=.62). 
Impact of UDCA dosage increase
After one year of treatment with UDCA the dosage was increased in a number of non-
responders and responders within the following two years. Importantly, 9/26 (35%) of the 
non-responders became responder within the next two years following dosage increase. 
When applying the more strict Paris-2 criteria for response,9 6/48 (13%) of non-responders 
became responder. 
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Eighteen of twenty-six (69%) non-responders in whom the UDCA dosage was increased 
were initially dosed inadequately (median daily dosage 9.60 mg/kg; IQR, 8.80-11.16 mg/
kg) according to current treatment guidelines.2, 3 Further analysis showed that this mainly 
applied to patients diagnosed in 1999 or before (median dosage 9.33 mg/kg; IQR, 8.21-9.93 
mg/kg) and not for those diagnosed in 2000 or thereafter (median dosage 12.69 mg/kg; 
IQR, 10.92-17.98 mg/kg). 
Baseline factors predictive of response
Since biochemical response is of major importance in risk stratification baseline factors were 
determined predictive of response (Table 2). Higher serum albumin levels and higher UDCA 
dosage per kg were associated with increased response to UDCA treatment, whereas higher 
levels of bilirubin, alkaline phosphatase, AST, ALT and more advanced disease stage (defined 
as abnormal bilirubin and/or albumin11) were all associated with decreased response. On 
multivariable analysis more advanced disease stage, lower UDCA dosage per kg and higher 
serum alkaline phosphatase levels were independent factors predictive of poor response. 
Table 2. Baseline factors predictive of response according to Paris-1 criteria
Univariate analysis Multivariable analysis
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Male sex 1.03 (0.61-1.74) ns - -
AMA positivity 1.75 (0.90-3.42) ns - -
Advancing age at study entry 1.02 (1.01-1.04) .0022 1.04 (1.01-1.06) .0021
Year of diagnosis 1.06 (1.03-1.08) <.0001 - -
UDCA dosage per kg 1.09 (1.02-1.16) .0095 1.15 (1.05-1.26) .0025
Disease stagea
Moderate 0.16 (0.10-0.26) <.0001 0.18 (0.10-0.32) <.0001
Advanced 0.02 (0.01-0.06) <.0001 0.02 (0.01-0.08) <.0001
Bilirubin (xULN) values 0.41 (0.32-0.54) <.0001 - -
Alkaline phosphatase (xULN) values 0.65 (0.59-0.72) <.0001 0.69 (0.60-0.78) <.0001
AST (xULN) values 0.78 (0.69-0.89) .00012 - ns
ALT (xULN) values 0.90 (0.82-0.99) .026 - -
Albumin (xLLN) values 33.05 (7.86-138.93) <.0001 - -
aDisease stage based on albumin and bilirubin according to biochemical disease classification of ter 
Borg et al.11
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DISCUSSION
To our knowledge, this large nationwide multi-center cohort study in PBC is the first to 
assess potential changes in patient management prompted by the 1-year response to UDCA 
treatment. We found that non-response to treatment did not result in management changes 
in nearly two-thirds of cases. In those patients in whom management was influenced, the 
most frequent change was an increase in the dosage of UDCA. Our data further show that 
the proportion of UDCA non-responders in whom management was modified did not 
increase over time, suggesting that awareness of the concept of biochemical response in 
clinical practice may still be suboptimal. 
Few data are available with respect to treatment policy based upon objective response 
criteria in PBC. Recently, preliminary data of an online survey among 200 gastroenterologists 
and hepatologists in the UK were presented.15 42% of gastroenterologists and 76% of 
hepatologists stated they used biochemical response criteria (e.g. Paris-1 criteria7 or 
Barcelona criteria5) to evaluate UDCA treatment. However, no information was provided 
about further treatment decisions based upon the observed response. 
Obviously, the results of our study should be interpreted with caution. In particular, it 
must be recognized that the majority of included patients were treated with UDCA well 
before emergence of the concept of biochemical response and that, in the context of this 
study, this response was assessed retrospectively. Therefore, by definition, decisions with 
respect to patient management could not have been influenced by assessing treatment 
response with one of the currently available tools. Irrespective of a formal response 
evaluation, however, our data suggest that management was modified in only a minority 
of cases despite persistently, occasionally markedly, abnormal biochemical liver tests. 
Moreover, our data demonstrate that during the last decade, despite increased awareness 
of the importance of sufficient biochemical improvement upon treatment with UDCA, this 
did not translate yet into an increase in response-guided management in general medical 
practice. 
Another major factor that must be stressed when interpreting the results of the present 
study is the lack of evidence-based alternative treatments for PBC until now. This may largely 
explain why potentially effective drugs, including budesonide and fibrates, were rarely used. 
During recent years, evidence is accumulating that fibrates may have an additional, beneficial 
effect in UDCA-treated PBC.16-20 The same applies to budesonide21-23 and obeticholic acid,24 
drugs that are currently undergoing randomized controlled trial evaluation. It seems likely 
that within a few years the therapeutic scenario in PBC will have changed considerably and 
an evidence-based approach of response guided treatment in PBC will be reality, potentially 
with a number of second-line treatment options available. 
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Our study emphasizes the importance of adequate UDCA dosage. About 40% of UDCA 
non-responders in whom the dosage was increased became responder according to the 
criteria we used. Indeed, a multivariable analysis of factors predictive of response confirmed 
that higher UDCA dosage per kilogram was an independent predictor of response. These 
findings are in line with previous studies showing that UDCA doses in the range of 13-15 
mg/kg/day are more effective than lower doses.25, 26 Therefore, adequate dosing of UDCA 
remains of crucial importance. 
A potential weakness of our study is its retrospective character, occasionally necessitating 
the retrieval of data from hand-written patient records more than 20 years old. Also, it may 
be very well possible that management changes did occur more frequently than documented 
in the present study, but that this was after more prolonged follow-up. On the other hand, 
we believe that this study of a large PBC population gives unique and representative insight 
into general clinical practice since it was not restricted to high-volume university centers but 
also involved many smaller community hospitals. 
In conclusion, in this long-term cohort study of PBC we found that changes in medical 
management occurred in a minority of patients who, retrospectively, responded insufficiently 
to UDCA treatment. During the last decade this did not change despite the emergence of 
established stratification tools. Now new therapeutic options for PBC are becoming available 
awareness of the concept of biochemical response requires further attention. 
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ABSTRACT 
Background & Aims: Approaches to risk stratification for patients with primary biliary 
cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to 
develop and validate a better model for determining prognoses of patients with PBC. 
Methods: We performed an international, multicenter meta-analysis of 4119 patients with 
PBC treated with ursodeoxycholic acid (UDCA) at liver centers in 8 European and North 
American countries. Patients were randomly assigned to derivation (n=2488, 60%) and 
validation cohorts (n=1631, 40%). A risk score (GLOBE score) to predict transplantation-
free survival was developed and validated with univariate and multivariable Cox regression 
analyses using clinical and biochemical variables obtained after 1 y UDCA therapy. Risk 
score outcomes were compared with the survival of age-, sex-, and calendar time-matched 
members of the general population. The prognostic ability of the GLOBE score was evaluated 
alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and Paris-2 criteria. 
Results: Age (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.04–1.06; p<.0001); 
levels of bilirubin (HR, 2.56; 95% CI, 2.22–2.95; p<.0001), albumin (HR, 0.10; 95% CI, 
0.05–0.24; p<.0001), and alkaline phosphatase (HR, 1.40; 95% CI, 1.18–1.67; p=.0002); 
and platelet count (HR/10 units decrease, 0.97; 95% CI, 0.96–0.99; p<.0001) were all 
independently associated with death or liver transplantation (C statistic derivation, 0.81; 
95% CI, 0.79–0.83, and validation cohort, 0.82; 95% CI, 0.79–0.84). Patients with risk scores 
>0.30 had significantly shorter times of transplant-free survival than matched healthy 
individuals (p<.0001). The GLOBE score identified patients who would survive for 5 y and 10 
y (responders) with positive predictive values of 98% and 88%, respectively. Up to 22% and 
21% of events and non-events, respectively, 10 y after initiation of treatment were correctly 
reclassified in comparison with earlier proposed criteria. In subgroups of patients <45 y, 
45–52 y, 52–58 y, 58–66 y, and ≥66 y old, age-specific GLOBE-score thresholds beyond which 
survival significantly deviated from matched healthy individuals were –0.52, 0.01, 0.60, 1.01 
and 1.69, respectively. Transplant-free survival could still be accurately calculated by the 
GLOBE score with laboratory values collected at 2–5 y after treatment.
Conclusions: We developed and validated scoring system (the GLOBE score) to predict 
transplant-free survival of UDCA-treated patients with PBC. This score might be used to 
select strategies for treatment and care. 
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INTRODUCTION
Primary biliary cirrhosis (PBC) is the most common of the autoimmune liver diseases, with 1 
in 1000 women over the age of 40 affected.1 Prognosis largely depends on the development 
of liver cirrhosis and its complications.2 Presently, treatment with ursodeoxycholic acid 
(UDCA) represents the global standard of care,2, 3 and can delay histological progression4-6 
and can improve long-term survival.7, 8 However, UDCA is not an uniformly effective drug 
and the prognosis of patients insufficiently responding to treatment is markedly worse 
compared with the general population.9 Reliable identification of such individuals is of key 
importance to clinical management, particularly for selecting those who could benefit from 
additional second-line medical therapies, but equally for identification of patients at low risk 
of developing end-stage liver disease. 
A number of existing stratification tools, using biochemical liver tests applied after one 
or two years of UDCA exposure, will readily identify patients with or without sufficient 
treatment response.9-13 Paris-1 criteria is generally considered as the one with best 
predictability of transplant-free survival as validated in large studies, such as the UK-PBC 
consortium and our own group.11, 14-16 However, Paris-1 and other criteria were all based on 
dichotomized variables, potentially leading to loss of important predictive information. And 
even more important there is a relatively high disagreement between the different criteria 
in classifying someone among low- and high risk groups.17 
The Global PBC Study Group has representative data from an international PBC research 
collaboration that has already evaluated biochemical surrogates of disease progression and 
liver cancer risk.16, 18 The aim of present study was to utilise our unique dataset, alongside 
representative healthy population data, to develop a new unifying score with optimal ability 
to identify UDCA-treated patients with an insufficient treatment effect, based on readily 
obtainable, biochemical and clinical variables. 
METHODS
Study population and design
Patients were derived from the Global PBC Study Group database. This study group is 
an international and multicenter collaboration between 15 liver centers from 8 North 
American and European countries, which combined individual patient data from major long-
term follow-up cohorts. Most cohorts included prospectively collected follow-up data. All 
patients had an established diagnosis of PBC2, 3 and characteristics of the study population 
have been previously described elsewhere.18 For the current study only those patients 
treated with UDCA were included. Patients were excluded if follow-up data were insufficient 
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or unavailable, the start date of treatment or the exact date of major clinical events was 
unknown or in case of concomitant liver disease. Collected clinical and laboratory data 
included gender, age, PBC diagnosis, liver histology, treatment (type of medication, dosage 
and duration), duration and last date of follow-up, baseline antimitochondrial antibody 
status, baseline and yearly laboratory values (serum alkaline phosphatase, total bilirubin, 
albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and platelets 
and outcomes (death and cause of death, liver transplantation, hepatocellular carcinoma, 
ascites and variceal bleeding). 
Ethical approval
This study was conducted in accordance with the protocol and the principles of the 
Declaration of Helsinki. The protocol was approved by the Institutional Research Board of the 
corresponding center, and at each participating center, in accordance with local regulations. 
Statistical analysis
The study population was divided into a two cohorts, a derivation series comprising a 
randomly selected group of 2488 patients (60%), with the remainder serving as of a validation 
cohort (n=1631, 40%). Follow-up commenced at the start of UDCA therapy. Clinical outcome 
consisted of a composite endpoint of liver transplantation and all-cause mortality with the 
first event considered. Patients failing to reach a clinical endpoint were censored at time of 
last follow-up. 
For development of our risk score only easily and readily available clinical and laboratory 
variables were considered: sex, baseline age, and serum bilirubin, alkaline phosphatase, 
AST, ALT, albumin, platelet count, AST/ALT ratio, and AST to platelet ratio index (APRI) at 
one year follow-up. Where indicated, continuous variables underwent natural logarithmic 
transformation to correct for non-linearity. Multiple imputation was also applied to account 
for missing data wherein ten complete datasets were constructed by imputing missing 
values (SAS Proc MI, MCMC method; SAS 9.3).19 
Time-to-event analysis was conducted using univariate and multivariable cox 
proportional hazard regression, and a final model was selected by comparing the goodness 
of fit criteria (Akaike Information Criteria and maximum-likelihood estimation). The final 
model was checked for potential confounding factors and interactions between the included 
variables. A penalised maximum likelihood estimation was used to account for over fitting 
of the model.20 21 
A prognostic index (GLOBE score) was calculated with the beta coefficients of variables 
included in the final penalized multivariable model, along with a baseline survival estimate 
S0(t), t=time. The GLOBE score was centered on the median in the derivation set. 
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The overall discriminative ability of the GLOBE score was measured with C statistic in 
both the derivation and validation cohort. To visualise the discriminate ability Kaplan-Meier 
curves were plotted of 5 risk groups according to the 10th, 40th, 60th and 90th percentiles of 
the GLOBE score. 
Calibration of the GLOBE score was tested within the validation set.22 The calibration 
slope was calculated by estimating the regression coefficient on the GLOBE score. The 
necessity of recalibration was further tested by performing a Cox regression analysis on 
the variables included in the final model and including the GLOBE score with the regression 
coefficient constrained to 1. A good model fit was reached when the joint test of all beta 
coefficients did not significantly differ from 0. The accuracy of the baseline survival estimate 
S0(t) was investigated by comparing the predicted survival probabilities of the 5 risk groups 
as defined above in the validation set with the observed Kaplan-Meier survival probabilities.
In order to identify patients in whom prognosis significantly deviates from normal, the 
score was calculated beyond which prognosis was significantly worse than of a normal 
population. To determine this threshold, survival of patients with GLOBE scores below the 
tenth percentile was compared with that of an age-, sex- and calendar time matched Dutch 
population. During subsequent steps patients with scores within the next ten percentiles 
were added to the population and calculations were repeated until survival significantly 
deviated from that of the matched normal population (non-responders). Data of the 
matched population, a population with a life-expectancy comparable with that of the 
other participating countries, were retrieved from a Dutch registry (Statistics Netherlands, 
www.cbs.nl). The performance of the GLOBE score using this threshold was assessed with 
sensitivity, specificity, negative predictive value and positive predictive value at 5- and 10-
year follow-up. For this purpose a GLOBE score below the aforementioned threshold was 
considered as a positive test and the absence of adverse outcome was considered as an 
event. 
The overall predictive performance of previously reported tools (the Barcelona,9 Paris-1,10 
Rotterdam,11 Toronto12 and Paris-2 criteria13) was assessed with C statistic. To quantify the 
improvement in discriminative ability the net reclassification improvement (NRI) for both 
events and non-events23, 24 during the first 5 and 10 years follow-up was calculated. 
All analyses were 2 sided. p<.05 was considered statistically significant if not otherwise 
specified. Statistical analyses were performed with IBM SPSS Statistics 22.0 (SPSS Inc, 
Chicago, IL, USA) and SAS 9.3 (SAS institute, Cary, NC, USA).
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RESULTS
Clinical characteristics of the derivation cohort
The derivation cohort consisted of 2488 subjects with PBC, with a median age of 54.6 years 
at the time of diagnosis (Table 1). During a median follow-up of 7.8 years (interquartile 
range (IQR) 4.0-12.1) 558 patients reached a clinical endpoint; 369 patients died and 189 
patients underwent liver transplantation (center specific characteristics are described in 
Table 2). The 5-, 10- and 15-year transplant-free survival rates were 90.0%, 77.5% and 65.6% 
respectively, as shown in Figure 1. 
Table 1. Baseline characteristics 
Derivation cohort
(n=2488)
Validation cohort
(n=1631)
Age, years, mean (SD) 54.6 (11.7) 54.8 (11.9)
Female, n (%) 2253 (90.6%) 1453 (89.1%)
AMA+, n (%) 2208 (88.7%) 1425 (87.4%)
Year of diagnosis 1997 (1991-2003) 1998 (1992-2004)
Year of diagnosis, time frame 1961-2012 1970-2012
Histological disease stage, n (%)1
Stage I 336 (27.9%) 237 (28.6%)
Stage II 337 (28.0%) 211 (25.5%)
Stage III 171 (14.2%) 125 (15.1%)
Stage IV 138 (11.5%) 87 (10.5%)
Not available 222 (18.4%) 167 (20.2%)
Serum bilirubin (xULN) 0.65 (0.45-1.00) 0.67 (0.45-1.05)
Serum alkaline phosphatase (xULN) 2.11 (1.37-3.79) 2.16 (1.33-3.78)
Serum AST (xULN) 1.46 (0.94-2.20) 1.45 (0.94-2.27)
Serum ALT (xULN) 1.68 (1.05-2.59) 1.63 (1.00-2.67)
Serum albumin (xLLN) 1.14 (0.15) 1.14 (0.17)
Platelet count 246 (90) 240 (96)
AST/ALT ratio 0.90 (0.72-1.16) 0.92 (0.73-1.18)
APRI 0.60 (0.34-1.01) 0.62 (0.36-1.09)
Laboratory data after one year2
Serum bilirubin (xULN) 0.57 (0.41-0.86) 0.59 (0.41-0.90)
Serum alkaline phosphatase (xULN) 1.34 (0.93-2.26) 1.36 (0.93-2.25)
Serum AST (xULN) 0.90 (0.67-1.40) 0.90 (0.67-1.42)
Serum ALT (xULN) 0.90 (0.60-1.53) 0.90 (0.59-1.47)
Serum albumin (xLLN) 1.14 (0.15) 1.14 (0.17)
Plateletcount 237 (90) 237 (96)
AST/ALT ratio 1.03 (0.79-1.33) 1.03 (0.81-1.33)
APRI 0.38 (0.25-0.66) 0.39 (0.26-0.72)
1Baseline biopsies (obtained within one year of start of UDCA) were available in 1204/2488 (48%) 
patients of the derivation cohort and in 827/1631 (51%) patients of the validation cohort.
2laboratory variables are expressed as median and interquartile range; serum albumin and platelet 
count are expressed as mean and standard deviation.
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Figure 1. Liver transplant-free survival probability
Transplant-free survival probability of patients with primary biliary cirrhosis in the derivation cohort 
(N = 2488, solid line) and the validation cohort (N = 1631,dotted line).
Construction of the GLOBE score
Following univariate Cox regression analyses older age at start of UDCA therapy, male sex, 
elevated serum bilirubin, alkaline phosphatase, AST and ALT levels, lower serum albumin 
levels and thrombocytopenia and higher AST/ALT and APRI ratios after one year of UDCA 
therapy were all associated with higher risk of liver transplantation or death (Table 3). The 
final penalized multivariable model comprised age, bilirubin, albumin, alkaline phosphatase 
and platelet count as independent predictors of liver transplantation or death (Table 3). No 
significant interactions were found between these variables (Table 4). 
Table 3. Univariate and multivariable cox regression analysis for liver transplantation or death within 
the derivation cohort (n=2488)
Univariate analyses Multivariable analyses1
HR 95% CI P HR 95% CI P
Age at baseline, per year 1.038 1.030-1.046 <.0001 1.045 1.035-1.056 <.0001
Male sex 1.913 1.510-2.425 <.0001 - - -
Bilirubin xULN2 3.215 2.903-3.562 <.0001 2.560 2.219-2.952 <.0001
Alkaline phosphatase xULN2 1.929 1.687-2.204 <.0001 1.399 1.175-1.665 .0002
AST xULN2 2.560 2.220-2.952 <.0001 - - -
ALT xULN2 1.401 1.232-1.594 <.0001 - - -
Albumin xLLN 0.014 0.007-0.028 <.0001 0.104 0.045-0.238 <.0001
Platelet count (*109/L), per 10 units 0.993 0.992-0.995 <.0001 0.970 0.961-0.990 <.0001
AST/ALT ratio2 2.537 1.998-3.223 <.0001 - - -
APRI2 2.235 1.985-2.518 <.0001 - - -
Abbreviations: HR, hazard ratio; LLN, lower limit of normal; ULN, upper limit of normal; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; APRI, AST to Platelet Ratio Index.
1A P-value of <0.01 was considered as statistically significant.
2These biochemical variables were transformed with natural logarithm. 
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Table 4. Interactions tested between individual variables of the GLOBE score
Bilirubin Albumin Alkaline phosphatase Platelet count
Age 0.94* 0.25* 0.97* 0.75*
Bilirubin - 0.54* 0.63* 0.74*
Albumin - - 0.95* 0.89*
Alkaline phosphatase - - - 0.03*
*P-values of interaction terms tested in the final multivariable Cox regression model; a P <.01 was 
considered statistically significant. 
The GLOBE score was calculated as follows: 
GLOBE score = 0.044378*age at start of UDCA therapy + 0.93982*LN(bilirubin times the 
upper limit of normal [ULN] at 1 year follow-up) + 0.335648*LN(alkaline phosphatase times 
the ULN at 1 year follow-up) – 2.266708*albumin level times the lower limit of normal (LLN) 
at 1 year follow-up – 0.002581*platelet count per 109/L at 1 year follow-up + 1.216865.
The distribution of the GLOBE score is plotted in Figure 2. The baseline survival curve at 
the mean GLOBE score S0(t) was: 0.9652, 0.9385, 0.8429, 0.7361 at 3-, 5-, 10- and 15-year 
follow-up respectively. The survival S(t) for any given patients was then calculated by S(t) = 
S0(t) 
exp(GLOBE score).
Figure 2. Distribution of the GLOBE score within the derivation and validation cohort
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Example: 
For a 50-year old patient with a bilirubin level of 1 time the ULN, an alkaline phosphatase 
level of 3 times the ULN, an albumin level of 1.5 time the LLN and a platelet count of 250 
per 109/L: 
GLOBE score = -0.24; transplant-free survival at 5-year, S(5) = 95.1% and at 10-year, S(10) = 
87.4%.   
The overall predictive ability of the GLOBE score for transplantation or death, calculated 
with C statistic, was 0.81 (95% CI, 0.79-0.83). 
 
Validation of the GLOBE score
The clinical characteristics of the validation cohort (n=1631) are described in Table 1. During 
a median follow-up time of 7.5 years (IQR 3.8-11.8) 328 patients reached a clinical endpoint; 
197 died and 131 received a liver transplant (center specific characteristics are described in 
Table 2). The 5-, 10- and 15-year transplant-free survival rates were 90.0%, 79.6% and 66.3% 
respectively and not significantly different from those observed in the derivation cohort 
(Figure 1).
A comparable overall discriminative ability was found as in the derivation cohort 
(C statistic 0.82, 95% CI 0.79-0.84). To explore to what extent the GLOBE score might be 
influenced by the imputation process for missing variables, the discriminative ability of the 
GLOBE score was additionally tested in cases with complete data. These analysis showed 
comparable results (C statistic derivation cohort: 0.82, 95% CI 0.78-0.86 and validation: 
0.83, 95% CI 0.79-0.86). 
The discriminative ability of the GLOBE score was visualised by plotting the transplant-
free survival curves for 5 risk groups according to the 10th, 40th, 60th and 90th percentiles 
of the score (derivation cohort: GLOBE scores -1.26, -0.25, 0.30 and 1.69 respectively and 
validation cohort: GLOBE scores -1.26, -0.26, 0.30 and 1.75 respectively) (Figure 3). Good 
separation was shown for the survival curves of the 5 risk groups. 
There was a good agreement between the curves in the derivation and validation cohort 
as shown in Figure 3, with a good model fit (calibration slope, p=0.64). No re-calibration 
of the GLOBE score was necessary, when calculating the regression coefficient on the 
prognostic index (p=0.22). Further, the predicted survival probabilities corresponded well 
with the observed survival probabilities (Table 5). 
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Figure 3. Liver transplant-free survival probability of risk groups according to the GLOBE score
A) Transplant-free survival probability of 5 predefined risk groups according to percentiles of the 
GLOBE score: (1) <10th, (2) 10th-40th, (3) 40th-60th, (4) 60th-90th and (5) >90th, and B) accompanying 
hazard ratios between the risk groups in the derivation (N = 2488, solid line) and validation cohort 
(N = 1631, dotted line). 
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Table 5. Predicted against observed probability of transplant-free survival in the validation cohort 
(n=1631)
Risk groups according to 
percentiles of the GLOBE score 
Years of 
follow-up
Predicted 
probability1
Observed 
probability2 
<10th percentile 3-year 0.993 0.993
5-year 0.988 0.993
10-year 0.968 0.975
15-year 0.943 0.975
10th – 40th percentiles 3-year 0.982 0.993
5-year 0.968 0.985
10-year 0.918 0.949
15-year 0.857 0.882
40th – 60th percentiles 3-year 0.965 0.975
5-year 0.937 0.956
10-year 0.840 0.864
15-year 0.732 0.789
60th – 90th percentiles 3-year 0.915 0.924
5-year 0.854 0.854
10-year 0.660 0.720
15-year 0.484 0.478
>90th percentiles 3-year 0.617 0.638
5-year 0.460 0.474
10-year 0.183 0.181
15-year 0.067 0.069
1The predicted transplant-free survival probabilities for each risk group were assessed by first applying 
the GLOBE score of each individual in the validation cohort to the baseline survival estimate S0(t) 
derived from the derivation cohort: S
GLOBE SCORE
(t) = S0(t) 
exp(GLOBE SCORE). Than, the average of S
GLOBE score
(t) 
across each risk group was calculated. 
2The observed probabilities are observed from Kaplan-Meier estimation. 
Application of the GLOBE score
An overall threshold was determined for the GLOBE score in the derivation cohort beyond 
which prognosis of patients significantly deviated from a normal life-expectancy (non-
responders). Patients with a GLOBE score above 0.30, which applied to 40% of cases, had a 
significantly diminished survival compared with a matched general population (hazard ratio 
(HR) 5.51, 95%CI 4.52-6.72, p<.0001), with 5-, 10- and 15-year transplant-free survival rates 
of 79.7%, 57.4%, 42.5% respectively. Patients with a GLOBE score of 0.30 or less (responders) 
had a life-expectancy comparable with a matched general population; the 5-, 10- and 15-
year transplant-free survival rates were 98.0%, 92.0%, 82.3% respectively (p<.0001) (Figure 
4). 
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Figure 4. Liver transplant-free survival probability using a GLOBE score threshold
Transplant-free survival probability of patients with a GLOBE score of 0.30 or less compared with 
an age-, sex- and calendar-time matched population for patients within A) the derivation and C) the 
validation cohort, and for those with a GLOBE score greater than 0.30 this probability significantly 
deviated for patients within B) the derivation and D) the validation cohort. 
The performance of the GLOBE score was assessed using the aforementioned threshold. 
A high positive predictive value was found at 5-year follow-up (1057/1084, 98%) and at 
10-year follow-up (588/669, 88%), implying that the probability of reaching an adverse 
outcome is very low for patients identified as a responder. Also a high specificity was found 
at 5-year follow-up (193/220, 88%) and 10-year follow-up (328/409, 80%) which means 
that the majority of patients with an adverse outcome were identified as non-responder. 
Additionally, we found a sensitivity of 65% (1057/1623) at 5-year and 69% at 10-year 
(588/857) follow-up and a low negative predictive value at 5-year (193/759, 25%) and at 
10-year (328/597, 55%) follow-up.
  
The performance of the GLOBE score compared with other criteria
The overall discriminative ability of the GLOBE score was superior in comparison with 
previously proposed stratification tools9-13 (Table 6). To quantify the improvement in 
discriminative ability the NRI for both events and non-events in the validation set was 
calculated.23 The percentage of patients with an event at 5- and 10-year follow-up that were 
correctly reclassified with the GLOBE score as compared with existing criteria ranged from 
3% to 25% and 1% to 22% respectively, and in patients without an event at 5- and 10-year 
follow-up the NRI ranged from -15% to 18% and -14% to 21% respectively (Table 7). 
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The performance of the GLOBE score among different age groups, disease severity groups 
and at different time points
Additionally, we created five equal age groups (<45, 45-52, 52-58, 58-66 and ≥66 years), to 
perform an in-depth analysis of the threshold per age group. Patients within these groups 
were separately matched with an age- and sex-matched population and thresholds of -0.52, 
0.01, 0.60, 1.01 and 1.69 respectively were determined. When using these thresholds 70%, 
50%, 30%, 20% and 10% respectively of patients had a diminished survival compared with a 
matched population. Importantly, this implies that older patients inevitably may derive les 
impact ultimately from additional therapies. 
Within the derivation cohort the performance of the GLOBE score was tested within a 
subgroup of patients with histological early stage PBC (n=673), defined as stage I or II and 
a subgroup of patients with histological late stage PBC (n=309), defined as stage III or IV. 
In the early stage subgroup 280/1090 (26%) patients had a survival significantly deviating 
from that of a matched population and this were 373/540 (69%) patients in the advanced 
stage subgroup. In both subgroups the predictive ability of the score was satisfactory with 
a C statistic of 0.81 (95% CI 0.76-0.86) in the early stage subgroup and 0.78 (95% CI 0.74-
0.83) in the late stage. Comparable results were found when repeating these analyses in the 
validation cohort; with a C statistic in the early stage (n=448) of 0.85 (0.79-0.91) and in the 
late stage (n=212) of 0.79 (0.72-0.86). 
Importantly, the risk score was calculated based on lab values collected 1 y after UDCA 
therapy, but transplant-free survival could still be accurately calculated by the GLOBE score 
with laboratory values collected at 2–5 y after treatment (Table 8).
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Table 8. Predictive performance of the GLOBE score calculated after n years of UDCA therapy
Validation cohort 
n=1630
Follow-up C statistic 95% CI
1 year 0.82 0.79-0.84
2 years 0.83 0.80-0.85
3 years 0.83 0.80-0.85
4 years 0.83 0.80-0.86
5 years 0.84 0.81-0.87
DISCUSSION
In this study of over 4000 UDCA-treated patients with PBC from across Europe and 
North America we present the GLOBE score, an internationally relevant and validated 
risk assessment tool, able to accurately stratify patients to high and low risk. The score 
comprises five simple, readily available and objective variables: age, bilirubin, albumin, 
alkaline phosphatase and platelet count. Moreover, through robust evaluation and validation 
we demonstrate appropriate test characteristics in subgroups with early and advanced 
disease. Most importantly, the prognostic ability of the score was found to be markedly 
superior to previously proposed criteria for (non-)response to UDCA. The score has utility 
for patients managed with PBC internationally, as a means to more readily stratify risk of 
adverse outcomes, and hence tailor patient education. In particular, in an era of potential 
new therapies the GLOBE score is better able than current stratification tools to highlight 
patients at greatest need for new therapies. Of further relevance to the health economics 
of PBC, the GLOBE score improves capacity to identify individuals in whom UDCA mono-
therapy should be continued, with opportunities to de-escalate care back to their primary 
care provider. 
Previous studies have extensively documented the prognostic importance of the 
individual components of the GLOBE score. In particular, age, bilirubin and albumin have 
been recognized as important predictors of survival in PBC, irrespective of UDCA treatment7, 
8, 25, 26 In general, age and mortality are strongly correlated and not surprisingly age proved 
to be an independent predictor of liver transplantation or death in present study. Serum 
bilirubin is generally considered the strongest and most independent predictor of outcome 
in PBC,18, 27-29 and is a main component of prognostic models25, 30-32 and response criteria 
in PBC.10, 11, 13, 33 Serum bilirubin levels normally increase relatively late in the course of 
disease. However, its predictive value is not limited to late stage disease, as suggested by 
our previous finding that even in patients with normal levels, prognosis improves as levels 
fall.18 Alkaline phosphatase levels are of key importance in establishing the diagnosis PBC.2, 
3 Changes in alkaline phosphatase levels have previously been documented to provide 
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significant prognostic information, both in UDCA-treated9, 10, 12, 13, 18, 34 and non-treated PBC.18 
Finally, the platelet count, generally considered as a marker of portal hypertension,35 has 
been validated as an independent predictor of outcome in addition to current biochemical 
response criteria.15, 36 
Although some of the factors comprising the score, such as bilirubin and albumin, will 
change relatively late in the course of disease, the GLOBE score performed well in patients 
with early stage disease. This is probably largely explained by the well-documented strong 
predictive significance of alkaline phosphatase values, even in cases with normal bilirubin.18 
Our score provides improved identification of patients insufficiently responding to UDCA 
in comparison with previously reported criteria (Table 6). As reflected by the high positive 
predictive value, responders to UDCA according to the GLOBE score are at low risk for future 
adverse events. Therefore these patients can reliably be advised to continue with UDCA 
mono-therapy. The GLOBE score also allows more reliable identification of patients likely 
to have a future unfavourable health outcome. Thus, for healthcare providers the GLOBE 
score provides an improved instrument for selecting candidate patients for additional, 
second-line therapies. The superior performance of our score is likely attributable to the 
effect of dichotomization of every single variable in previously proposed response criteria. 
Dichotomization of continuous variables inevitably will have led to loss of predictive ability.37 
Moreover, age, as a recognized major predictor of survival, was included in our score. 
Importantly, we confirm that younger patients have the potential to benefit more from 
additional PBC therapies than older patients.14 Finally, the methodological approach to base 
the score on a prognostic index, corresponding with a continuum of possible outcomes, 
is an important factor explaining improved ability to reliably estimate prognosis using the 
GLOBE score. 
Other predictors of outcome in PBC have been suggested, including liver histology and 
elastography.38, 39 Liver histology has important prognostic meaning,38 but in the majority 
of cases liver biopsy is not considered necessary for diagnosis.3 Moreover, given other 
disadvantages, such as its invasive character, sampling error and inter-observer variation, 
liver biopsy is no longer routinely performed in the management of PBC patients. Non-
invasive assessment of liver fibrosis with transient elastography is an interesting alternative,39 
but data supporting this technique as an important clinical tool are still limited and further 
validation is required. Elastography may be less suitable for assessing the response to 
medical treatment, especially after a relatively short duration of treatment, as PBC is 
a slowly progressive disease, suggesting it might take longer before reliably detectable 
changes in liver stiffness will ensue.4-6 Biochemical markers are routinely checked during 
yearly check-up of PBC patients, and levels of biochemical variables after a short period of 
UDCA treatment are strongly associated with long-term outcome.9-13, 18, 34 Considering the 
fact that biochemical markers are easily obtainable and readily available, they seem more 
attractive and preferable for first-line patient stratification. 
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A potential limitation to our study is the use of reference population data originating 
from only one country, namely the Netherlands, for developing the Global PBC Study Group 
Score. However, according to life table data of the World Health Organisation (WHO) life 
expectancy was comparable among the countries involved in this study.40 Therefore, this 
may not be a factor of major relevance. Further, we were not able to take into account 
other laboratory variables of potential interest in PBC, such as gamma-GT, IgM, IgG and 
prothrombin time. Due to the nature of our study laboratory data were also not always fully 
complete, especially when inclusion in the original cohort studies occurred more than 15-20 
years ago. However, considering the exceptionally large dataset, we believe our results are 
sufficiently robust, as well as notably representative. Finally, the reliability of our findings is 
supported by the validation of the prognostic model in a separate population of considerable 
size. The complex calculation of the GLOBE score has been simplified by the development of 
a web application to improve its usage in clinical practice (www.globalpbc.com). 
In conclusion, we demonstrate that the prognosis of patients with PBC, irrespective 
of the stage of disease, who have been treated with UDCA for one year can be readily 
determined using a de novo derived and validated, risk calculation. Our score performs 
significantly better than thus far proposed criteria for response to UDCA thereby providing 
internationally representative data to quantify the needs of low- and high-risk patients with 
PBC. The GLOBE score therefore complements efforts to develop and implement a more 
stratified, evidence-based, approach to the care of patients with PBC. 
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ABSTRACT
Background & Aim: Hepatocellular carcinoma (HCC) is an infrequent yet critical event in 
primary biliary cirrhosis (PBC); however, predictive tools remain ill-defined. Our objective 
was to identify candidate risk factors for HCC development in patients with PBC.
Methods: Risk factor analysis was performed in over 15 centres from North America and 
Europe spanning >40 years observation period using Cox proportional hazards assumptions, 
logistic regression, and Kaplan-Meier estimates. 
Results: Of 4565 patients with PBC 123 developed HCC, yielding an incidence rate (IR) of 3.4 
cases/1000 patient-years. HCC was significantly more common in men (p<.0001), and on 
univariate analysis factors at PBC diagnosis associated with future HCC development were 
male sex (unadjusted HR 2.91, p<.0001), elevated serum aspartate transaminase (HR 1.24, 
p<.0001), advanced disease (HR 2.72, p=.022), thrombocytopenia (HR 1.65, p<.0001), and 
hepatic decompensation (HR 9.89, p<.0001). As such, non-treatment with ursodeoxycholic 
acid itself was not associated with cancer development; however, 12-month stratification 
by biochemical non-response (Paris-I criteria) associated significantly with future risk of HCC 
(HR 4.52, p<.0001; IR 6.6 vs 1.4, p<.0001). Non-response predicted future risk in patients 
with early stage disease (IR 4.7 vs 1.2, p=.005), advanced disease (HR 2.79, p=.02; IR 11.2 
vs 4.4, p=.033), and when restricting the analysis to only male patients (HR 4.44, p<.001; 
IR 18.2 vs 5.4, p<.001). On multivariable analysis biochemical non-response remained the 
most significant factor predictive of future HCC risk (adjusted HR 3.44, p<.0001).
Conclusions: This uniquely powered, internationally representative cohort robustly 
demonstrates that 12-month biochemical non-response is associated with increased 
future risk of developing HCC in PBC. Such risk stratification is relevant to patient care and 
development of new therapies.
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INTRODUCTION
Primary biliary cirrhosis (PBC) is the most prevalent autoimmune liver disease, characterised 
by ductopenia, cholestasis and a risk of progressive liver fibrosis. Life expectancy is reduced 
in PBC and prognosis largely dictated by development of cirrhosis and portal hypertension,1-3 
including for some the development of hepatocellular carcinoma (HCC). Given the relative 
infrequency of PBC compared to other chronic liver diseases, large scale, robust and 
representative analyses of HCC risk in PBC remain limited. 
Presently, the majority of patients with PBC are treated with ursodeoxycholic acid 
(UDCA).1,4 Treatment benefit is best highlighted by applying biochemical stratification to 
therapy,3,5-9 and up to two-thirds of patients have an improved transplant-free/overall survival 
in this regard. However, there is a paucity of data with regard to biochemical response and 
modification of cancer risk in PBC.10,11 Consequently it remains unclear how much risk/
benefit there is in performing HCC surveillance for patients with well-treated disease.12 
Across the spectrum of liver disease generally, HCC incidence appears greatest among 
individuals with advanced fibrosis/cirrhosis, particularly men;13 however, such observations 
in PBC frequently represent single centre studies, or are not immediately generalisable to 
Western practice.7,10,14-24 For example, a recent nationwide population survey from Japan 
identified a sex-specific contribution to HCC risk with respect to disease stage in Japanese 
patients with PBC.24 
To address and overcome limitations to current knowledge and practice, we now 
describe the incidence of HCC across a global PBC cohort, with the specific aim of identifying 
predictive factors in a robust, statistically powered and internationally representative 
population. In so doing we document critical insight into challenges pertaining to long term 
patient follow-up, hepatocellular cancer susceptibility and disease outcome. Furthermore 
we identify a protective association in patients meeting specific biochemical endpoints that 
can be used to stratify HCC risk in the clinic setting. 
PATIENTS AND METHODS
Study setting and design
We collected and analysed data from well-characterised patients with an established 
diagnosis of PBC,1,4 who had previously attended or were under current clinical follow-up 
between 1959 and 2012. Our catchment population comprised over 15 centres across the 
UK, Europe, the USA and Canada, as detailed elsewhere.25 Both UDCA-treated and non-
treated individuals with an established diagnosis of PBC in accordance with European and 
American guidelines were eligible for inclusion. Individual centre datasets (ICDs) contained 
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mostly prospectively collected follow-up data on patients from diagnosis and/or start 
of UDCA therapy. Upon study initiation, ICDs were transferred onto a standardised case 
record form formulated by the Global PBC Study Group committee and amalgamated onto 
a common ‘master’ database for downstream analysis. Individual clinical and laboratory 
characteristics pertained to gender, clinician reported age and date of PBC diagnosis, liver 
histology, UDCA treatment (start date, dosage and duration of therapy), antimitochondrial 
antibody serology, laboratory values (serum alanine transaminase, aspartate transaminase 
(AST), alkaline phosphatase, bilirubin, albumin and platelets) at PBC diagnosis and annually 
thereafter, date of HCC diagnosis, and liver transplantation and mortality status. 
Baseline was set as the point of starting therapy for patients in receipt of UDCA ≥12 
months; and the date of first centre visit in non-treated individuals. Adopted biochemical 
response criteria for this study were as previously documented; specifically those from 
Barcelona,6 Paris,5,8 Rotterdam7 and Toronto.9 Liver biopsy performed within 1 year of study 
entry was classified as baseline histological assessment. Tissue material was assessed 
for liver disease severity according to the Ludwig and Scheuer classification, and staged 
histologically as early (I/II) or late (III/IV). Any individual with evidence of cirrhosis before 
confirmed PBC diagnosis was classified as cirrhotic at baseline. Given that liver biopsy is 
no longer standard practice in PBC, advanced baseline disease was also deemed present 
according to clinical features (eg, hepatic decompensation) and/or biochemical indices as 
per the criteria established by ter Borg et al.26 
Individual patient follow-up was as per centre-specific practice, which although slightly 
variable included a clinic review at a minimum of every 12 months in the absence of cirrhosis, 
and at 6-monthly intervals for patients with evidence of advanced disease. Surveillance for 
HCC was conducted according to accepted international protocols, specifically 6-monthly 
ultrasound ± serum α-fetoprotein quantification. Confirmatory diagnosis was as per (timeline 
specific) internationally accepted protocols, either: (a) histopathological confirmation; (b) 
two coincident imaging techniques (CT, MRI, or contrast-enhanced ultrasonography) showing 
a focal lesion >2 cm with arterial phase enhancement; or (c) one imaging technique showing 
a focal lesion >2 cm with arterial phase enhancement in the presence of an α-fetoprotein 
serum titre >400 ng/mL.
Quality control
Individuals were excluded from analysis if follow-up data were insufficient or unavailable 
(<6 months’ follow-up or <2 clinic visits recorded), the start date of treatment or the exact 
date of major clinical events was unknown, and in the event of confirmed past/concomitant 
hepatitis B (HBV) or hepatitis C virus (HCV) infection, Wilson disease, α-1 antitrypsin 
deficiency, hereditary haemochromatosis, alcoholic liver disease, or overt overlapping 
features with autoimmune hepatitis. 
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Completeness, plausibility and validity of the data were carefully verified (by PJT, WJL 
and BEH). Extensive efforts, including individual site-centre visits (WJL) with personalised 
objective review of historical medical charts, were undertaken to retrieve missing data. Data 
pertaining to all cohorts were collected through to the end of December 2012. 
Statistical analysis
The primary endpoint of this study was defined as development of HCC, and patients without 
a clinical event in this regard were censored at date of last follow-up, liver transplantation 
or death. Univariate and multivariable Cox proportional hazards models were fit in order 
to assess the impact of individual covariates on the instantaneous rate of events, with 
time-to-event analysis also being ascertained through Kaplan-Meier estimates. In order 
to account for possible heterogeneity across centre-specific populations, analyses were 
further stratified by centre. 
Data are presented using the median and interquartile range for continuous variables 
and a value of P<.05 considered statistically significant. Analyses were conducted using 
SPSS Statistics V.22.0 (SPSS Inc, Chicago, Illinois, USA), and repeated in a multiple imputed 
database to validate findings and study any potential bias. SAS V.9.0 (SAS Institute, Cary, 
North Carolina, USA) was used to generate 10 imputed datasets before combining results 
and retesting of multivariable analysis. 
RESULTS
Characteristics of the patient population
Our study cohort comprised 4845 patients (Figure 1A and see Supplementary Table 1); 
however, those without clear documentation of HCC status (presence or absence thereof) 
during follow-up were exempt from further analysis, as were individuals diagnosed with 
HCC simultaneously or within 12 months of PBC diagnosis. Therefore the final working 
group consisted of 4565 patients with PBC (90% female), of which 123 developed evidence 
of HCC during their clinical course, yielding an actuarial incidence rate of 3.4 cases/1000-
patient years (Figure 1B). 
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Figure 1. Study cohort 
At time of analysis (A) data were available from 4845 patients; however, 257 patients were excluded 
given that documentation of HCC status (presence or absence thereof) was not recorded in medical 
records. A further 23 patients were excluded given that they were diagnosed at the same time (within 
the 1st year) of PBC diagnosis and identification of risk factors pertaining to HCC risk would have been 
inaccurate. The final study group therefore consisted of 4565 patients (B) of which 123 developed HCC 
over 36,577 patient years.
In PBC, HCC incidence is increased in men and patients with advanced disease at baseline
Development of HCC was associated with significantly poorer transplant-free and overall 
survival (hazard ratio [HR] 22.61, 95% CI 18.34 to 27.87; P<.0001), and at baseline future risk 
of HCC was increased particularly in patients of male gender (Figure 2A and Supplementary 
Table 2) and those having moderate/late (advanced) biochemical disease (Figure 2B). Men 
were observed to have a significantly greater incidence of HCC when analysis was restricted to 
patients with advanced disease (Supplementary Figure 1), and gender remained a significant 
risk factor following multivariable adjustment of baseline covariates (Supplementary Table 
2). Subsequent transplant-free survival following development of cancer was not, however, 
different between men and women (Supplementary Figure 2).
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Overall, the proportion of patients with histological evidence of advanced fibrosis at 
PBC diagnosis was also significantly greater in patients who developed HCC (P<.0001); but 
the absence of baseline liver biopsy in many of our study group (n=2685) precluded further, 
more explicit analysis pertaining to histological characteristics. 
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Figure 2. Cumulative HCC incidence according to gender and baseline PBC disease severity
Kaplan Meier estimates of HCC incidence in: (A) Men vs. women, 6.7 vs. 2.6 cases per-1,000 patient 
years; and (B) patients with advanced vs. early disease, 7.6 vs. 1.3 cases per-1,000 patient years 
(according to criteria by ter Borg et al. [26]).
Biochemical non-response predicts future risk of HCC in PBC patients
Overall, 96% (n=4361) of individuals remained under follow-up for a minimum of 12 months. 
Analysing this cohort in its entirety, 85% (n=3724) of patients were in receipt of UDCA therapy 
for ≥1 year, in keeping with the demographic of PBC treatment reported elsewhere.27 No 
significant difference between HCC appearance rates was observed, however, between 
treated versus non-treated patients (P=.972; Supplementary Figure 3). 
Twelve-month biochemical response (Paris-I) was calculable in 65% (n=2425) of all 
treated individuals and met by an inclusive 72% (n=1734). On univariate analysis HCC risk 
was observed to be significantly greater in biochemical non-responders according to Paris-I, 
Paris-II, Rotterdam and Toronto (Table 1 and Figure 3) but not Barcelona criteria (HR 1.48, 
95% CI 0.93 to 2.36; P=.099). Furthermore, biochemical non-response retained its predictive 
value when analysis was inclusive of patients not receiving UDCA (Supplementary Figure 
4), and when extending the period over which response was assessed from 1 to 2 years 
(calculable in n=2725 (73%) of all UDCA-treated patients—HR 4.41, 95% CI 2.60 to 7.47; 
P<.0001; Supplementary Figure 5). Given that the most widely adopted criterion in clinical 
practice is Paris-I,3,27,28 this model is used to classify biochemical response in subsequent 
discussion unless otherwise specified. 
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Figure 3. Cumulative HCC appearance rates according to biochemical response 
Kaplan Meier estimates of HCC incidence in biochemical non-responders (NR) versus responders (R)
as per the following criteria: (A) Paris I, 6.6 vs. 1.4 cases per-1,000 patient years; (B) Paris II, 4.3 vs. 
1.2 cases per 1,000 patient years; (C) Rotterdam, 11.9 vs. 1.8 cases per 1,000 patient years; and (D) 
Toronto, 4.5 vs. 2.4 cases per 1,000 patient years. No significant differences were observed when 
biochemical response was stratified using Barcelona criteria (data not presented).
Analysis restricted to UDCA-treated patients only in whom 12-month biochemical data available to 
calculate response (24-months in the case of Toronto criteria [9]). Time measured in years following 
calculation of biochemical response. 
Biochemical non-response predicts added HCC risk in men with PBC
Having identified that HCC developed more frequently in male patients compared to females, 
we next analysed the performance of biochemical response criteria specifically in men with 
PBC. Indeed, HCC incidence was greater in male non-responders versus responders (HR 
4.44, 95% CI 1.29 to 10.20; P<.001) (Figure 4), and the former represented the group at 
highest future risk. 
Given that gender and advanced disease may adversely influence attainment of 
satisfactory biochemical response,27,29 an assessment of interaction terms was conducted. 
Although a greater proportion of men relative to women were observed to have advanced 
baseline disease (Supplementary Figure 1), no significant interactions between gender and 
disease stage (P=.346), gender and biochemical response (P=.285) or biochemical response 
and disease stage (P=.690) were identified; thus strengthening the independent value of 
biochemical non-response in predicting future HCC risk. 
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Figure 4. HCC incidence stratified according to gender and biochemical response
Kaplan Meier plot comparing cumulative HCC incidence in male non-responders vs. female non-
responders (HR: 3.70, 1.71-8.00, P<.001; 18.2 vs. 5.2 cases per 1,000 patient years, log-rank P<.001); 
male non-responders vs. male responders (HR: 4.44, P<.001; 18.2 vs. 5.4 cases per 1,000 patient years, 
log-rank P<.001); male responders vs. female non-responders (HR: 0.90, 0.36-2.21, P=.811; 5.4 vs. 
5.2 cases per 1,000 patient years. log-rank P=.766); female non-responders vs. female responders 
(HR: 4.74, 2.44-9.22, P<.0001; 5.2 vs. 1.1 cases per-1,000 patient years, log-rank P<.0001); and male 
responders vs. female responders (HR: 5.29, 2.03-13.78, P<.001; 5.4 cases vs.1.1 cases per-1,000 
patient years, log-rank P=.0001).
Analysis conducted in UDCA-treated patients only, for whom 12-month biochemical data was available 
to calculate response. Time measured in years following calculation of biochemical response.
Biochemical non-response predicts HCC risk irrespective of baseline PBC disease stage
As HCC most often develops on a background of severe fibrosis/cirrhosis—a factor associated 
with reduced biochemical response to treatment29—subsequent analysis focused exclusively 
on patients with evidence of advanced hepatic disease at time of PBC diagnosis. Within 
this inherently high risk population, stratification through biochemical response identified 
that the subgroup at greatest hazard of HCC fell into the non-response category (HR 2.79, 
95% CI 1.18 to 6.94; P=.02), whereas in biochemical responders of matched disease stage, 
development of HCC was much less apparent (Figure 5A). Although fewer patients with 
advanced disease at baseline were exposed to UDCA therapy (Supplementary Table 3), 
when the cohort was extended to include non-UDCA-treated patients, biochemical non-
response was still able to identify those at increased future HCC risk (Supplementary Figure 
6A).
Given reports of HCC developing in the absence of advanced fibrosis,15,24 thereafter we 
conducted an evaluation of risk factors exclusively in patients presenting with early-stage 
PBC at baseline. Across this subgroup, HCC developed infrequently and as a relatively late 
event (Figure 5B and Supplementary Figure 6B); however, future HCC risk was observed to 
be significantly greater in patients who failed to achieve 12-month biochemical response 
(P=.005). 
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Figure 5. HCC incidence in patients with varying disease stage stratified according to biochemical 
response
Kaplan Meier estimate restricted to those with: (A) Advanced presenting disease and biochemical non-
response (NR) versus response (R), 11.2 vs. 4.4 cases per 1,000 patient years; and (B) Early presenting 
disease and biochemical non-response versus response, 4.7 vs. 1.2 cases per 1,000 patient years.
Analysis conducted in UDCA-treated patients only in whom 12-month biochemical data available to 
calculate response. Time measured in years following calculation of biochemical response. 
Biochemical non-response remains the most significant predictor of future HCC risk in PBC
When performing a multivariable analysis of all hitherto identified risk factors—both 
those present at time of PBC diagnosis as well as over time—only thrombocytopenia and 
biochemical response retained statistical significance (Table 1). This observation held true 
when extending the analysis to include patients not receiving UDCA as well as when the 
model was adjusted for centre-specific heterogeneity. 
In order to confirm an absence of bias from missing data we next performed multiple 
imputation analysis (Supplementary Figure 7).30 In doing so, biochemical non-response was 
validated as an independent and significant predictor of future HCC risk (Table 1 and Figure 
6).
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Rotterdam non-response
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Paris-I non-response
Hazard ratio (95% CI)
Adjusted HR: 3.44; P < .0001
Adjusted HR: 2.88; P = .011
Adjusted HR: 3.83; P < .0001
Adjusted HR: 2.10; P = .001
Adjusted HR: 3.42; P < .0001
Adjusted HR: 2.75; P < .0001
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Adjusted HR: 3.77; p < .0001
Adjusted HR: 1.37; P < .0001
A
B
C
Figure 6. Comparative (multivariable) evaluation of biochemical response in predicting HCC risk
Performance of biochemical response criteria in predicting future HCC risk following: (A) Individual 
multivariable analysis (stepwise backward model) adjusted for age at PBC diagnosis, sex, disease stage, 
hepatic decompensation, remaining laboratory parameters (not included in respective biochemical 
response criteria) and centre-specific heterogeneity; (B) Analysis as in A following multiple imputation 
to correct for missing data values – UDCA treated patients only; and (C) Analysis as in B following 
inclusion of non-UDCA untreated patients in whom 12-month biochemical response criteria was 
calculable.
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DISCUSSION
We report a robust and uniquely powered evaluation of the largest internationally 
representative PBC cohort assembled to date, with the specific aim of identifying risk factors 
for HCC. In doing so we demonstrate that HCC is a critical event in the clinical course of PBC 
and associated with significantly poorer transplant-free survival. Although the incidence 
is significantly greater in male patients and those with advanced disease, 12-month 
biochemical non-response represents an independent and additive predictor for HCC, and 
on performing a comparative assessment of all identified covariates remained the most 
significant risk factor.
Historically, development of HCC in PBC was considered to be predominantly restricted 
to men, with a more variable correlation reported for disease stage.10,11,14,17,21,22 Initially 
perceived as a relatively rare complication, some report that the incidence is in fact 
comparable to chronic HCV infection,20,31 and indeed we found a similar frequency of HCC 
in PBC as previously documented.16 Larger, more contemporary reports also describe an 
association with male gender,24 as well as older age and advanced histological disease. 
However, the relatively low number of patients included in several earlier studies, as well 
as restricted geographical influence across others, have yielded many inconsistent results. 
In agreement with preceding investigators we now robustly validate male sex as a risk 
factor,21,24,32 although on further analysis statistically significant differences between genders 
appear restricted to patients with advanced disease at presentation. Although suggestive 
that as a subgroup men are more likely to be diagnosed with PBC at a later stage,27 advanced 
disease was not found to be an interaction moderator in this regard. Prior studies have 
also documented relatively higher rates of past HBV infection and alcohol consumption in 
men.24 Despite being considered as exclusion criteria in our study, the complete distribution 
of past viral infection by gender across our global cohort could not be obtained, and viral 
serology would not have been routinely tested in patients diagnosed with PBC pre-1980. 
The reason for increased hepatocarcinogenesis in male patients across a disease with 
such overwhelming female predisposition remains unknown, although may be due to a 
lack of protective effect from oestrogen-mediated inhibition on specific cytokines such as 
interleukin-6.33 This however remains speculative.
In addition to male gender, advanced biochemical disease and thrombocytopenia were 
factors identifiable at PBC diagnosis associated with future risk of HCC—in keeping with 
many early reports wherein tumours developed exclusively on a background of late-stage 
disease.14,17,21,22,34 The majority of patients in our cohort received UDCA, and the effect 
of PBC-specific therapy with regard to HCC risk represented an understudied topic.10,11 
UDCA therapy per se had no apparent effect on risk of HCC development across our 
cohort; but when stratifying according to several biochemical response criteria, patients 
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classified as non-responders developed significantly more HCC during their clinical course. 
Indeed, risk was significantly greater in biochemical non-responders and this observation 
retained significance when inclusive of patients who never received UDCA but for whom 
categorisation of response was possible. It is likely therefore that achievement of biochemical 
response according to specific criteria—irrespective of whether this occurs in the context 
of therapy—infers a surrogate associated with improved HCC-free survival rather than a 
chemo-preventative effect of UDCA. The present evaluation not only validated findings of 
a previous much smaller study,11 but on performing a sub-analysis in patients identified as 
inherently high risk (men and those with advanced disease), biochemical non-response 
was associated with additional future risk of HCC. Indeed, on multivariable analysis only 
thrombocytopenia and biochemical non-response retained statistical significance and 
superseded the effect of gender and other tested parameters of disease stage. Of interest, 
platelet count is commonly employed as a surrogate of portal hypertension,35 and as part of 
the AST/platelet ratio has recently been validated as an independent and additive biomarker 
of transplant-free survival in biochemical responders.3 However, given the relatively small 
number of HCC observed in responding patients, substratification of cancer risk in such 
regard would prove difficult. 
The lower incidence in patients achieving biochemical response has practical implications 
for HCC surveillance (Supplementary Table 4), which at present is advocated for all chronic 
liver disease patients in which the annual incidence approaches or exceeds 1.5%.12,36 Specific 
to PBC, surveillance recommendations apply to all with advanced histological disease; 
however, in the present day clinical setting liver biopsy is rarely performed, and the advent 
of progressive imaging techniques makes tissue analysis rarely necessary in the ‘diagnostic 
work-up’ of suspected HCC.13,36 The use of transient elastography as an alternative risk 
marker of disease stage is also evolving,37 although due to limited availability still requires 
aetiology-specific validation. The prevalence of a globally aging population represents a 
further impending burden on healthcare services. In this regard, older age is increasingly 
recognised to confer additional HCC risk;38,39 the average age at time of HCC diagnosis being 
67 years across our study population. 
The emergence of well-substantiated treatment response criteria has allowed accurate 
prediction of transplant-free survival in patients with PBC,3,5-9,27 and herein we illustrate that 
failure to achieve the same biochemical endpoints confers increased HCC risk. Moreover, 
the relatively low incidence among those who achieve adequate biochemical response, 
even in men and individuals with evidence of advanced presenting disease, questions 
routine HCC surveillance in well-treated patients irrespective of gender and disease stage. 
Therefore, we recommend particular attention to: (1) male patients who either fail to 
achieve biochemical response (irrespective of disease stage), or in whom cirrhosis is already 
established (irrespective of biochemical response status); and (2) all female non-responders 
with evidence of advanced disease. 
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As with any longitudinal study evaluating long term outcomes, some patient data were 
inevitably not available during follow-up, whereas censoring at time of liver transplantation 
or death (free of HCC) may have led to pre-selection bias by restricting inclusion of patients 
who survive without transplant. However, such patients are no longer at risk of native 
liver HCC over time, and this approach is commonly adopted in studies where transplant-
free mortality is not the primary endpoint. Moreover, all explanted livers were rigorously 
examined for the presence of HCC irrespective of transplant indication. In addition, our 
overall large sample size as well as validation of results through multiple imputation (Table 
1; Figure 6 and Supplementary Figure 7) demonstrate that any missing data have not 
introduced meaningful bias. Nevertheless, it is plausible that a proportion of patients who 
died during follow-up may have had undiagnosed HCC, and complete post-mortem data in 
this regard are not possible to obtain. Another limitation to our study is that disease stage 
was assessed non-invasively for the most part—a reflection of the current standard of care 
in PBC. Further external validation of our results in this regard is important, albeit accepting 
the considerable challenges to long term prospective studies in PBC: slowly progressive 
and uncommon, with currently only one established treatment, and an absence of routine 
histological evaluation as part of standard clinical practice. We were also unable to obtain 
data pertaining to smoking status and comorbidities/coexisting extrahepatic autoimmune 
diseases;40 however, many previous studies have failed to confirm an association with HCC 
in this regard.16,24 While the demography of our cohort is consistent with prior reports, we 
recognise that studies such as ours are heterogeneous with respect to referral practice 
between centres and countries. Opportunities therefore continue for large scale population 
studies in PBC to confirm our findings and better define strategies for clinical practice. 
In conclusion, based on our results from the largest multicentre international study to 
date, we report that HCC is a rare yet critical event in the clinical course of PBC, and one 
associated with significantly poorer outcome. While the frequency of HCC was increased 
in men and those with advanced disease, biochemical non-response remained the most 
important risk factor, retaining predictive value independently and additively of disease 
stage and patient gender. Our globally representative data therefore add new knowledge to 
HCC risk in PBC and informs ongoing discussions about stratified treatment and surveillance. 
Additionally, given the potential use of surrogate endpoints in development of new therapies 
beyond UDCA, our data lend support to a meaningful reduction in HCC risk for PBC patients 
meeting specific biochemical response criteria.
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Supplementary Figure 1. HCC incidence stratified according to gender and disease stage at 
presentation
Kaplan Meier estimates illustrating differences of HCC incidence rate in male patients with advanced 
disease vs. females with advanced disease (HR: 2.90, 1.60-5.32, P<.001; log-rank P<.001); male 
patients with advanced disease vs. males with early disease (HR: 8.86, 2.58-30.49, P<.0001; log-rank 
P<.001); male patients with early disease vs. females with early disease (HR: 1.56, 0.47-5.18, P=.47; 
log-rank P=.47); female patients with advanced disease vs. males with early disease (HR: 3.06, 0.94-
9.94, P=.06; log-rank P=.06); and female patients with advanced disease vs. females with early disease 
(HR: 4.77, 2.84-8.01, P<.0001; log-rank P<.0001). 
Time measured in years following PBC diagnosis.
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Supplementary Figure 2. Transplant-free survival according to gender in patients diagnosed with 
HCC
Kaplan Meier plot of subsequent transplant-free survival in men vs. women following development 
with HCC. 
Time represented in months following tumor diagnosis.
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Supplementary Figure 3. Cumulative HCC incidence stratified according to UDCA treatment 
Kaplan Meier estimate of HCC incidence in UDCA treated versus untreated patients. 
Time measured in years following calculation of biochemical response.
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Supplementary Figure 4. Cumulative HCC appearance rates according to biochemical response 
criteria
Kaplan Meier estimates of HCC incidence in biochemical non-responders (NR) versus responders (R)
as per the following criteria: (A) Paris I, 6.0 vs. 1.3 cases per-1,000 patient years; (B) Paris II: 4.4 vs. 1.1 
cases per 1,000 patient years; (C) Rotterdam: 9.9 vs. 1.6 cases per 1,000 patient years; and (D) Toronto: 
4.0 vs. 2.1 cases per 1,000 patient years. No significant difference in HCC incidence was observed 
through biochemical stratification via Barcelona criteria (data not presented).
Analysis pertains to UDCA-treated as well as untreated individuals in whom 12-month biochemical 
data was available to calculate response (24-months in the case of Toronto criteria). Time measured in 
years following calculation of biochemical response. 
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Supplementary Figure 5. Cumulative HCC appearance rates according to biochemical response 
assessed at 12-24 months
Kaplan Meier estimates of HCC incidence stratified according to biochemical response assessed at 12-
24 months: 6.5 (non-responders) vs. 1.4 (responders) cases per-1,000 patient years.
Analysis restricted to UDCA-treated patients only, in whom 12-24month biochemical data available to 
calculate response. Time measured in years following calculation of biochemical response. 
A Advanced Presenting Disease B           Early Presenting Disease
151050
Cu
m
ul
ati
ve
 H
CC
 In
ci
de
nc
e 
(%
) 20
15
10
5
0
436             185               71             33  Patients at Risk NR
R
P = .05
Time (Years)
198             116               55       21   Patients at Risk 
20151050
Cu
m
ul
ati
ve
 H
CC
 In
ci
de
nc
e 
(%
) 40
30
20
10
0
216        138         75            34            6  Patients at Risk  
Time (Years)
1160      770        383   141         26 Patients at Risk  
NR
R
P = .003
A Advanced Presenting Disease B           Early Presenting Disease
151050
Cu
m
ul
ati
ve
 H
CC
 In
ci
de
nc
e 
(%
) 20
15
10
5
0
436             185               71             33  Patients at Risk NR
R
P = .05
Time (Years)
198             116               55       21   Patients at Risk 
20151050
Cu
m
ul
ati
ve
 H
CC
 In
ci
de
nc
e 
(%
) 40
30
20
10
0
216        138         75            34            6  Patients at Risk  
Time (Years)
1160      770        383   141         26 Patients at Risk  
NR
R
P = .003
Supplementary Figure 6. HCC incidence in patients with varying disease stage stratified according to 
biochemical response 
Kaplan Meier estimate restricted to those with (A) advanced presenting disease and biochemical non-
response (NR) versus response (R); 10.8 vs. 4.8 cases per 1,000 patient years; and (B) early presenting 
disease and biochemical non-response versus response: 4.0 vs. 1.0 cases per 1,000 patient years.
Analysis conducted in UDCA-treated and untreated patients in whom 12-month biochemical data 
available to calculate response. Time measured in years following calculation of biochemical response.
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Supplementary Figure 7. Estimated HCC appearance rates according to biochemical response 
following multiple imputation
Kaplan Meier estimates of HCC incidence in biochemical non-responders versus responders (Paris-I) 
following multiple imputation: 59.6 vs. 15.4 cases per-1,000 patient years (HR: 3.74, 3.24-4.33; 
P<.0001).
Data presented for UDCA-treated patients only. Time zero from point of assessment of biochemical 
response.
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SUPPLEMENTARY TABLES 
Supplementary Table 1. Patient characteristics 
Total group 
(n=4565)
No HCC
(n=4442)
HCC
(n=123)
Median age time of diagnosis 
(IQR)
53.2 (45.1-62.1) 53.2 (45.1-62.1) 54.0 (47.3-62.1)
Males 468 (10%) 441 (10%) 27 (22%)
AMA positive* 4041 (89%) 3929 (89%) 112 (91%)
Not available 105 (2.3%) 100 (2.2%) 5 (4.1%)
Biochemical stage**
Early 2020 (44%) 1993 (45%) 27 (22%)
Advanced 960 (21%) 908 (20%) 52 (42%)
Laboratory parameters (baseline)
Albumin*** 1.14 (1.06-1.23) 1.14 (1.06-1.23) 1.08 (1.00-1.19)
ALP*** 2.10 (1.31-3.72) 2.10 (1.31-2.72) 2.23 (1.33-3.70)
ALT*** 1.61 (1.00-2.58) 1.60 (1.00-2.57) 1.80 (1.21-2.90)
AST*** 1.40 (0.92-2.20) 1.40 (0.92- 2.20 1.74 (1.21-2.82)
Bilirubin*** 0.66 (0.45-1.06) 0.64 (0.45-1.00) 1.10 (0.80-2.18)
Platelets 240 (181-294) 242 (184-295) 182 (120-231)
Hepatic decompensation**** 140 (3.1%) 122 (2.7%) 18 (15%)
* AMA status not available in 2.3% (n=105; total cohort), 2.2% (n=100; no HCC group) and 4.1% (n=5; 
HCC group) of patients.
** Rotterdam classification as per ter Borg et al. Baseline biochemical disease stage not calculable 
in 35% (n=1583; total cohort), 35% (n=1541; no-HCC group) and 34% (n=42; HCC group) of patients.
*** Given variations in assay techniques across the studied institutions, a ratio to the upper limit of 
normal (ULN) was taken.
**** Within 1st year of PBC diagnosis.
Supplementary Table 2. Baseline factors predictive of future HCC risk 
Univariate analysis Multivariable analysis*
Hazard ratio 
(95% CI)
P-value Adjusted hazard ratio* 
(95% CI)
P-value
Advancing age at PBC diagnosis** 1.21 (1.14-1.41) .022 - n.s.
Male gender 2.91 (1.90-4.48) <.0001 5.41 (1.56-18.76) .008
Higher serum AST 1.24 (1.13-1.36) <.0001 - n.s.
Advanced biochemical disease*** 2.72 (1.43-5.18) .022 2.71 (1.43-5.15) .023
Thrombocytopenia**** 1.65 (1.42-1.90) <.0001 1.42 (1.11-1.92) .013
Hepatic decompensation 9.89 (5.89-16.59) <.0001 - n.s.
* Adjusted for center-specific heterogeneity
** Per 10-year increase
*** As per to the criteria by ter Borg et al. Given that no significant difference in HCC incidence existed 
between those with moderate vs. late-stage disease, these two groups were combined in further 
analyses (‘advanced biochemical disease’).
**** Per-50 x103/mm3 decline in platelet count
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Supplementary Table 3. UDCA treatment exposure according to disease severity*
Early disease Advanced disease Total P-value
UDCA treated 1679 770 2449
.015UDCA non-treated 309 182 491
Total 1988 952 2940
Years to UDCA treatment initiation 
(median; IQR)
0.3 (0.0-2.7) 0.4 (0.0-3.6) .588
* Data presented for patients in whom > 12-month follow-up and baseline biochemical disease 
severity available.
Supplementary Table 4. HCC incidence in varying risk groups*
Overall Male Female Advanced 
baseline 
disease
Early 
baseline 
disease
Biochemical 
non-
response** 
Biochemical 
response**
Male 6.7 - - 18.9 2.4 18.2 5.4
Female 2.6 - - 6.9 1.5 5.2 1.1
Advanced baseline 
disease
7.6 18.9 6.9 - - 11.2 4.4
Early 
baseline disease
1.3 2.4 1.5 - - 4.7 1.2
Biochemical 
non-response** 
6.6 18.2 5.2 18.2 4.7 - -
Biochemical response** 1.4 5.4 1.1 5.4 1.2 - -
* Expressed per 1,000-patient-years
** Paris-I; data presented for UDCA-treated patients only
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Age, but not sex, alters response to ursodeoxycholic acid in 
patients with primary biliary cirrhosis – an international and 
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ABSTRACT
Background & Aim: Primary biliary cirrhosis (PBC) predominantly affects middle-aged 
women, whereas phenotypic and outcome data pertaining to men, and younger patients is 
limited. The aim of this study was to identify whether sex and/or age associate with distinct 
patterns of biochemical response and variation in transplant-free survival. 
Methods: A longitudinal study was performed evaluating 4117 patients from the Global 
PBC Study cohort, with regards to biochemical response to ursodeoxycholic acid (UDCA) 
according to Paris-1 criteria and transplant-free survival. Both logistic regression and Cox 
regression analyses were performed, adjusted for age, sex, disease severity and center. 
Results: Men were older at baseline (56.7±12.6 vs. 52.4±11.7, p<.0001), with more advanced 
disease as demonstrated by higher serum bilirubin, lower albumin and lower platelet count 
and exhibited lower biochemical response rates than women (Paris I criteria at 1 yr: 60% vs. 
70%, p<.0001). On multivariable analysis, however, sex was not an independent predictor 
of response (OR 0.81, 95% CI, 0.62-1.07, p=.13) or transplant-free survival (HR 1.10, 95% 
CI 0.74-1.11, p=.34). By contrast, PBC patients with better biochemical profiles (serum 
bilirubin, alkaline phosphatase and AST levels) had a higher probability of response to UDCA 
(p<.0001). Younger patients had lower biochemical response rates than older individuals of 
matched disease stage, regardless of sex (OR 2.35, 95% CI 1.53-3.61, p<.0001). 
Conclusion: Advanced baseline stage and age (but not male sex) are predictive of therapeutic 
failure and adverse clinical outcome in PBC. Increasing recognition of these phenotypic 
variants may contend for the earlier application of additional therapies prior to evaluation 
of 1-yr UDCA response. 
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INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic autoimmune disorder of cholestasis, in which 
patient outcome is largely dictated by development of cirrhosis and portal hypertension. 
Classical phenotypic descriptors imply disease restriction to middle-aged, often post-
menopausal women with peak incidence between 40-60 years of age.1-3 Thus, even large 
studies have provided limited insight into the influence of gender and age on disease 
outcomes.4, 5 
Several studies have demonstrated that the clinical impact of PBC differs between the 
sexes and different age groups. Women are frequently symptomatic at presentation, with 
an increasing burden of pruritus,6, 7 and scores higher in the fatigue domain of the PBC-
40 quality of life questionnaire.5 By contrast, male PBC patients more often present with 
advanced baseline disease,5-7 harbor a greater risk of hepatocellular carcinoma (HCC)8 and 
experience significantly poorer transplant-free survival.4 Moreover, male sex has recently 
identified as an independent risk factor for incomplete response to ursodeoxycholic acid 
(UDCA), independent of presenting age, presence of portal hypertension, and biochemical 
indices of disease severity,5 alluding to the possibility of a more rapidly progressive clinical 
course. 
Age at baseline appears to add another layer of complexity to clinical phenotypes and 
the recent study conducted by the UK-PBC consortium not only recognized an increased 
prevalence of younger presenting women (25% aged 49 or less), but also an inverse 
correlation of patient age and likelihood of meeting biochemical response in females, but in 
males age appeared to have no significant impact on response.5 
The aims of this study were to validate the negative prognostic impact of patient age 
and sex on treatment response and transplant-free survival using a large internationally 
representative and statistically powered cohort of PBC patients.
METHODS
Subjects and study design 
This was a longitudinal retrospective study of treatment response and clinical outcomes in 
a well-defined cohort of adult PBC patients. Demographic, clinical and outcome data were 
collected from 15 centers across Europe and North America as part of the Global PBC Study 
Group database, as previously described.9 The cohort included adult patients > 18 years of 
age diagnosed with PBC between 1959 and 2012, as defined by published criteria.1, 10 
Time zero (baseline) was defined as the date of initiation of UDCA. The primary endpoints 
were biochemical response as per the Paris-I criteria (alkaline phosphatase [ALP] <3 times 
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the upper limit of normal (xULN), aspartate aminotransferase (AST) < 2xULN and normal 
serum bilirubin level),11 generally considered as the criteria with best performance in 
predicting outcome,5, 8 and liver transplant-free survival. Patients who did not meet clinical 
endpoints (liver transplant or death) were censored at their last date of available follow-up. 
This study was reviewed and approved by all local Institutional Review Boards across the 15 
centers. 
Statistical analysis
Continuous data are expressed as mean ± standard deviation (SD) or median and interquartile 
range (IQR) depending on data distribution, and categorical data as proportions. Unpaired 
t-tests or the Mann-Whitney U-test were used to determine whether there were significant 
differences between groups for continuous variables, and differences in categorical data 
were analyzed using the Chi-square test. Unadjusted differences in survival between males 
and females were assessed using Kaplan-Meier analysis with comparisons made using 
the log-rank test. Univariable and multivariable associations were computed using logistic 
regression for biochemical response (odds’ ratio, OR, and 95% confidence interval, CI) and 
Cox proportional hazards regression for transplant-free survival (hazards’ ratio, HR, and 95% 
CI). Univariable analysis included: sex, age at diagnosis, era of diagnosis (before or after 
1998, ie. the median date of diagnosis for the whole cohort), histologic stage as defined by 
Scheuer’s12 and Ludwig’s criteria2, biochemical stage as defined by the Rotterdam criteria13 
(early disease: normal bilirubin and albumin, moderately advanced: either abnormal 
bilirubin or albumin, advanced: abnormal bilirubin and albumin), biochemical response and 
surrogate of portal hypertension (platelet count < 100x103/mm3 or < 150x103/mm3).14, 15 Age 
at baseline was analyzed as both a continuous variable and as a categorical variable grouped 
as < 35 and > 65 years and the intervening decades to allow for an equitable distribution for 
analysis. 
The analyses were performed using multiple imputation by MCMC method for missing 
data (Proc MI in SAS version 9.3). Multiple imputation was based on the assumption that 
data were missing at random, with 10 imputed datasets created from iterations to reduce 
sampling variability. Rubin’s rules were used for estimation of parameters of interest and 
standard error.16, 17 The variables included in the process of imputation were: AST, alanine 
aminotransferase (ALT), ALP, total bilirubin, albumin and platelets. 
Non-normally distributed data were transformed using log transformation. A two-sided 
P<.05 was considered statistically significant. Statistical analysis was performed using SPSS 
Software version 21.0 (SPSS Inc., Chicago, IL) and SAS version 9.3 (SAS Institute Inc., Cary, 
NC). 
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RESULTS
Patient characteristics
4845 patients were included in the Global PBC study group dataset; a full description of 
the cohort can be found in our previously published work.8, 9 For the current study, a total 
of 4117 patients were analyzed after excluding those < 18 years of age and those with no 
or unknown treatment status. 413 (10%) were male and 3704 (90%) were female with a 
median follow-up of 7.7 years (IQR 3.9-12.0); 566 patients died and 320 were transplanted. 
Clinical differences at start of follow-up between sexes and age groups
At baseline men were older (56.7 ± 12.6 years vs 52.4 ± 11.7 years, P<.0001), with lower 
serum albumin (1.12 times the lower limit of normal [xLLN] vs 1.14xLLN, P=.03), higher 
bilirubin (0.82xULN vs 0.62xULN, P<.0001) and were more likely to have thrombocytopenia 
(22% vs 14% with platelets <150x103//mm3, P<.0001) in comparison with women (Table 1). 
Meanwhile, younger patients were more likely to be diagnosed at an earlier disease stage 
than older patients, with higher albumin and platelets (P<.0001) as well as lower bilirubin 
(P<.0004), though higher transaminases (P<.0001) (Table 2). 
Effect of gender on biochemical response to UDCA
3978 (97%) of patients had at least 1 year of follow-up. Prior to adjusting for baseline factors, 
there was a significant difference in the crude biochemical response rate between males 
and females (60% vs 70%, P<.0001). However, after adjusting for parameters corresponding 
to disease severity (ie. platelet count, biochemical disease stage, baseline bilirubin and ALP), 
year of diagnosis and center, male sex was no longer an independent predictor of response 
(OR 0.81, 95%CI 0.62-1.07, P=.13) (Table 3). There were no clinically significant differences 
between bilirubin and albumin values for males and females within each biochemical 
disease stage (Table 4). 
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Table 1. Baseline Characteristics
Parameter All patients
N=4117
Male patients
N=413
Female patients
N=3704
P-value
Age at start of follow-up, mean ± SD 54.2 ± 11.8 57.8 ± 12.3 53.4 ± 11.7 < .0001
AMA positive, no. (%) 3631 (91) 379 (92) 3252 (90) .19
Year of diagnosis, no. (%) .68
  <1990 811 (20) 811 (19) 732 (20)
   1990-2000 1633 (39) 1633 (38) 1478 (39)
   2000-2010 1515 (37) 1515 (39) 1352 (37)
   >2010 158 (4) 158 (4) 142 (4)
Disease stage (biochemical),b no. (%) < .001
   Early 1686 (68) 133 (52) 1553 (70)
   Moderately advanced 598 (24) 85 (34) 513 (23)
   Advanced 192 (8) 36 (14) 156 (7)
Disease stage (histological),c no. (%) .84
   Early stage disease (I or II) 1089 (68) 104 (68) 985 (68)
   Late stage disease (III or IV) 521 (32) 48 (32) 473 (32)
Laboratory parametersd
   AST (xULN) 1.45 (0.94-2.23) 1.40 (0.92-2.13) 1.47 (0.94-2.25) .37
   ALT (xULN) 1.66 (1.03-2.60) 1.64 (1.03-2.68) 1.66 (1.03-2.60) .89
   ALP (xULN) 2.14 (1.36-3.79) 2.02 (1.40-3.49) 2.15 (1.35-3.80) .39
   Albumin (xLLN) 1.14 (1.06-1.23) 1.12 (1.03-1.23) 1.14 (1.06-1.23) .03
   Total bilirubin (xULN) 0.65 (0.46-1.00) 0.82 (0.59-1.44) 0.62 (0.44-1.00) < .0001
   Platelets, x103/mm3 243 (186-297) 215 (160-261) 247 (189-301) < .0001
Abbreviations: AMA, anti-mitochondrial antibody, SD, standard deviation; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ULN, upper limit of 
normal; LLN, lower limit of normal. 
aAMA status was unavailable for 112 patients (3 males and 109 females).
bBiochemical disease stage defined as per ter Borg et al.15 (early: normal serum bilirubin and albumin 
levels, moderately advanced: abnormal bilirubin or albumin levels, advanced: abnormal serum 
bilirubin and albumin levels)
cBaseline biopsy was performed in 49% (2029 patients; 207 males and 1822 females). Baseline 
histological disease stage was unavailable in 21% (n=419, all patients), 27% (n=55, male patients) and 
20% (n=364, female patients).
dDue to differences in normal thresholds between centers, laboratory values are listed as factors of the 
upper limit of lower limit of normal. 
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Table 3. Multivariable logistic regression for factors affecting biochemical response to UDCA (Paris-I)
 Entire cohort (n=4117)
Baseline variable OR 95% CI P-value
Male sex 0.81 0.62 - 1.07 .13
Older age (per decade) 1.10 1.10 - 1.22 < .001
Later era 1.02 1.01 - 1.03 < .0001
Platelet count (per 50x103/mm3 decline) 0.94 0.89-0.98  .01
Early stagea 1.00   
Moderately advanced stagea 0.54 0.43-0.69 < .0001
Advanced stagea 0.46 0.31-0.67 < .0001
Baseline log bilirubin (xULN) 0.22 0.18 - 0.27 < .0001
Baseline log ALP (xULN) 0.37 0.32 - 0.42 < .0001
Abbreviations: ALP, alkaline phosphatase; OR, Odds’ ratio; ULN, upper limit of normal.
a Biochemical disease stage defined as per ter Borg et al.15 (early: normal serum bilirubin and albumin 
levels, moderately advanced: abnormal serum bilirubin or albumin levels, advanced: abnormal serum 
bilirubin and albumin levels).
Table 4. Median bilirubin and albumin levels stratified by biochemical stage
Bilirubin xULN (IQR) Bilirubin xULN (IQR) P-value
Biochemical disease stagea
Early 0.6 (0.5-0.8)  0.5 (0.4-0.7) < .0001
Moderately advanced 1.2 (0.9-1.9)  1.1 (0.7-1.8) .21
Advanced 2.3 (1.3-3.0)  1.9 (1.0-3.3) .79
Albumin xLLN (IQR  Albumin xLLN (IQR)  P-value
Biochemical disease stagea
Early 1.2 (1.1-1.3)  1.2 (1.1-1.3) .22
Moderately advanced 1.1 (1.0-1.2)  1.1 (1.0-1.2) .63
Advanced 0.9 (0.8-1.1)  0.9 (0.8-1.0) .49
Abbreviations: IQR, interquartile range; LLN, lower limit of normal; ULN, upper limit of normal.
a Biochemical disease stage defined as per ter Borg et al.15 (early: normal serum bilirubin and albumin 
levels, moderately advanced: abnormal serum bilirubin or albumin levels, advanced: abnormal serum 
bilirubin and albumin levels).
Effect of age on biochemical response to UDCA
On univariable analysis, older age at diagnosis was associated with improved biochemical 
response (per-decade increase in age: OR 1.01, 95%CI 1.01-1.02, P<.0001). After adjusting 
for baseline factors associated with disease severity, older patients overall appeared to have 
significantly better response than younger patients according to the Paris-I criteria (Table 3). 
For each decade in age, there was an increase in response ranging from 10-50%: <35 years 
(reference), 36-45 years (OR 1.53, 95%CI 1.26-2.86, P=.05), 46-55 years (OR 1.90, 95%CI 
1.26-2.86, P=.002), 56-65 years (OR 2.03, 95%CI 1.35-3.07, P=.001), >65 years (OR 2.35, 
95%CI 1.53-3.61, P<.0001), (Table 5). There was no significant interaction between age and 
sex (P=.59). 
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Importantly, there was a strong interaction between age and bilirubin (P<.0001) and age 
and ALP levels (P=.0005); PBC patients with better biochemical profiles (serum bilirubin, 
ALP and AST levels) had a higher probability of response to UDCA (Figure 1). When 
categorizing patients according to their baseline biochemical profile older patients had a 
higher probability of response than younger patients (Figure 1 A-C), except for patients with 
extreme high baseline biochemical indices (Figure 1 D). 
 
Table 5. Multivariable logistic regression evaluating the effect of age on biochemical response to UDCA 
(Paris-I)
Entire cohort (n=4117)
Baseline parameter OR 95% CI P-value
Male sex 1.22 0.93-1.59 .15
Later era 1.02 1.01-1.03 < .0001
Age at diagnosis (years)    
     <35 1.00
     36-45 1.53 1.00-2.35 .05
     46-55 1.90 1.26-2.86 .002
     56-65 2.03 1.35-3.07 .001
     >65 2.35 1.53-3.61 < .0001
Platelet count (per 50x103/mm3 decline) 1.07 1.02-1.12  < .001
Early biochemical stagea 1.00
Moderate biochemical stage 2.19 1.50-3.21 < .0001
Advanced biochemical stage 1.19 0.85-1.68 .30
Log bilirubin (xULN)  0.22 0.18-0.27  < .0001
Log ALP (xULN)  0.37  0.32-0.42  < .0001
Abbreviations: AST, aspartate aminotransferase; ULN, upper limit of normal; ALP, alkaline phosphatase
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A B
C D
OR 1.03, 95% CI 1.01-1.06, p value 0.004
OR 1.03, 95% CI 1.00-1.05, p value 0.02 OR 1.01, 95% CI 0.99-1.04, p value 0.42
OR 1.03, 95% CI 1.01-1.05, p value 0.005
A B
C D
OR 1.03, 95% CI 1.01-1.06, p value 0.004
OR 1.03, 95% CI 1.00-1.05, p value 0.02 OR 1.01, 95% CI 0.99-1.04, p value 0.42
OR 1.03, 95% CI 1.01-1.05, p value 0.005
Figure 1. Predicted probability of response according to Paris-1 criteria age groups
Bar plots of the predicted probability of response according to Paris-1 criteria among age groups in 
(A) patients with a biochemical profile according to the 25th percentile of baseline serum alkaline 
phosphatase, bilirubin and AST levels (OR young vs. older patients 1.03, 95% CI 1.01-1.06, P = .0004), 
(B) according to the 50th percentile (OR young vs. older patients 1.03, 95% CI 1.01-1.05, P = .0005), (C) 
according to the 75th percentile (OR young vs. older patients 1.03, 95% CI 1.00-1.05, P = .02) and (D) 
according to the 50th percentile (OR young vs. older patients 1.03, 95% CI 0.99-1.04, P = .42). The dark 
bars represent the males and the light bars the females. 
Effect of age and gender on transplant-free survival
On crude analysis of overall transplant-free survival, significantly more males died (20% vs 
13%) or underwent liver transplant (11% vs 7%) (Log-rank P<.0001) (Figure 2A). However, 
after adjusting for age at start of treatment, year of diagnosis, biochemical disease stage, 
baseline bilirubin, baseline ALP and platelet count, the differences in survival between males 
and females was no longer significant (HR 1.10, 95%CI 0.74-1.11, P=.34) (Figure 2B, Table 6). 
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Table 6. Multivariable logistic regression for factors affecting survival
 Entire cohort (n=4117)
Baseline variable HR 95% CI P-value
Males 1.10 0.74-1.11 .34
Older age (per decade) 1.54 1.43-1.64 < .0001
Later era 0.99 0.98-1.00 .21
Platelet count (per 50x103/mm3 decline) 0.88 0.83-0.93 < .0001
Early biochemical stage 1.00   
Moderate biochemical stage 2.10 1.67-2.63 < .0001
Late biochemical stage 3.56 2.59-4.88 < .0001
Baseline log bilirubin (xULN) 1.95 1.73–2.19 < .0001
Baseline log ALP (xULN) 1.13 1.01–1.27 .04
Abbreviations: ULN, upper limit of normal; ALP, alkaline phosphatase.
a Biochemical disease stage defined as per ter Borg et al.15 (early: normal serum bilirubin and albumin 
levels, moderately advanced: abnormal serum bilirubin or albumin levels, advanced: abnormal serum 
bilirubin and albumin levels).
P < .0001 P = .26
Figure 2. Crude and adjusted transplant-free survival curves between males & females
Survival curves showing (A) unadjusted (crude) survival and (B) adjusted survival between males and 
females with PBC. Differences in transplant-free survival between males and females were adjusted 
for age at start of treatment, year of diagnosis, biochemical disease stage, serum bilirubin levels, 
serum alkaline phosphatase levels and platelet count. Biochemical disease stage defined as per ter 
Borg et al.15 (early: normal serum bilirubin and albumin levels, moderately advanced: abnormal serum 
bilirubin or albumin levels, advanced: abnormal serum bilirubin and albumin levels). 
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DISCUSSION
Similar to other diseases of autoimmune origin, the pathogenesis of PBC appears to be 
driven by fundamental differences in susceptibility across males and females, as well as 
across different age groups. The inherent challenges posed by the disease epidemiology of 
PBC has led to an elusive understanding of whether males or younger patients have a more 
aggressive disease phenotype. The cohort established by the Global PBC Group provides 
the opportunity to include subjects from both transplant and non-transplant centers from 
across Europe and North America. Owing to the size of the cohort and statistical validation 
through the use of center-specific stratification and multiple imputation, our study is strongly 
positioned to explore outcomes in small subgroups while minimizing bias. The results 
of our study demonstrate that sex does not appear to be an independent determinant 
of biochemical response or transplant-free survival, but rather that males present with 
more advanced disease, which has previously been associated with diminished treatment 
response and prognosis.3, 8, 13 Younger patients are more likely to present with early disease, 
but have impaired biochemical response to UDCA compared with older patients, even after 
adjusting for disease severity. This effect was maintained across both male and female 
patients. 
Earlier studies have demonstrated that male PBC patients generally present with more 
advanced disease, with higher rates of jaundice, variceal bleeding and thrombocytopenia5, 
6. Asymptomatic males also presented at an older age than females, with a mean difference 
of approximately 5 years5, 6. Carbone et al. demonstrated in the UK-PBC cohort that male sex 
was an independent predictor of biochemical response (OR 0.90, 95% CI 0.83-0.97, P=.007) 
after adjusting for age, splenomegaly, creatinine, log bilirubin and log ALP. By contrast, our 
study demonstrated that male sex was not independently associated with biochemical 
response or with transplant-free survival. The lack of association between male sex and 
clinical outcomes in PBC suggests that sex is not an inherent determinant of treatment 
response or prognosis, but rather that male PBC patients are at greater risk of presenting 
with more advanced disease, with a greater degree of synthetic dysfunction and portal 
hypertension. A possible factor explaining this finding could be that the diagnosis of PBC is 
not sufficiently considered in males presenting with features of liver disease. However, this 
is highly speculative and it may well be that male PBC patients develop less frequent or less 
severe symptoms and therefore remain undiagnosed until later in the course of the disease. 
Previous studies found that older patients appeared to have significantly better response 
than their younger counterparts5 and that life expectancy of PBC patients diagnosed at 
55 years or older is comparable with a matched population.18 In particular, Carbone et al. 
found that when results were stratified by sex, it appeared that older female patients have 
significantly better response than younger females, but that males had similar response 
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across all age groups. Our data demonstrated instead that the differences in response 
across age groups were associated with differences in disease stage, rather than sex. This 
difference in results may have in part be due to the smaller number of male patients in each 
age category in the UK cohort, with less than 10 patients in the under 40 and above 70 year 
age categories and less than 40 patients in the remaining age categories. Thus, it is possible 
that patients with early disease may not have been as well represented, particularly in 
males, given their propensity for presenting with advanced disease. Notably, while response 
appeared to increase with age, our study did not reveal a clear age threshold below which 
there was a significant reduction in biochemical response. 
There are several potential reasons for diminished biochemical response in younger 
patients. One possibility is that younger patients may have reduced compliance. Disparities 
in response may also be related to underlying disease pathology. Patients with ductopenia 
have been previously demonstrated to have diminished response to UDCA19, and 
descriptions of a severe ductopenic variant of PBC all involved patients younger than 50 
years of age,20 Thus, it is possible that younger patients who present with early PBC have a 
predominantly ductopenic phenotype which is particularly resistant to UDCA treatment, but 
whose symptoms or cholestatic biochemistry lead to a diagnosis early in the disease course. 
Additionally, in our cohort, patients under the age of 45 appeared to have higher AST and 
ALT, suggesting more exuberant histologic inflammation. Interestingly, Carbone et al. found 
that younger patients were more likely fail therapy based on transaminase criteria,5 which 
collectively implies a more hepatitic phenotype. 
In conclusion, age, irrespective of sex, has the greatest impact on biochemical response 
and transplant-free survival. Our data suggests that males appear to be diagnosed at more 
advanced stages of disease rather than that they exhibit a more aggressive phenotype. 
It is thus important to prevent diagnostic delays by maintaining a high index of suspicion 
for PBC in male patients and aggressively managing any potential concomitant causes of 
progressive fibrosis. Additionally, young patients with early disease should be monitored 
carefully, with early consideration for additional therapies, as they appear to be at greatest 
risk of incomplete biochemical response to UDCA. Further studies are required to unravel 
the mechanisms underlying the diminished treatment response to UDCA in young patients.
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BACKGROUND
Chapter 1 provides a general overview of primary biliary cirrhosis (PBC) and summarizes 
current knowledge regarding the prediction of complications and long-term outcomes. PBC, 
occurring in 1 in 1000 women over the age of 40,1 is a prototype vanishing bile duct disorder, 
characterized by a chronic non-suppurative destructive cholangitis and usually a slowly 
progressive course.2 The reported incidence and prevalence varies worldwide; a recent 
Dutch study found an incidence of 1.1 per 100,000 and a prevalence of 13.2 per 100,000 
Dutch inhabitants.3 The disease may ultimately lead to severe bile duct loss (ductopenia) 
accompanied by increasing fibrosis, finally resulting in cirrhosis, liver failure and premature 
death. Liver transplantation has a significant beneficial effect on outcome in patients who 
progress to end-stage disease, however this ultimate therapeutic option is only available for 
a selected group of patients. Ursodeoxycholic acid (UDCA) is the only established medical 
treatment over the past 25 years.4, 5 It is generally accepted that UDCA improves prognosis 
in the majority of cases. However, the response to treatment is insufficient in a subset 
of patients who still have an unmet medical need for effective additional therapy. Timely 
and reliable assessment of the response to therapy and prediction of outcome is of key 
importance in clinical management and an essential requirement in patient counseling and 
timing of diagnostic and therapeutic interventions.
SURROGATE ENDPOINTS IN PRIMARY BILIARY CIRRHOSIS
At present there is considerable interest from hepatologists and the pharmaceutical industry 
to expand the available medical treatment options for PBC. The efficacy of a number of 
new drugs has been explored during the last decade including budesonide,6-8 anti-retroviral 
therapy,9 rituximab,10 beza- and fenofibrates11 and obeticholic acid.12 The ultimate goal 
of treatment is to cure or completely inactivate the disease and thereby prevent the 
development of liver cirrhosis and liver failure. Other equally important goals are to improve 
quality of life and effectively deal with invalidating symptoms, such as fatigue and pruritus. 
Ideally, in clinical trials evaluating disease modifying therapies the effect of treatment 
on hard clinical endpoints, such as complications, liver transplantation or death, should 
be evaluated.13 However, PBC runs a slowly progressive course over many years or even 
decades. Evaluation of the efficacy of therapeutic interventions on hard clinical outcomes 
is therefore highly problematic as this requires unrealistic, long-term studies including large 
number of patients, especially when the study aims to modify early disease. This challenge 
can be clearly illustrated by the results of UDCA trials performed in the early nineties;14, 
15 although significant improvements of laboratory variables, such as alkaline phosphatase 
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and bilirubin, were shown in UDCA-treated patients within a follow-up period of 1 or 2 
years, many studies were unable to document a beneficial effect on the natural course of 
the disease. Thus, there is an urgent need of reliable surrogate endpoints of outcome to 
predict the effect of an intervention on clinical outcome in an early phase of treatment. 
Biochemical variables are of particular interest as surrogate endpoints, since they are 
readily available, objective and cheap to measure. Serum bilirubin is well established as 
an independent predictor of prognosis in PBC.16, 17 However, serum bilirubin levels will 
change relatively late in the course of disease, implying that changes in this variable will 
not provide useful information in patients with non-advanced disease and normal levels. 
Alkaline phosphatase, a well-established marker of cholestasis and of key importance from 
a diagnostic point of view, may potentially be a more broadly applicable surrogate endpoint 
in PBC. Chapter 2.1 contains a study that aimed to determine to what extent serum alkaline 
phosphatase and bilirubin levels individually and in combination, correlate with transplant-
free survival and whether these variables can be regarded as robust surrogate endpoints 
in therapeutic PBC trials. We analysed an unprecedented large international database of 
patients from European and North-American centers and we were able to show that both 
increased serum alkaline phosphatase and bilirubin levels were strongly associated with 
reduced transplant-free survival in patients with PBC and that a combination of both variables 
improved their prognostic significance. These associations were independent of the use of 
UDCA and follow-up time and held for multiple subgroups. These data support that both 
alkaline phosphatase and bilirubin provide meaningful surrogate endpoints in PBC that can 
reasonably be used in clinical trials. There is a high unmet medical need for new therapies 
for this rare autoimmune liver disease, and this study provides an important impetus for the 
selection of appropriate endpoints and to facilitate the conduct of meaningful therapeutic 
intervention trials in the absence of long-term outcome studies.
Chapter 2.1 also discusses optimal thresholds for alkaline phosphatase and bilirubin 
levels to discriminate high- and low-risk patients that may be used as clinical trial surrogate 
endpoints. For alkaline phosphatase this was 2.0 times the upper limit of normal (ULN) after 
one year UDCA therapy, although other thresholds between 1.5 and 3.0 times the ULN may 
work equally well. Further, a percentage decrease of alkaline phosphatase or bilirubin levels 
after one year UDCA therapy from baseline was not superior in comparison to absolute 
levels after one year therapy in predicting transplant-free survival. For bilirubin levels 1.0 
time the ULN appeared to be the optimal threshold. Based on current study, we were not 
able to recommend specific thresholds for a clinical trial in general, since the designation 
of clinical trials implies the a priori requirement to estimate the quantitative effect of an 
experimental intervention on a given endpoint. 
In chapter 2.2 we showed that bilirubin and alkaline phosphatase have not been fully 
validated as true surrogate endpoints with the highest level of evidence. According to strict 
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and difficult to meet criteria, relatively few really validated surrogate endpoints have been 
established.18 It has been suggested that the best way to evaluate the utility of a biomarker 
as a good surrogate endpoint, might be a meta-analysis of clinical trials of one or more 
interventions.18 Unfortunately, this is not feasible in a disease as PBC with only one licensed 
therapy. Our approach was therefore to conduct a rigorous patient-level meta-analysis using 
data collected from existing cohorts of patients at centers across North America and Europe 
with long-term follow-up data of large numbers of PBC patients. This design has sufficient 
power to intensively study alkaline phosphatase and bilirubin as potential surrogate 
endpoints in different settings, sub-populations and at different time points. Based on our 
current results we postulate that alkaline phosphatase and bilirubin are “reasonably likely 
to predict clinical benefit” in PBC,19 of relevance to future trial design for new therapeutic 
agents. Future studies should be performed in PBC patients treated with new agents to 
increase the levels of evidence for alkaline phosphatase and bilirubin levels as surrogate 
endpoints.
RISK STRATIFICATION OF OUTCOMES IN PRIMARY BILIARY CIRRHOSIS
Liver transplantation or death
UDCA is not an uniformly effective drug and the results of several studies indicate that the 
prognosis of patients insufficiently responding to treatment is markedly worse compared with 
the general population.20-24 These studies used quantitative biochemical changes (response 
criteria) to classify patients as either responders or non-responders to UDCA. Despite the 
clear relevance of biochemical response it has not been established whether biochemical 
response to UDCA is considered an important tool in clinical practice and whether it is used 
to guide further decision-making, in particular with respect to possible additional second-
line treatment. Chapter 3 reports a retrospective study assessing the impact of biochemical 
response to UDCA regarding management decisions in a large, nationwide cohort of PBC 
patients. We found that for the majority of UDCA non-responders medical management 
was not changed. 
Obviously, the results of this study should be interpreted with great caution. In particular, 
it must be recognized that the majority of included patients were treated with UDCA well 
before emergence of the concept of biochemical response and that, in the context of this 
study, this response was assessed retrospectively. Therefore, by definition, decisions with 
respect to patient management could not have been influenced by assessing treatment 
response with one of the currently available tools. Irrespective of a formal response 
evaluation, however, our data suggest that management was modified in only a minority 
of cases despite persistently, occasionally markedly, abnormal biochemical liver tests. 
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Moreover, our data demonstrate that during the last decade, despite increased awareness 
of the importance of sufficient biochemical improvement upon treatment with UDCA, this 
did not translate yet into an increase in response-guided management. 
Another major factor that must be stressed when interpreting the results of this study is 
the lack of evidence-based alternative treatments for PBC until now. This may largely explain 
why potentially effective drugs, including budesonide and fibrates, were rarely used. During 
recent years, evidence is accumulating that fibrates may have an additional, beneficial effect 
in UDCA-treated PBC.25-29 The same applies to budesonide6-8 and obeticholic acid,12 drugs 
that are currently undergoing randomized controlled trial evaluation. It seems likely that 
within a few years the therapeutic landscape for PBC will have changed considerably and an 
evidence-based response guided treatment in PBC will be reality, potentially with a number 
of second-line treatment options available. To further study and assess the relevance of 
biochemical response criteria in current clinical practice and to overcome limitations of 
current study a cross-sectional study may be performed.
Further, this study emphasizes the importance of adequate UDCA dosage. About 40% of 
UDCA non-responders in whom the dosage was increased showed laboratory improvements 
allowing them to be reclassified as responders. Indeed, a multivariable analysis of factors 
predictive of response confirmed that higher UDCA dosage per kilogram was an independent 
predictor of response. These findings are in line with previous studies showing that UDCA 
doses in the range of 13-15 mg/kg/day are more effective than lower doses.30, 31 Therefore, 
adequate dosing of UDCA remains of crucial importance. 
Stratification tools, based on biochemical liver tests results after one or two years of UDCA 
exposure, such as the Barcelona, Paris I and II, Toronto and Rotterdam criteria, have all 
been shown useful to identify patients with or without sufficient treatment response.20-24 
However, these criteria were all based on dichotomized variables, potentially leading to 
loss of important predictive information. Further, comparison of these tools resulted in 
considerable differences in risk stratification.32 Not less important, none of the models 
included age as established key prognostic factor. In chapter 4, we developed and validated a 
new unifying score (GLOBE score) with optimal ability to identify UDCA-treated patients with 
an insufficient treatment effect, based on the readily obtainable, biochemical and clinical 
variables age, bilirubin, alkaline phosphatase, albumin and platelet count. The prognostic 
performance of this score (C statistic 0.81, 95% CI 0.79-0.83) was markedly better than that 
of previously proposed criteria. Whilst the GLOBE score accurately predicts high risk, equally 
it predicts low risk, allowing development of care pathways that de-escalate follow-up back 
to primary care in appropriately stratified low risk patients. This is as important as high risk 
identification, in an era where cost-efficacy of new therapies is paramount. We believe that 
the GLOBE score represents a major step forward in the management of patients with PBC. 
The score is readily calculated, using a web application (www.globalpbc.com).
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Hepatocellular carcinoma (HCC)
Life expectancy of PBC patients is largely determined by development of cirrhosis, portal 
hypertension and HCC.4, 33, 34 HCC is the fifth most common cause of cancer and the third 
most common cause of cancer-related death35 and usually arises in patients with underlying 
chronic liver disease. Across the spectrum of liver disease the incidence of HCC appears 
greatest among individuals with advanced fibrosis/cirrhosis, particularly men.36 However, 
such observations in PBC frequently represent the results of single centre studies of limited 
size, or are not immediately generalisable to Western practice.37-47 To address and overcome 
limitations to current knowledge we described in chapter 5 the incidence of HCC, and risk 
factors for development of this tumour across a large, and internationally representative 
population. In doing so we confirmed that HCC is a critical event in the clinical course of PBC 
and is associated with a poor outcome. 
In agreement with previous studies male sex and advanced biochemical disease were 
found to be major risk factors. Although the incidence was significantly greater in male 
patients and those with advanced disease, on multivariable analysis only thrombocytopenia 
and biochemical non-response retained statistical significance and superseded the effect 
of gender and other tested parameters of disease stage. Risk was significantly greater in 
biochemical non-responders and this also applied to patients who fulfilled criteria for non-
response but never received UDCA. It is likely therefore that achievement of biochemical 
response according to specific criteria—irrespective of whether this occurs in the context 
of therapy—infers a surrogate associated with improved HCC-free survival rather than a 
chemo-preventative effect of UDCA. 
The emergence of well-substantiated treatment response criteria has allowed accurate 
prediction of transplant-free survival in patients with PBC,20-24, 48 and herein we illustrated 
that failure to achieve the same biochemical endpoints confers increased HCC risk. The low 
risk for HCC among biochemical non-responders, even in men and individuals with evidence 
of advanced disease at presentation, questions routine HCC surveillance in well-treated 
patients irrespective of gender and disease stage. Therefore, we recommend particular 
attention to: (1) male patients who either fail to achieve biochemical response (irrespective 
of disease stage), or in whom cirrhosis is already established (irrespective of biochemical 
response status); and (2) all female non-responders with evidence of advanced disease. 
Herein our globally representative data add new knowledge to HCC risk in PBC and informs 
ongoing discussions about stratified treatment and surveillance. We recommend that future 
studies should investigate the role of the earlier proposed GLOBE score with respect to 
stratification of HCC risk. 
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THE IMPACT OF AGE AND SEX ON OUTCOMES IN PRIMARY BILIARY 
CIRRHOSIS
The epidemiology of PBC poses inherent challenges in understanding the natural history 
of the disease in different subgroups. About 90% of patients with PBC are women, with 
the highest incidence occurring between 40-60 years of age, thus even large studies have 
provided limited insight into the influence of gender and age on disease outcomes.49, 50 
Several studies have demonstrated that the clinical impact of PBC differs between the 
sexes and different age groups. Women are frequently symptomatic at presentation, with 
an increasing burden of pruritus,51, 52 and scores higher in the fatigue domain of the PBC-
40 quality of life questionnaire.53 By contrast, male PBC patients more often present with 
advanced baseline disease,51-53 harbor a greater risk of hepatocellular carcinoma (HCC)54 and 
experience significantly poorer transplant-free survival.50 Moreover, male sex has recently 
identified as an independent risk factor for incomplete response to ursodeoxycholic acid 
(UDCA), independent of presenting age, presence of portal hypertension, and biochemical 
indices of disease severity,53 alluding to the possibility of a more rapidly progressive clinical 
course. 
Age at baseline appears to add another layer of complexity to clinical phenotypes and 
the recent study conducted by the UK-PBC consortium not only recognized an increased 
prevalence of younger presenting women (25% aged 49 or less), but also an inverse 
correlation of patient age and likelihood of meeting biochemical response in females, but in 
males age appeared to have no significant impact on response.53 Chapter 6 shows the results 
of a study addressing the question whether younger age or male sex are independently 
associated with diminished biochemical response and impaired transplant-free survival. 
We showed that sex does not appear to be an independent determinant of biochemical 
response or transplant-free survival, but rather that males present with more advanced 
disease, a condition that has previously been associated with diminished treatment 
response and prognosis.22, 55 Further, our data demonstrated that younger patients respond 
less favorably to treatment and that the differences in response across age groups were 
associated with differences in disease stage, rather than sex. This is in contrast with the 
finding of Carbone et al. who showed that older female patients respond significantly better 
than younger females, while no effect of age on treatment response was apparent in males. 
This difference in results may have in part be due to the smaller number of male patients 
in each age category in the UK cohort. Thus, it is possible that patients with early disease 
may not have been as well represented, particularly in males, given their propensity for 
presenting with advanced disease. 
There are several potential reasons for diminished biochemical response in younger 
patients. One possibility is that younger patients may have reduced compliance. Disparities 
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in response may also be related to underlying disease pathology. Patients with ductopenia 
have been previously demonstrated to have diminished response to UDCA23, and 
descriptions of a severe ductopenic variant of PBC all involved patients younger than 50 
years of age,56 Thus, it is possible that younger patients who present with early PBC have a 
predominantly ductopenic phenotype which is particularly resistant to UDCA treatment, but 
whose symptoms or cholestatic biochemistry lead to a diagnosis early in the disease course. 
Additionally, in our cohort, patients under the age of 45 appeared to have higher AST and 
ALT, suggesting more exuberant histologic inflammation. Interestingly, Carbone et al. found 
that younger patients were more likely fail therapy based on transaminase criteria,53 which 
collectively implies a more hepatitic phenotype. 
Thus, age, irrespective of sex, has the greatest impact on biochemical response and 
transplant-free survival. It is thus important to prevent diagnostic delays by maintaining a 
high index of suspicion for PBC in male patients and aggressively managing any potential 
concomitant causes of progressive fibrosis. Additionally, young patients with early disease 
should be monitored carefully, with early consideration for additional therapies, as they 
appear to be at greatest risk of incomplete biochemical response to UDCA. Further studies 
are required to unravel the mechanisms underlying the diminished treatment response to 
UDCA in young patients.
CONCLUSIONS AND FUTURE PERSPECTIVES
With new promising drugs under evaluation risk stratification of patients at high- or low-risk 
of outcomes is of critical importance in UDCA-treated PBC at an early phase of the disease 
course. Biochemical variables, such as bilirubin and alkaline phosphatase, are attractive in 
this regard and can reasonably be used as surrogate endpoints of clinical endpoints, such as 
liver transplantation and death. To increase the levels of evidence for alkaline phosphatase 
and bilirubin levels as surrogate endpoints and to support its generalizability, additional 
studies should be performed in PBC patients treated with new agents. Currently, a risk 
score (GLOBE score), which comprises the readily available variables age, bilirubin, alkaline 
phosphatase, albumin and platelet count, could be an easy to use clinical tool to select 
UDCA-treated PBC patients in need of additional therapies. 
With respect to liver cancer development in PBC, there is a relatively low incidence of 
HCC development among those who achieved adequate biochemical response, even in men 
and individuals with evidence of advanced presenting disease. This questions routine HCC 
surveillance in well-treated patients irrespective of gender and disease stage. Future studies 
should investigate the role of the GLOBE score with respect to stratification of HCC risk. 
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Sex does not appear to be an independent determinant of biochemical response or 
transplant-free survival. Particular awareness should be given to young patients with 
early PBC who do not respond well to UDCA. It seems likely that these patients have the 
potential to benefit more from additional PBC therapies than older patients. Further studies 
are required to unravel the mechanisms underlying the diminished treatment response to 
UDCA in young patients.
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NEDERLANDSE SAMENVATTING
ACHTERGROND
In hoofdstuk 1 wordt een algemeen overzicht gegeven van de ziekte primaire biliaire cirrose 
(PBC). Er wordt dieper ingegaan op de prognose van de aandoening en het voorspellen van 
de noodzaak tot een levertransplantatie en van sterfte. 
PBC is een auto-immuunziekte van lever met een kenmerkend langzaam progressief 
beloop. Een chronische non-suppuratieve ontsteking van de kleine galwegen kan leiden tot 
verlies van de galgangen (ductopenie), het ontstaan van leverfibrose, oftewel verlittekening 
van de lever, en uiteindelijk levercirrose.1 Cirrose wordt over het algemeen beschouwd als 
het eindstadium van de leverziekte waarbij er leverfalen kan optreden waaraan patiënten 
vroegtijdig kunnen overlijden. Levertransplantatie is een goede therapeutische optie 
bij vergevorderde ziekte die echter alleen kan worden toegepast bij een selecte groep 
van patiënten. Verder gaat levertransplantatie gepaard met belangrijke morbiditeit en 
mortaliteit en terugkeer van de ziekte in de nieuwe lever is mogelijk. 
De ziekte is relatief zeldzaam en komt met name voor bij vrouwen van middelbare 
leeftijd. In Nederland wordt er elk jaar 1 persoon per 100.000 Nederlandse inwoners 
gediagnosticeerd met de ziekte PBC (incidentie) en er zijn op dit moment ongeveer 13 
personen met PBC per 100.000 inwoners (prevalentie).2 Wereldwijd worden uiteenlopende 
incidentie- en prevalentiecijfers beschreven;3 gemiddeld genomen komt PBC voor bij 1 op 
de 1000 vrouwen boven de 40 jaar.
Er is op dit moment slechts één officieel geregistreerde medicamenteuze behandeling, 
namelijk ursodeoxycholzuur (UDCA).4, 5 UDCA kan de ziekte niet genezen, maar kan het 
ziekteproces wel vertragen, waardoor er een positief effect is op de levensverwachting 
van PBC patiënten. Een deel van de met UDCA behandelde patiënten heeft een normale 
levensverwachting. Helaas hebben sommige patiënten die met UDCA behandeld worden 
toch een progressief ziektebeloop en deze patiënten zouden gebaat kunnen zijn bij nieuwe 
therapieën die op dit moment worden onderzocht. Het tijdig bepalen van de respons op 
UDCA behandeling en het vroegtijdig kunnen voorspellen welke patiënten een hoog risico 
hebben op het ontwikkelen van leverfalen zijn van kritisch belang voor een adequate 
behandeling van PBC patiënten. 
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SURROGAAT EINDPUNTEN IN PRIMAIRE BILIAIRE CIRROSE
De afgelopen jaren zijn diverse geneesmiddelen onderzocht op hun effectiviteit, zoals 
budesonide,6-8 retuximab,9 antivirale middelen,10 bezafibraat, fenofibraat11 en obeticholzuur.12 
Het belangrijkste doel van nieuwe therapieën is om de ziekte volledig te genezen dan wel 
om het ziekteproces te inactiveren, zodat de ontwikkeling van levercirrose en leverfalen 
kan worden voorkomen. Een ander belangrijk doel is om de kwaliteit van leven van PBC 
patiënten te verbeteren, met name door het behandelen van invaliderende symptomen, 
zoals jeuk en moeheid. 
Idealiter worden in klinische studies harde klinische uitkomstmaten gebruikt, zoals 
leverfalen of overlijden,13 echter door het langzaam progressieve beloop van PBC treden 
deze uitkomstmaten vaak pas na jaren op. Om klinisch relevante verschillen aan te tonen 
in uitkomstmaten tussen patiënten die behandeld worden met een nieuw geneesmiddel 
of de standaardbehandeling krijgen moeten langdurige studies worden verricht, met grote 
aantallen patiënten. De klinische studies uit de jaren negentig naar de werkzaamheid van 
UDCA zijn illustratief voor dit probleem.14, 15 Ondanks dat er in diverse studies een significante 
verbetering werd aangetoond van serum levertesten na 1 of 2 jaar behandeling met UDCA, 
konden er geen significante verschillen worden aangetoond in de transplantatievrije 
overleving. Een latere meta-analyse van individuele patiëntengegevens van meerdere 
gecontroleerde trials, waarbij patiënten tot 4 jaar werden vervolgd, was wel in staat om 
een overlevingswinst aan te tonen. In PBC is er dus een grote behoefte aan surrogaat 
eindpunten; eindpunten die al vroeg in het beloop van de ziekte het risico op harde klinische 
eindpunten kunnen voorspellen. 
Biochemische variabelen zijn interessant als potentiële surrogaat eindpunten, aangezien 
ze direct beschikbaar, objectief, niet-invasief en goedkoop zijn. Veel studies hebben laten 
zien dat serum bilirubine een onafhankelijke prognostische marker is in PBC;16, 17 hogere 
bilirubinewaarden zijn geassocieerd met een kortere transplantatievrije overleving. 
Echter, serum bilirubinewaarden stijgen pas relatief laat in het ziekteproces, waardoor 
bilirubine minder aantrekkelijk is als surrogaat eindpunt. Het serum alkalische fosfatase lijkt 
daarentegen een interessantere surrogaat marker, aangezien dit enzym indicatief is voor 
de mate van cholestase en de waarden karakteristiek verhoogd zijn in alle ziektestadia. 
In hoofdstuk 2.1 hebben we onderzocht of alkalische fosfastase en bilirubine waarden, 
alleen of in combinatie, geassocieerd zijn met transplantatievrije overleving en of deze 
bloedtesten gebruikt kunnen worden als robuuste surrogaat eindpunten in therapeutische 
trials. Hiervoor hebben we een grote internationale PBC database, the Global PBC Study 
Group database, geanalyseerd met langetermijngegevens van PBC patiënten uit diverse 
Europese en Amerikaanse ziekenhuizen. We waren in staat om aan te tonen dat hogere 
alkalische fosfatase en bilirubine waarden sterk geassocieerd zijn met een verminderde 
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transplantatievrije overleving en dat de combinatie van beide variabelen het voorspellend 
vermogen verbetert. Deze associatie werd gevonden op verschillende tijdstippen, in 
verschillende subgroepen en bij zowel UDCA behandelde als onbehandelde patiënten. 
Hiermee werd aannemelijk gemaakt dat alkalische fosfatase en bilirubine waarden 
kunnen worden gebruikt in klinische studies als surrogaat eindpunten voor harde klinische 
uitkomstmaten, zoals levertransplantatie of overlijden. 
Daarnaast hebben we in hoofdstuk 2.1 afkapwaarden voor alkalische fosfatase en 
bilirubine waarden bepaald, waarmee hoog- en laagrisico patiënten het beste kunnen 
worden onderscheiden. Voor alkalische fosfatase bleek dit afkappunt 2.0x de bovenste 
normaalwaarde te zijn, echter andere afkapwaarden tussen de 1.5-3.0x de bovenste 
normaalwaarde bleken even effectief te zijn. Voor bilirubine bleek 1.0x de bovenste 
normaalwaarde het optimale afkappunt te zijn. 
In hoofdstuk 2.2 gaan we in op een commentaar van Giljaca et al.18 die stellen dat er 
onvoldoende bewijs geleverd is om alkalische fosfatase en bilirubine te beschouwen als 
valide surrogaat eindpunten. In de literatuur wordt gesuggereerd dat het beste bewijs 
geleverd kan worden door een meta-analyse te verrichten van klinische trials van het liefst 
zoveel mogelijk onderzochte interventies.19 Helaas is dit niet mogelijk bij een ziekte zoals 
PBC, aangezien er slechts één geregistreerde behandeling is. Strikt genomen zijn er van de 
surrogaat eindpunten die in de kliniek worden gebruikt maar weinig die op deze manier 
gevalideerd zijn. Door gebruikt te maken van een groot, internationaal en multicenter 
cohort met langetermijngegevens van individuele PBC patiënten hebben we een uitgebreide 
meta-analyse kunnen verrichten, waarin we onder diverse omstandigheden en in multipele 
subgroepen, waaronder UDCA behandelde en onbehandelde patiënten, hebben laten zien 
dat alkalische fosfastase en bilirubine waarden geassocieerd zijn met levertransplantatievrije 
overleving. Ondanks dat niet aan het hoogste level van bewijs kan worden voldaan, suggereren 
onze resultaten dat alkalische fosfatase en bilirubine redelijkerwijs gebruikt kunnen worden 
als eindpunten in klinische studies.20 Om het bewijs te vergroten voor alkalische fosfatase en 
bilirubine waarden als surrogaat eindpunten zouden toekomstige studies moeten worden 
verricht in PBC patiënten die worden behandeld met nieuwe geneesmiddelen.
RISICO STRATIFICATIE IN PRIMAIRE BILIAIRE CIRROSE
Lever transplantatie of overlijden
Helaas blijkt dat in een deel van de PBC patiënten de resultaten van behandeling met 
UDCA suboptimaal zijn. Diverse studies hebben respons criteria beschreven, bestaande 
uit bloedtesten, om patiënten na 1 of 2 jaar behandeling te kunnen classificeren als 
responder of non-responder.21-25 Ondanks dat deze criteria gevalideerd zijn, is het 
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onduidelijk of ze ook daadwerkelijk gebruikt worden in de praktijk om beslissingen te 
nemen aangaande de behandeling van PBC patiënten. In hoofdstuk 3 presenteren we de 
resultaten van een retrospectief verrichtte Nederlandse studie waarin onderzocht werd 
welke behandelbeslissingen er genomen zijn bij UDCA non-responders. Als belangrijkste 
bevinding vonden wij dat er in het merendeel van de gevallen geen veranderingen van het 
(medicamenteuze) beleid volgden bij onvoldoende respons op behandeling. 
Deze studie moet met de nodige voorzichtigheid worden geïnterpreteerd. In deze studie 
werden patiënten in retrospectie ingedeeld in responders en non-responders. Een groot 
deel van de patiënten werd echter reeds behandeld met UDCA voordat het concept van 
biochemische respons ingang vond en voordat respons criteria werden gepubliceerd in 
de literatuur. Voor dat deel van de patiënten konden behandelbeslissingen uiteraard niet 
worden beïnvloed door de berekende respons criteria. Echter, onze studie toont wel aan 
dat ondanks dat er nog geen formele biochemische respons criteria beschikbaar waren, er 
nauwelijks aanpassingen aan de behandeling werden gemaakt, ook niet bij patiënten met 
persisterende en soms sterk abnormale levertestafwijkingen. Verder tonen onze gegevens 
dat de introductie van de thans algemeen geaccepteerde biochemische respons criteria 
vooralsnog niet heeft geleid tot een significante stijging van het aantal patiënten bij wie het 
beleid hierop werd afgestemd. 
Van belang is verder erop te wijzen dat er tot op heden slechts één behandeling officieel 
geregistreerd is voor de ziekte PBC. Dit verklaard waarschijnlijk waarom niet-geregistreerde, 
maar wel potentieel effectieve medicijnen, zoals budesonide en fibraten, zelden werden 
voorgeschreven. Naast toenemend bewijs voor de effectiviteit van budesonide6-8 en 
fibraten26-30 lijkt ook obeticholzuur12 een potentieel effectief geneesmiddel te zijn. De 
verwachting is dat in de komende jaren diverse middelen geregistreerd zullen worden voor 
de tweedelijnsbehandeling van PBC. 
Verder bevestigde deze studie dat een adequate UDCA dosering, 13-15mg/kg/dag, van 
belang is.31, 32 Ongeveer 40% van de patiënten die in eerste instantie geclassificeerd werden 
als non-responder voldeden na het ophogen van de dosering tot een adequaat niveau aan 
de criteria voor respons. Met een multivariabele analyse bevestigden we dat de UDCA 
dosering een belangrijke factor is voor de kans op een voldoende behandelrespons. 
Ondanks dat het mogelijk is om met de biochemische respons criteria, zoals Barcelona, Paris 
I en II, Toronto en Rotterdam criteria,21-25 patiënten te classificeren als responder of non-
responder, kennen deze criteria ook nadelen. Zo maken ze gebruik van gedichotomiseerde 
variabelen, waardoor potentieel belangrijke prognostische informatie verloren gaat. 
Daarnaast blijken er forse verschillen te bestaan tussen de diverse criteria in welke 
patiënten ze classificeren als responder of non-responder.33 In hoofdstuk 4 wordt een 
nieuw ontwikkelde en gevalideerde score (GLOBE score) gepresenteerd, bestaande uit 
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leeftijd, serum bilirubine, alkalische fosfatase, albumine en trombocyten. Het voorspellende 
vermogen van deze score na 1 jaar UDCA behandeling (C statistic 0.81, 95% CI 0.79-0.83) 
was significant beter dan dat van de eerder genoemde respons criteria. Met de GLOBE score 
kunnen dus patiënten met een hoog risico op verminderde transplantatievrije overleving 
worden geïdentificeerd; patiënten die in potentie baat hebben bij additionele therapieën. 
Vanuit kostenperspectief is het tegenovergestelde ook van belang. Met de GLOBE score 
kunnen namelijk ook patiënten met een laag risico op een slechte uitkomst op meer 
betrouwbare wijze worden geïdentificeerd. De zorg van deze laag risico patiënten zou 
daarop afgestemd kunnen worden. Om de klinische toepasbaarheid te vergroten, kan de 
score makkelijk worden uitgerekend via een webapplicatie (www.globalpbc.com). 
Hepatocellulair carcinoom (HCC)
De levensverwachting van patiënten met PBC wordt voornamelijk bepaald door de 
ontwikkeling van cirrose, portale hypertensie en HCC.4, 34, 35 HCC staat vijfde op de lijst van 
de meest voorkomende vormen van kanker en staat als derde genoteerd als oorzaak voor 
kanker gerelateerd overlijden.36 HCC komt vrijwel uitsluitend voor bij patiënten met een 
onderliggende leverziekte met ernstige fibrose of cirrose, met name geldt dit voor mannen.37 
Veel studies die gedaan zijn ten aanzien van HCC in PBC betreffen monocenter studies met 
relatief kleine groepen patiënten en beperken daarom de mogelijkheid tot het bepalen van 
betrouwbare risicofactoren.38-48 In hoofdstuk 5 beschrijven we de incidentie van HCC en 
risicofactoren voor het ontwikkelen van HCC in een grote, voor de ziekte representatieve en 
internationale populatie van PBC patiënten. 
In overeenstemming met eerdere studies bleken het mannelijk geslacht en een ernstiger 
ziektestadium belangrijke risicofactoren voor het ontwikkelen van HCC. Echter, een 
multivariabele analyse toonde aan dat trombocytopenie en biochemische non-respons op 
UDCA therapie de belangrijkste risicofactoren waren. Het risico op het ontwikkelen van een 
HCC bleek niet alleen hoger te zijn in UDCA behandelde patiënten met non-respons, maar 
ook in onbehandelde patiënten die voldeden aan de criteria van non-respons. Het voldoen 
aan biochemische respons criteria, onafhankelijk van therapie, lijkt dus een surrogaat voor 
een verbeterde HCC-vrije overleving. 
Biochemische respons criteria21-25, 49 spelen dus een belangrijke rol in het voorspellen 
van transplantatievrije overleving en het risico op het ontwikkelen van HCC. Een belangrijke 
vraag ten aanzien van HCC is in hoeverre routinematige surveillance geïndiceerd geacht 
kan worden. Op basis van onze bevindingen adviseren we om extra beducht te zijn op HCC 
in 1) mannelijke PBC patiënten met biochemische non-respons op UDCA, ongeacht het 
ziektestadium, of mannen met cirrose, ongeacht respons en 2) vrouwelijke patiënten met 
ernstige fibrose of cirrose en een biochemische non-respons. Een aanbeveling voor een 
toekomstige studie is om te onderzoeken welke rol de GLOBE score heeft in risicostratificatie 
van HCC. 
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DE PROGNOSTISCHE BETEKENIS VAN LEEFTIJD EN GESLACHT IN PRIMAIRE 
BILIAIRE CIRROSE
Ongeveer 90% van de patiënten met PBC is vrouw en het merendeel is van middelbare 
leeftijd. Daarom is het onderzoeken van bepaalde subgroepen, zoals hele jonge, oudere, of 
mannelijk PBC patiënten lastig.3, 50 
Verschillende studies hebben laten zien dat de klinische betekenis van PBC anders is 
voor mannen dan voor vrouwen. Vrouwen zijn vaker symptomatisch op het moment van 
diagnose; met name jeuk51, 52 en vermoeidheid. Mannen daarentegen presenteren zich 
vaker met een verder gevorderd ziektestadium,51-53 met een groter risico op het ontwikkelen 
van een HCC54 en een verminderde transplantatievrije overleving.50 Tevens heeft een 
recente studie laten zien dat het mannelijk geslacht, onafhankelijk van ziektestadium, een 
onafhankelijke risicofactor is voor een incomplete respons op UDCA therapie,53 wat er op 
kan wijzen dat de ziekte bij mannen sneller progressief is. 
Recent werd door een omvangrijke studie van het UK-PBC consortium gesuggereerd dat 
er een omgekeerde correlatie is tussen leeftijd en de kans op respons in vrouwen, maar niet 
in mannen; jongere vrouwelijke patiënten hadden een lagere kans op een biochemische 
respons op UDCA.53 In hoofdstuk 6 presenteren we een studie die ook ingaat op de vraag of 
leeftijd en geslacht inderdaad onafhankelijke risicofactoren zijn voor een verminderde kans op 
biochemische respons en transplantatievrije overleving. Wij toonden in een eveneens grote 
studiepopulatie aan dat gecorrigeerd voor het ziektestadium, geslacht geen onafhankelijke 
risicofactor is. Het lijkt er eerder op dat de lagere kans op therapierespons bij mannen 
verklaart wordt doordat zij zich vaker presenteren in een verder gevorderd ziektestadium; 
een factor waarvan eerder is aangetoond dat deze geassocieerd is met een lagere kans op 
therapierespons.23, 55 Verder lieten we in deze studie zien dat jongere patiënten, ongeacht 
geslacht, een lagere kans op therapierespons hebben. Dit in tegenstelling tot de eerder 
genoemde studie van het UK-PBC Consortium, die suggereerde dat oudere vrouwen een 
betere respons op therapie hebben dan jongere vrouwen met PBC, echter dat dit verschil 
niet aanwezig is bij mannen. Dit verschil in resultaat kan mogelijk worden verklaard door 
het kleinere aantal mannen in de diverse patiëntengroepen die onderzocht werden in de 
Engelse studie. 
Een reden voor een lagere behandelrespons in jongere patiënten zou kunnen zijn dat ze 
minder therapietrouw zijn dan oudere patiënten. Een andere verklaring zou gelegen kunnen 
zijn in verschillen in pathofysiologische mechanismen. Eerder werd een groep patiënten 
beschreven met een ernstig ductopene variant van PBC en deze patiënten bleken allen 50 
jaar of jonger te zijn, relatief hoge transaminasen waarden te hebben en niet te reageren 
op (UDCA en corticosteroïd) therapie.56 Een andere studie suggereerde dat ductopenie 
een belangrijke risicofactor is voor verminderde behandelrespons.24 Het kan dus zijn dat 
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jonge patiënten met een vroeg stadium PBC vooral een “ductopeen fenotype” hebben wat 
in zichzelf een risicofactor is voor verminderde respons. In onze studie lieten we zien dat 
patiënten jonger dan 45 jaar vaak hogere serum transaminases hebben, wat een aanwijzing 
kan zijn voor meer inflammatoire activiteit in deze leeftijdsgroep. Dit is overigens in 
overeenstemming met de bevinding van Carbone et al. die vonden dat jongere patiënten 
vaker therapiefalen kennen dan oudere patiënten wanneer een transaminase criterium 
werd gebruikt.53 
Samenvattend speelt leeftijd lijkt een belangrijke rol te spelen bij het therapeutische 
effect van UDCA en daarmee op de prognose op lange termijn. Het is daarom belangrijk om 
extra alert te zijn bij jonge patiënten met PBC. Het toevoegen van tweedelijns therapieën 
moet waarschijnlijk laagdrempel worden overwogen in deze patiëntengroep wanneer de 
standaard UDCA behandeling onvoldoende effect heeft. Additionele studies zijn nodig naar 
de mechanismen die ten grondslag liggen aan de verminderde behandelrespons in jongere 
PBC patiënten. 
CONCLUSIES
Het lijkt een kwestie van tijd voordat er nieuwe geneesmiddelen worden geregistreerd 
als tweedelijnsbehandeling voor de ziekte PBC. Het is daarom van belang om vroeg in de 
behandeling UDCA- behandelde PBC patiënten te selecteren die een hoog risico hebben op 
het ontwikkelen van leverfalen of overlijden. Voor dit selectieproces lijken biochemische 
variabelen, zoals alkalische fosfatase en bilirubine, geschikt aangezien deze de capaciteit 
hebben om te functioneren als surrogaat eindpunten voor klinische eindpunten, zoals 
leverfalen of overlijden. In de kliniek kan de GLOBE score worden gebruikt om patiënten te 
selecteren die baat kunnen hebben bij nieuwe therapieën; een risico score bestaande uit 
leeftijd, bilirubine, alkalische fosfatase, albumine en trombocyten. 
PBC patiënten met een goede response op UDCA behandeling hebben een relatief laag 
risico op het ontwikkelen van HCC. Dit geldt ook voor mannen en patiënten die zich in 
een gevorderd ziektestadium bevinden. Ten aanzien van de behandeling met PBC hoeven 
er geen verschillen te worden verwacht tussen mannen en vrouwen ten aanzien van de 
response op behandeling. Extra aandacht dient te worden gegeven aan jonge PBC patiënten 
in een vroeg ziektestadium, aangezien zij niet goed responderen op UDCA behandeling. Met 
name deze groep patiënten kan baat hebben bij nieuwe therapieën.
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Ondanks dat het voorgaande in dit proefschrift, het eigenlijke proefschrift, de meeste tijd 
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Nu wordt er over statistici van alles beweerd. Zo schreef Godfried Bomans eens: “Een 
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immuunziektes van de lever, en daar is primaire biliaire cirrose er natuurlijk één van, is een 
internationale samenwerking uitermate verstandig’. Verschillende vraagstellingen bleken 
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als begeleidende email van een revisie: ‘Beste Wim, zeer goed! Hierbij enkele suggesties! 
Groet, Henk’. Vervolgens kwam ik er bij het openen van de bijlage achter hoe rekbaar het 
begrip ‘enkele’ eigenlijk is. Bij het nadenken over nieuwe wetenschappelijke vraagstukken 
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dr. G.M. Hirschfield wil ik danken voor het zitting nemen in de promotiecommissie. Dear 
Gideon (dr. G.M. Hirschfield) and prof. F. Nevens, I am honoured that both of you are willing 
to take place in the PhD committee for my thesis defence. 
Er zijn nog diverse andere mensen die ik wil bedanken voor hun hulp tijdens mijn 
promotieonderzoek. De studenten Lotte Kehrer, Marjolijn Leeman, Bibi Bouwen en Esther 
Zoutendijk hielpen mij met het verzamelen en invoeren van patiëntengegevens in een 
database, waarvoor hartelijk dank! Irene en Edith, dank voor jullie ondersteuning vanuit 
het Clinical Trial Bureau bij diverse klinische studies die we hebben verricht op het gebied 
van PBC en PSC. Melek, Heleen en Esther, dank voor jullie hulp tijdens de Hepatitis B, PSC 
en PBC trialpoli’s die ik mocht doen tijdens mijn promotie. De samenwerking heb ik als 
prettig ervaren. Marion en Margriet, jullie als secretaresses bleken onmisbaar. Dank voor 
jullie gezelligheid en fantastische inzet tijdens diverse onderdelen van mijn promotie. 
Beste Rob (dr. R.A. de Man), dank voor het gestelde vertrouwen mij te willen opleiden tot 
maag-, darm- en leverarts. In mei 2015 ben ik begonnen met de vooropleiding interne 
geneeskunde in het Sint Franciscus Gasthuis te Rotterdam onder supervisie van dr. A.P. 
Rietveld. Graag wil ik hem danken voor het prettige opleidingsklimaat in het SFG. 
Dat de tweeërlei betekenis van promoveren ook daadwerkelijk van toepassing bleek op 
het arts-onderzoeker zijn, werd direct duidelijk na mijn aanstelling. De eerste betekenis het 
verwerven van de academische graad van doctor was iets wat in de loop van de tijd wel 
gebeuren zou. De tweede betekenis bleek onverwachts in werking te treden toen ik qua 
werkplek promoveerde naar de dakpoli. Die benaming slaat op de ooit als noodvoorziening 
gebouwde keet bovenop het polikliniekcomplex. De dakpoli had in de tussentijd een 
behoorlijk aantal illustere voorgangers gehuisvest en gezien de populariteit van de dakpoli 
mocht het als voorrecht worden beschouwd daar een plek toebedeeld te krijgen. Ik kreeg een 
plek op kamer Ca-413. Dat ik de in de tussentijd gedateerde computer ‘mocht’ overnemen, 
was slechts bijzaak. De bijbehorende opstarttijd van circa 15 minuten nam ik voor lief. In de 
tussentijd probeerde ik wat van de intelligentie op te snuiven die hier toch zeker nog moest 
rondwaaien. Dat dit regelmatig tot niesbuien leidde, werd niet in de minste plaats veroorzaakt 
door het stof in, op en tussen de ruimte-innemende ordners met onderzoeksgegevens van 
weleer, soms decades geleden. Deze tot trofeeën gepromoveerde ordners, die de planken 
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boven mijn werkplek volledig in bezit namen, bleken museumstukken geworden te zijn die 
onder geen beding verplaatst mochten worden, laat staan vernietigd. 
In de jaren die volgden op de dakpoli, deelde ik de kamer achtereenvolgens met 
Dewkoemar, Vivian, Annemarie, Ingrid en Anniek. Met elkaar doorleefden we praktisch 
elk jaargetijde tot in z’n volle wasdom; de gure wind tijdens stormachtige herfstdagen 
die door kieren en gaten waaide die ons tot dat moment niet waren op gevallen, de 
vrieskou in de winter die de werking van de radiatoren haast volledig neutraliseerde en de 
verzengende hitte tijdens de zomermaanden die een constante stroom zweetdruppels op 
onze voorhoofden produceerde. Misschien was het voorjaar wel de periode waarin we de 
minste extreme ervoeren en onze grootste productiviteit behaalden. Zeer gewaardeerde 
kamergenoten van weleer, het was mij een waar genoegen met jullie een kamer te hebben 
mogen delen. Dank voor de vele gezellige en motiverende gesprekken. 
Daarnaast dank ik al mijn collega arts-onderzoekers. Aan de ene kant was er een strikte 
scheiding tussen de MD-ers en de hepa’s, gezien de afzonderlijke casusbesprekingen 
en congressen. Aan de andere kant waren daar de vele gezamenlijke activiteiten. Een 
onvolledige lijst zou kunnen zijn: dagelijkse lunches waar uiteenlopende zaken besproken 
werden, jaarlijkse picknick in het Erasmuspark, sportactiviteiten waar meedoen belangrijker 
was dan winnen, skivakanties waar skiën slechts één van de programmaonderdelen was, 
sinterklaasavonden inclusief het declameren van persoonlijke en ontroerende gedichten, 
kerstmaaltijden zonder kalkoen en de borrels na werktijd bij Rotterdamse, befaamde 
cafés. Collega’s, jullie gaven kleur aan de soms wat eenzame werkzaamheden van mij als 
promovendus. Allen hartelijk dank voor de fantastische tijd op ‘het dak’.
Dan de Hepa’s: Heng (3 jaar lang mijn ‘roomie’ tijdens de vele congressen), Lisanne, 
Michelle, Raoel en Willem-Pieter, met elkaar hebben we vele congressen bezocht. Postertjes, 
praatjes, borrels en steden verkennen. In eerste instantie werden we op sleeptouw genomen 
door de oude rotten in het vak: Ad, Daphne, Edith, Ludi, Milan, Pauline en Roeland en later 
namen wij Maren, Margo en Marjolein mee op stap (dat de nieuwelingen allemaal vrouw 
bleken te zijn met de beginletters ‘Mar-‘, moest puur toeval zijn). Dank voor de bijzonder 
leuke, gezellige en leerzame periode waarin hoogte- en dieptepunten met elkaar werden 
gedeeld! 
Nu is het jouw beurt, Maren. Je startte in september 2014 en gedurende het afgelopen 
jaar hebben we samen kunnen werken aan diverse projecten. Het is voor mij een hele 
geruststelling te weten dat jij mij opvolgt. Je enthousiasme en talent zullen er zeker voor 
zorgen dat the Global PBC Study Group succesvol zal blijven. Ik zie uit naar het vervolg van 
onze samenwerking! 
Graag wil ik mijn vrienden danken voor hun medeleven en interesse in mijn onderzoek. Dit 
doe ik, met een enkele uitzondering daar gelaten, zonder specifieke namen te noemen (jullie 
weten wie ik bedoel)! Alex, dank voor je ontwerp van het the Global PBC Study Group logo. 
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zou gaan en momenteel gebruikt wordt op menig officieel document. Willem, samen 
beleefden we menig Afrikaans en Chinees avontuur. Graag wil ik niet onbenoemd laten 
dat jij, als pragmatisch ingesteld medicus, degene bent met wie ik de eerste stappen in de 
wetenschappelijke wereld zette. Momenteel woon en werk je in Congo samen met Joanne 
en jullie zoon Lukas. Ik heb veel bewondering en respect voor jullie gedrevenheid en passie 
om onder soms erbarmelijke omstandigheden primaire medische zorg te verlenen. Het ga 
jullie goed. 
Dan mijn beide paranimfen. Wouter, ongekend dat we als vrienden en oud-huisgenoten 
al zolang dezelfde weg bewandelen. We startten in 2004 tegelijkertijd met de opleiding 
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werden we in 2014 allebei aangenomen voor de opleiding tot maag-, darm- en leverarts (jij 
in Leiden en ik in Rotterdam). Het is voor mij dan ook bijzonder dat je vandaag mijn paranimf 
wilt zijn! Succes met het afronden van je eigen proefschrift. 
Mark, sinds jaar en dag zijn we vrienden en hebben we veel gemeenschappelijke 
interesses. Echter, de medische wereld is voor jou, als civiel ingenieur, een ver-van-je-bed-
show. Dat je dit graag zo houdt, blijkt wel als ik zo nu en dan een medische casus in geuren 
en kleuren aan je vertel. Ik waardeer je interesse en betrokkenheid bij mijn onderzoek. Fijn 
dat je vandaag naast me wilt staan als paranimf! 
Lieve pa & ma, Lydia & Lennart & Jort, Roel en Annemarij, met elkaar hebben we veel mooie 
en verdrietige momenten gedeeld. Ik waardeer onze hechte onderlinge band en ik ben 
enorm blij dat jullie vandaag getuigen zijn van mijn promotie. Daarnaast wil ik jullie danken 
voor jullie onophoudelijke interesse tijdens de afgelopen jaren. 
Tevens dank ik mijn opa & oma Vastenhoud en mijn schoonouders, Niek & Miranda en 
opa en oma Rook, voor hun oprechte interesse voor deze lastige materie. Het is voor mij een 
eer dat jullie allen aanwezig kunnen zijn bij de verdediging van mijn proefschrift.
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Early morning session, department of Gastroenterology and Hepatology, Azienda 
Ospedaliera di Padova, Padua, Italy 
2013 6 hours
First analysis. Database and syntax
PhD day, department of Gastroenterology and Hepatology, Erasmus MC, 
Rotterdam
2013 6 hours
Multi-center studies on location
PhD day, department of Gastroenterology and Hepatology, Erasmus MC, 
Rotterdam
2014 6 hours
Pathophysiology of cholestasis
Minor 3rd year curriculum, study of Medicine, Erasmus University Rotterdam. 
Rotterdam, the Netherlands
2014 18 hours
State of the art lecture: primary biliary cirrhosis, current insights into diagnostics 
and treatment
Nascholingsavond regionale MDL opleiding, Nijmegen, the Netherlands
2015 18 hours
Supervising graduation project
Marjolijn Leeman, medical student, Erasmus University Rotterdam
Master’s thesis, 2013-2014 about How the concept of biochemical response 
influenced the management of primary biliary cirrhosis in 831 patients over 
three decades
60 hours
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
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R20
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List of Abbreviations 
AASLD   American Association for the Study of Liver Disease
ALT   Alanine aminotransferase
AMA   Antimitochondrial autoantibody
ANA   Antinuclear autoantibody
APRI   AST to platelet ratio index
AST   Aspartate transaminase
CI   Confidence interval
FXR   Farnesoid-X receptor
γ-GT   Gamma-glutamyl transpeptidase
HBV   Hepatitis-B virus 
HCC   Hepatocellular carcinoma
HCV   Hepatitis-C virus
HR   Hazard ratio
ICD   Individual centre dataset
IQR   Interquartile range
LLN   Lower limit of normal
MELD   Model of end stage liver disease
NL   Natural logarithm
NRI   Net reclassification improvement
OCA   Obeticholic acid (INT-747)
PBC   Primary biliary cirrhosis
PDC-E2   Pyruvate dehydrogenase complex – E2 subunit
PPAR   Peroxisome proliferator-activated receptors
PT   Prothrombin time 
UDCA   Ursodeoxycholic acid
ULN   Upper limit of normal
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